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Colorectal cancer is one of the most prevalent forms of cancer and the third leading cause of 
cancer related death worldwide.1;2 Disease stage is the most important prognostic factor, with 
a 5-year survival of only ten percent for patients with stage IV metastatic disease.3 At present, 
approximately 20 percent of patients present with distant metastases4;5, and another 26 percent 
will develop metastases in the first 5 years after surgery.6 
Survival for metastasized colorectal cancer (mCRC) has increased substantially over the 
last four decades. This increase in survival is due to the improvement of surgical techniques, 
including the introduction of hepatic resection for liver-only metastases, but it is also largely 
the result of the implementation of new multidrug systemic therapies.5;7 
Whereas 5-fluorouracil (5-FU) was the only systemic treatment available until the turn 
of the century, the treatment arsenal has since then been expanded and now also includes 
other fluoropyrimidine analogues (such as capecitabine), oxaliplatin, irinotecan, and drugs 
targeted against angiogenesis (bevacizumab) or the endothelial growth factor receptor (EGFR; 
cetuximab and panitimumab). During this time, overall survival for mCRC patients has risen 
from 5.9 months on 5-FU monotherapy, to 23 months for patients treated with modern-day 
combination treatment.4 At the same time, a larger proportion of mCRC patients are now 
prescribed chemotherapy, increasing from 23 to 64 percent between 1989 and 2006 in the 
Netherlands.5 
Despite encouraging results, not all patients benefit equally from these developments. There 
is great inter-patient variation in efficacy of treatment, and adverse events do not affect all 
patients to the same extent. Pretreatment predictors of efficacy and toxicity could safeguard 
patients from unnecessary adverse events, as well as reduce health care costs by preventing 
pointless treatments in patients who will not respond. 
Genetic variation between patients and between their tumors is responsible for at least some 
of the inter-patient difference in treatment response. Tumor DNA harbors somatic mutations, 
on top of germline genetic characteristics, which can interfere with treatment efficacy. As an 
example, mutations in Ras oncogenes restrict activity of EGFR-inhibiting treatment, reducing 
its efficacy to almost zero percent.8-11 
In contrast, pharmacogenetics focus on variation in germline DNA, present in all 
nucleated cells. Genetic alterations in a myriad of genes are thought to induce phenotypic 
changes in pharmacokinetics and dynamics for cytostatic drugs. The information obtained 
from genotyping in healthy DNA can therefore be of aid in the choice and dosage of anti-
cancer treatment. Whereas treatment efficacy is mostly affected by tumor characteristics, 
toxicity associated with anti-cancer treatment is determined by its effect on healthy tissues. 
Therefore, it is likely that adverse events are far better predicted by germline genetic variation 
than by somatic changes in tumor DNA. 
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Scope of this thesis
The aim of this thesis is the search for germline genetic markers to pre-emptively predict 
treatment efficacy and adverse events of capecitabine and oxaliplatin, prescribed to patients 
with advanced colorectal cancer. For this thesis, patient data and DNA were obtained from 
patients included in the CAIRO and the CAIRO2 study by the Dutch Colorectal Cancer Group 
(DCCG). The CAIRO trial was a multicenter open label randomized phase III trial, comparing 
sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin 
in a total of 803 patients with mCRC.12 The phase III CAIRO2 trial was conducted in 755 
mCRC patients, and randomized between first-line treatment with capecitabine, oxaliplatin 
and bevacizumab (CAPOX-B) versus CAPOX-B plus cetuximab.13
The studies described in this thesis address different aspects of pharmacogenetic research in 
colorectal cancer. Chapter 2 gives an overview of the current knowledge on the effect of genetic 
variation on chemosensitivity for most common anti-cancer drugs prescribed in colorectal 
cancer treatment. New studies are reported every week and knowledge is constantly increasing. 
As a result, at the moment this thesis is published, more recent and more elaborate information 
will certainly be available. 
Germline DNA for pharmacogenetic research is derived from peripheral blood leukocytes 
or other healthy tissue in most studies. However, all early pharmacogenetic studies in colorectal 
cancer treatment, as well as several more recent publications, have used archived paraffin-
embedded surgical resection samples as the primary source of DNA for their analyses. For 
reliable comparison between studies, it is essential to know if the source of DNA affects genotype 
for the markers under investigation. Chapter 3 addresses a basic element of pharmacogenetics 
research, whether there is sufficient concordance between tumor and germline DNA, to exclude 
the source of DNA as a confounding factor in the interpretation of data from different studies. 
In the following section of this thesis, focus is on pharmacogenetics of capecitabine. 
Fluoropyrimidines have been the mainstay of systemic treatment for metastatic colorectal 
cancer, since their first development in 1957. The oral pro-drug capecitabine is equal to 5-FU in 
terms of efficacy, although pharmacokinetics differ.14 The cytotoxic effect of fluoropyrimidines 
is thought to derive from interference with the thymidylate synthase (TS), an essential enzyme 
for the formation of DNA precursors, as well as direct incorporation into DNA and RNA. 
Methylenetetrahydrofolate, which is under the direct influence of methylene tetrahydrofolate 
reductase (MTHFR), is an essential component for binding of 5-FU to TS. MTHFR poly-
morphisms could therefore influence 5-FU chemosensitivity. Chapter 4 focuses on the effect of 
MTHFR polymorphisms on adverse effects of capecitabine-based chemotherapy. In chapter 5, 
additional single nucleotide polymorphisms (SNPs) are investigated for their association with 
capecitabine efficacy. Some of these SNPs were selected based on their genome wide significance 
in an in vitro study using lymphoblastoid cell lines. Additionally, SNPs were selected based on 
their location in the gene encoding for methylene synthase reductase (MTRR), which, like 
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MTHFR, is involved in the folate pathway. 
Next, focus is shifted to oxaliplatin. Organic cation transporters (OCTs) play an important 
role in the uptake of oxaliplatin into the cells.15 Several types of OCTs have been associated 
with adverse effects of oxaliplatin, specifically platinum-induced neurotoxicity.16 Chapter 6 
focusses on genetic variation in the genes encoding for three OCTs and the correlation with 
oxaliplatin-induced neurotoxicity. 
The cytotoxic effect of oxaliplatin depends on the formation of DNA interstrand crosslinks. 
Repair of this DNA damage by the nucleotide excision repair (NER) system is likely to affect 
cellular chemosensitivity to oxaliplatin. Excision Repair Cross-Complementation group 1 
(ERCC1) is a major component of the NER system. In chapter 7, the effect of a common 
variation in this gene, ERCC1 C118T, on oxaliplatin response is addressed, combining in vitro 
studies and clinical association analysis.
In addition to the candidate-gene approach that was adopted in the previous chapters, 
in chapter 8 a genome wide search for predictors of efficacy of combination chemotherapy is 
presented. Progression free survival of patients treated with first-line chemotherapy consisting 
of capecitabine-oxaliplatin-bevacizumab (CAPOX-B), either with or without cetuximab, is 
explored.
Finally, chapter 9 gives a summary and general discussion on the results presented in this 
thesis. 
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Pharmacogenetics in chemotherapy 
of colorectal cancer
Lieke Henriëtte Tanja, Henk-Jan Guchelaar, Hans Gelderblom




Although in recent years, chemotherapeutic options for colorectal carcinoma have expanded, overall 
response rates are still too low, with high rates of toxicity. Pharmacogenetics aim at predicting both 
treatment response and adverse effects in individual patients. 
This review describes the current knowledge of pharmacogenetic markers in the systemic 
treatment of colorectal cancer. UGT1A1*28 leads to reduced conjugation of SN-38, the active 
metabolite of irinotecan, resulting in an increased rate of adverse effects, especially neutropenia. 
To a lesser extent, increased 5-FU toxicity is predicted by DPYD*2A. A variable number of tandem 
repeats polymorphism in the thymidylate synthase enhancer region, in combination with a single 
nucleotide polymorphism C>G, may predict poorer response to 5-FU. Efficacy of oxaliplatin is 
influenced by polymorphisms in components of DNA repair systems, such as ERCC1 and XRCC1. 
Polymorphic changes in the endothelial growth factor receptor probably predict cetuximab efficacy. 
Furthermore, the antibody-depended cell-mediated cytotoxic effect of cetuximab may be reduced 
by polymorphisms in the immunoglobin G fragment C receptors. Bevacizumab efficacy is suspected 
to be influenced by polymorphisms in the VEGF gene and the hypoxia inducible factor 1a gene. 
Although the interpretation of pharmacogenetic studies is complicated, results imply a promising 
way of pretreatment prediction of chemotherapy efficacy and toxicity.
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Introduction
In the last decades, important developments in the chemotherapeutic treatment of colorectal 
cancers have taken place. Since its discovery in 1957, 5-fluorouracil (5-FU) has played an 
important role in the therapy of colorectal carcinoma, both in adjuvant treatment combined 
with oxaliplatin, as well as in metastatic disease, where it is also combined with irinotecan. 
Recently, the anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody 
bevacizumab and the human epidermal growth factor receptor (EGFR)-targeted monoclonal 
antibodies cetuximab and panitimumab have been included in the treatment for advanced 
colorectal carcinoma. The addition of either of these compounds to conventional chemotherapy 
has led to a significant increase in progression free survival (PFS), although including both 
substances in first line treatment does not further increase PFS.1
However, the prognosis for patients with metastatic colorectal cancer patients is still 
limited. Moreover, many patients suffer from severe toxic side effects of chemotherapy. It would 
be useful to identify patients who are most likely to benefit from a specific chemotherapeutic 
regimen, as well as those who may experience severe adverse reactions. Clinical parameters 
alone have proven to be inadequate in predicting chemosensitivity. Pharmacogenetics aims at 
developing germline genetic markers to be used for predicting pharmacological response in 
the individual patient.2 This review presents recent developments in pharmacogenetic studies 
in chemotherapy of colorectal cancer.
5-Fluorouracil (5-FU)
The fluoropyrimidine derivative 5-fluorouracil (5-FU) is thought to have two major mecha-
nisms of action to explain its cytotoxic effect. Most importantly, the active metabolite of 
5-FU (5-FdUMP) prevents DNA synthesis by forming a complex with thymidylate synthase 
(TS) that is stabilized by 5,10-methylenetetrahydrofolate (5,10-MTHF), thereby inhibiting 
the conversion of 2’-deoxyuridine-5’-monophosphate (dUMP) to 2’-deoxythymidine-5’-
monophosphate (dTMP), the latter of which is an essential precursor for DNA-synthesis. 
(Figure 1) Furthermore, incorporation of 5-FU nucleotides into DNA and RNA leads to altered 
RNA processing and DNA damage.
Thymidylate synthase (TS)
The gene encoding for TS contains a unique tandemly repeated 28bp sequence in the enhancer 
region (TSER) in the 5’-untranslated region (5’-UTR), that was shown to be polymorphic with 
regard to the number of repeats (variable number of tandem repeats, VNTR). Although alleles 
containing up to 9 repeats have been described, two (2R) and three (3R) repeat copies are 
the most prevalent alleles in all ethnic populations.3;4 The 3R-allele leads to increased tumoral 
TS expression, due to either enhanced mRNA translation efficiency5 or increased TS mRNA 
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levels.6 In addition to this VNTR polymorphism, a single nucleotide polymorphism (SNP) 
G>C at bp12 of the second repeat in 3R individuals has been described, leading to a three-allelic 
locus (2R, 3RC, 3RG). The 3RC allele leads to a reduced transcriptional activity comparable to 
that of the 2R allele, by disrupting an area critical to TS promoter activation.4
Figure 1. Schematic simplified overview of enzymes involved in the cellular response  
and metabolism of chemotherapeutic compounds in colorectal cancer
5-FU: 5-fluorouracil; ABC: ATP-binding cassette; DPD: Dihydropyrimidine dehydrogenase; dTMP: 
deoxythymidine monophosphate; dUMP: deoxyuridine monophosphate; EGFR: endothelial growth factor 
receptor; ERCC1: Excision repair cross complementation group 1; HIF-1α: hypoxia inducible factor 1α ; 
KDR: Kinase domain receptor; MTHF Methylene hydrofolate; MTHFR: Methylene hydrofolate reductase; 
Pt: Platinum; SN-38: active metabolite of irinotecan; SN-38G: SN-38 glucoronide; TS: Thymidylate synthase; 
UGT: UDP-glucuronosyl transferase; VEGF: vascular endothelial growth factor; XRCC1: X-ray repair cross 
complementation group 1.
In several studies, carriers of the 3R allele showed a poorer response to 5-FU chemo therapy6-9, 
as well as decreased rates of grade 3-4 overall toxicity3;6 and diarrhea10, as would be expected 
from the higher TS levels associated with this allele.(Table 1) Conversely, two independent 
studies found a significantly better response rate and survival for 3R3R homozygotes, compared 
with individuals carrying at least one 2R allele.11;12 The C>G SNP has frequently been used 
to explain the discrepancies in studies addressing only the VNTR polymorphism. The 3RG 
genotype was most often associated with either shorter response duration13;14, shorter OS14;15 
or reduced overall response14 to 5-FU, when compared to 2R or 3RC genotypes. However, 
although a lower rate of toxicity for 3RG3RG individuals was found in some studies3;11, another 
study found a trend towards more toxicity during the first cycle of capecitabine treatment.13 
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Another explanation for these discrepant findings may be the ethnic diversity in relative allele 
frequencies, with only 3-4% 2R homozygotes in most Asian populations, compared to 17-24% 
in Caucasians.3;6
In addition to the TSER polymorphism another polymorphic locus is found in the TS 
3’-UTR, consisting of a 6bp deletion at position 1494.16 The del6 allele has been associated 
with better response rate17;18 and reduced risk of death19, although in another study ins6 
homozygotes showed significantly better response to capecitabine or raltitrexed.9 Regarding 
adverse reactions, although several studies showed the 3’-UTR polymorphism had no influence 
on toxicity3;13;20, one study found a higher incidence of toxicity in del6 homozygotes.18
Methylenetetrahydrofolate reductase (MTHFR)
Methylenetetrahydrofolate reductase (MTHFR) catalyzes the irreversible conversion MTHF to 
5-methyltetrahydrofolate. The former is essential in stabilizing the complex formed by TS and 
5-FdUMP. (Figure 1)
The MTHFR gene is subject to several polymorphisms. Most common are two SNPs, 
677C>T (Ala222Val, MTHFR*4) and 1298A>C (Glu428Ala, MTHFR*6), that are in linkage 
disequilibrium.3;13;21 These polymorphisms lead to decreased MTHFR enzyme activity, and 
may thereby induce more effective stabilization of the FdUMP-TS ternary complex. In vivo 
studies showed a significantly better response rate for genotypes with at least one MTHFR 677T 
allele.12;22(Table 1) Conversely, a study in 142 patients with primary rectal adenocarcinoma 
showed increased tumor regression for MTHFR 677CC homozygotes after preoperative 5-FU 
based chemoradiation therapy.21 However, most studies found that both the MTHFR 677C>T 
and MTHFR 1298A>T polymorphisms were not predictive of objective response or survival 
in patients treated with 5-FU chemotherapy.12;20;23;24 Enhanced stability of the ternary complex 
could also be expected to increase 5-FU toxicity. However, a recent study unexpectedly found 
lower rates of toxicity for the MTHFR 677TT and 1298AA genotypes.20 Most studies found 
both MTHFR variants were not associated with altered toxicity rates in diverse patient groups 
treated with 5-FU derivatives.13;22;23 
Dihydropyrimidine dehydrogenase (DPD)
5-FU depends on the activity of dihydropyrimidine dehydrogenase (DPD) for 80% of its 
catabolism.25 Deficiency of DPD-activity leads to prolongation of the plasma half-time with 
resulting accumulation of 5-FU and has been associated with severe, mainly hematological 
toxicity and even death after administration of 5-FU.26 DPD deficiency is present in 
approximately 3% of all cancer patients27 but accounts for approximately 50% of patients with 
unexpected severe 5-FU toxicity.28 
To date, over 30 polymorphisms in the DPYD gene (encoding for DPD) have been identified, 
many of which were found to be common variants with no apparent effect on DPD-activity.29;30 
However, a G>A mutation of the invariant splice site in exon 14 (IVS14+1G>A, DPYD*2A) 
leads to skipping of exon 14 and formation of a truncated protein with no apparent residual 
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activity. Homozygosity for DPYD*2A can lead to complete DPD-deficiency.26 Although the 
incidence of this allele is rare, with a population frequency of 0,9-1,8% heterozygotes9;26;31, it is 
estimated to be responsible for about 25% of all cases of unexpected severe 5-FU-toxicity.10;28;31 
However, it has also been described in individuals with normal DPD-activity.28 There are 
profound ethnic differences in the incidence of DPD gene mutations. Although DPYD*2A is 
the most common polymorphism in Caucasians, it is rare in Asians.29 
Irinotecan
Irinotecan (CPT-11), a potent inhibitor of topoisomerase I, is widely used in the therapy for 
various solid tumors, including advanced colorectal carcinoma. Irinotecan undergoes several 
metabolic steps, both anabolic and catabolic.(Figure 1) It undergoes biotransformation by 
CYP3A-mediated oxidation to form APC, a substance which shows little cytotoxic activity. By 
another route, it is converted by liver carboxylesterases to its active metabolite (SN-38). This 
compound is then further conjugated by several UDP-glucuronyltransferases (UGTs) to yield 
the inactive SN-38G, which is mainly excreted with bile and urine. To enable excretion, SN-
38 and irinotecan are actively transported out of the cell by an ATP-dependent efflux pump 
(ABC-binding cassette B1, ABCB1). After biliary excretion, SN-38G can be converted to active 
SN-38 by bacterial β-glucuronidase, which can lead to gastro-intestinal toxicity. Finally, SN-38 
is subject to enterohepatic recirculation, leading to an unexpected peak in plasma after gall 
bladder emptying. 
UDP-glucuronosyltransferase (UDP)
Reduced glucuronidation of SN-38 has been shown to significantly increase gastro-intestinal 
toxicity of irinotecan.32 The principle UGT involved in the conjugation of SN-38 is UGT-1A1.33 
Up to 25 polymorphisms have been described for UGT1A134, of which a polymorphism in the 
promoter region, consisting of seven instead of six TA-repeats (-53(TA)6>7, UGT1A1*28) is the 
most common. The higher number of TA-repeats is associated with reduced transcriptional 
activity of UGT1A1, leading to various degrees of impaired glucuronidation.35-39 This allele 
is also associated with Gilbert’s syndrome.40 The presence of the UGT1A1*28 allele in 
either heterozygote or homozygote form, was shown to be a significant predictor for severe 
toxicity after the admission of irinotecan41, with up to seven times increased risk of severe 
neutropenia37;39;42;43 or diarrhea36;42;43, and a severely increased risk of febrile neutropenia.44 This 
increase in toxicity, however, may only be present in the first cycle of chemotherapy.39 Although 
most studies have shown no significant association between UGT1A1-genotype and objective 
response42-44, a study in 250 white patients with advanced colorectal cancer showed a higher 
incidence of partial or complete response for UGT1A1*28 patients.39
Although, with a population frequency of 43% heterozygotes, the UGT1A1*28 poly-
morphism is the most frequent mutation in Caucasians36;38, it is significantly less frequent in 
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Asians.45;46 Contrary, in the Asian population, the most common polymorphism is a SNP in the 
3’-UTR (211G>A, UGT1A1*6)45, which is also associated with significantly reduced enzyme 
activity.47 One study showed a higher incidence of grade 4 neutropenia after administration of 
irinotecan for UGT1A1*6 homozygotes, combined with a significantly lower response rate and 
shorter PFS.45 Conversely, most studies showed no increased risk of toxicity for the UGT1A1*6 
allele.42 
Two other UGT isoenzymes are thought to be involved in the glucuronidation of SN-
38: the hepatic UGT1A9 and the extra-hepatic UGT1A7.48 The -118 in/del polymorphism 
(-118(T)9>10, UGT1A9*22), showing higher UGT1A9 mRNA expression for the -118(T)9 allele, 
might explain part of the phenotypic variability in SN-38 glucuronidation that is not explained 
by UGT1A1*28.46 
Oxaliplatin
Platinum-containing drugs exert their cytotoxic effect by forming bulky interstrand and 
intrastrand DNA-adducts, resulting in DNA replication inhibition and apoptosis. The major 
pathway for removal of these adducts is nucleotide excision repair (NER).(Figure 1) During 
NER, damaged DNA is recognised and DNA helixes are unwound by the action of several 
factors, including xeroderma pigmentosum complementation group D protein (XPD, also 
known as ERCC2), XPC and XPA. The DNA strands are separated and a DNA residue containing 
the adducts is removed. Cleaving of the damaged strand is performed by the nucleases XPG 
and excision repair cross-complementing group 1 protein (ERCC1) on the 3’ and 5’ side, 
respectively. Suboptimal repair mechanisms may lead to increased sensitivity to platinum 
containing chemotherapy.49 Higher tumoral ERCC1 mRNA levels have been associated with 
significantly worse outcome in gastric cancer50 and advanced colorectal cancer51 treated with 
cisplatin or oxaliplatin based chemotherapy. Polymorphisms have been described for many of 
the constituents of NER. However, to date, only few have proven clinically significant. 
Xeroderma pigmentosum complementation group D (XPD)
The synonymous XPD Arg156Arg (C>A) polymorphism was associated with a higher response 
rate and longer time to progression for C/A or A/A genotypes in gastric cancer patients treated 
with oxaliplatin based chemotherapy.17 A trend towards higher response and longer median sur-
vival rate for these genotypes was also seen in metastasized colorectal cancer patients.52(Table 1)
Another polymorphism, XPD Lys751Gln (A>C), was shown to reduce DNA repair capacity 
for the 751Gln/Gln genotype in normal cells of lung cancer patients.53 Conversely, a reduced 
capacity for DNA repair for 751Lys/Lys genotype was found in another report, possibly because 
of methodological differences.54 The XPD Lys571Gln polymorphism did not show significant 
survival difference according to genotype in gastro-oesophageal cancer14;55 and colorectal 
cancer56;57 in response to various platinum based chemotherapy regimens. 
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Excision repair cross complementing group 1 (ERCC1)
A synonymous C>T (Arg118Arg) polymorphism in the ERCC1 gene has been described. 
Although the mechanism by which this substitution affects ERCC1 activity is unknown, it has 
been suggested that replacement of the common codon AAC by the infrequently used codon 
AAT affects translation efficiency, with a 50% decrease for the variant allele.58 Advanced colorectal 
cancer patients carrying the -118TT genotype experienced higher response rates to oxaliplatin 
treatment59 and longer progression free survival60 in two studies.(Table 1) However, in another 
two studies survival was most favorable for patients who carried the ERCC -118CC genotype.23;61 
Two studies in gastric cancer patients found no predictive effect of this polymorphism.14;17
X-ray cross complementing group 1 (XRCC1)
In addition to NER, the basepair excision repair pathway (BER) is also involved in 
chemosensitivity to platinum agents. An important player in BER is X-ray repair cross 
complementing group 1 (XRCC1). A common polymorphism, XRCC1 Arg399Gln (G>A), 
has been suggested to produce significant conformational changes at a domain important 
for XRCC1 interaction with other components of BER.62 The germline wildtype allele has 
been associated with significant survival benefit in gastric cancer patients55 and lung cancer 
patients63 in response to platinum compounds.(Table 1) Expression of the wildtype allele in 
colorectal tumoral tissue was also associated with better survival and response to oxaliplatin.24 
However, in recent studies in advanced colorectal cancer and gastric cancer patients, XRCC1 
genotype did not predict outcome after oxaliplatin treatment.23;56;61 
Cetuximab
Cetuximab, a chimeric immunoglobin G1 monoclonal antibody, exerts is action by binding to 
the extracellular domain of the epidermal growth factor receptor (EGFR) with a higher affinity 
than epidermal growth factor (EGF), thereby blocking ligand-induced phosphorylation of 
EGFR.(Figure 1) So far, only clinical parameters have been used to predict cetuximab efficacy, 
of which the grade of skin toxicity is the most important.64 However, pretreatment markers for 
selecting patients who may benefit from therapy are currently lacking. EGFR-staining intensity 
in tumor tissue is not associated with response, survival or toxicity.65-67 Pharmacogenetics may 
prove a possible way of optimizing monoclonal antibody therapy.68
Epithelial growth factor receptor (EGFR)
A polymorphic (CA)n-repeat variant in EGFR intron-1 has been described with 16 up to 26 
repeats and EGFR gene transcription declines with increasing number of (CA)-repeats.69 In a 
study in 110 heavily pretreated patients with advanced colorectal carcinoma, the homozygous 
EGFR intron-1 short allele was associated not only with favorable survival, but also with a 
higher grade of skin toxicity.64(Table 1) In an earlier study, however, no relation between this 
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polymorphism and colorectal cancer survival was detected.67 Another polymorphic locus in 
the EGFR gene has been described, consisting of a SNP G>A leading to substitution of arginine 
by lysine at codon 497 (also denominated 521). This polymorphism was shown to be predictive 
of cetuximab efficacy, with a better response rate as well as longer PFS and OS for advanced 
colorectal cancer patients carrying at least one A allele.70;71 Earlier studies, however, showed no 
influence of this and another (EGFR -216G>T) polymorphism on cetuximab efficacy.64;67 
Induction of downstream pathways of EGFR leads to synthesis of various ligands, such 
as Cyclin-D1 (CCND1). Therefore, genetic variation in the cyclin-D1 gene might affect 
cetuximab efficacy, and germline polymorphisms have been described for CCND1. In 
metastatic colorectal cancer patients receiving cetuximab single-agent therapy, harboring the 
SNP (CCND1 870 A>G) is associated with longer OS for the G allele.67(Table 1) Conversely, in 
another study in advanced colorectal patients treated cetuximab and irinotecan combination 
therapy, this polymorphism was not associated with PFS or OS.64 In addition, Cox-2 acts as an 
upstream regulator of EGFR. A frequent Cox2 -756G>C polymorphism has been described, 
leading to decreased COX-2 expression.72 Until recently, this polymorphisms had not been 
related to response or outcome in patients treated with cetuximab67, but in a recent study Cox-2 
-756CC individuals showed longer PFS.71
A difference in the expression of the natural ligand for the EGFR might also influence 
cetuximab efficacy. A SNP is found in the EGF gene 61G>A, which leads to upregulated EGF 
levels for the transcriptionally more active G allele. Although higher circulating EGF levels 
have been associated with higher tumor aggressiveness, the EFG 61GG genotype was associated 
with a more favorable overall survival in patients treated with cetuximab and irinotecan.64;71 
However, in another study AA homozygosity tended to associate with longer overall survival.67
Antibody-dependent cell-mediated cytotoxicity
Cetuximab may also exert an indirect anti-tumor activity by attracting cytotoxic host effector 
cells, like monocytes and natural killer cells. The effect of this antibody-dependent cell-
mediated cytotoxicity (ADCC) may depend on the degree of activation of effector cells after 
engagement of immunoglobin G fragment C receptors (FcγR) IIa and IIIa. Polymorphic alleles 
have been described for FcγR-IIIa (559T>G, Val158Phe) and FcγR-IIa (535G>A, His131Arg), 
that were shown to negatively affect receptors’ affinities for the fragment C of antibodies, and 
probably ADCC efficiency.73 FcγR-IIIa 158VV genotype was associated with a higher affinity of 
natural killer cells for the chimeric IgG1 monoclonal antibody rituximab in vitro74, and with a 
higher response rate and longer progression free survival in breast cancer patients treated with 
the humanized anti-Her2/neu immunoglobin G monoclonal antibody trastuzumab.75 (Table 
1) A study in 39 mCRC patients treated with cetuximab monotherapy unexpectedly showed 
a significantly shorter PFS for FcγR-IIa 131A and FcγR-IIIa 158V homozygotes.76 However, 
another study in advanced colorectal patients treated with irinotecan an cetuximab, showed 




Bevacizumab is a humanized recombinant monoclonal IgG type antibody, directed against all 
VEGF-A isoforms.(Figure 1) VEGF is an important regulator of angiogenesis and its inhibition 
by bevacizumab not only reduces tumor volume, but also large vessel density in a colorectal 
tumor model in mice.77 Hypoxia is a potent stimulus for VEGF expression and one of the 
regulating elements in this mechanism is hypoxia-inducible factor 1α (HIF-1α). This factor 
binds to a 28-bp enhancer in the 5’ upstream region of the VEGF-gene, thereby stimulating 
transcription. Under normoxic cellular conditions, HIF-1α rapidly degrades. However, it may 
be strikingly induced under hypoxic conditions, which are often found in tumor mass. In 
addition to HIF-1α, other regulating elements for VEGF expression are located in the 3’-UTR. 
Vascular endothelial growth factor
Several polymorphisms have been described for the VEGF promoter region, 5’-UTR and 
3’-UTR78;79, but only few have shown functional implications.80 Two SNP’s (VEGF +936C>T 
and VEGF -1154G>A) lead to decreased VEGF expression for the variant allele.78;81-84 A third 
SNP (VEGF-2578C>A), that is in complete linkage disequilibrium with an 18bp insertion 
at bp -2549, has also been associated with higher VEGF expression and serum levels for the 
wildtype -2578C/-2549del allele.78;79 However, lower VEGF expression for the VEGF-2578CC 
genotype was found in one study.78;81 Another common polymorphism (VEGF -634G>C, also 
denominated +405G>C) was most commonly reported to induce lower VEGF expression 
and serum protein levels for wildtype homozygotes81;83;85, although one study conversely 
found decreased VEGF expression for the variant allele.86 In addition, recent studies found 
no association between these VEGF polymorphisms and tumoral VEGF protein expression 
or circulating VEGF levels.87;88 Methodological differences may have contributed herein, since 
one report found increased VEGF mRNA expression in colorectal carcinoma tissue, but not in 
adjacent healthy tissue.89 
So far, only one study on the pharmacogenetic interaction between bevacizumab and 
VEGF polymorphisms has been published. A recent study in 363 breast cancer patients found 
improved median survival time for patients with the VEGF -2578AA and -1154AA genotypes 
when treated with paclitaxel combined with bevacizumab.90 Instead, most studies have focused 
on prognostic, rather than predictive effects. VEGF -634CC genotype was associated with 
higher tumor stage and grade in one study in breast cancer patients91, but with increased OS 
in another.92 In colorectal cancer patients, this polymorphism was not associated with tumor 
differentiation93 or time to tumor recurrence.94 In early stage gastric carcinoma the VEGF-
460CC genotype was associated with a better DFS and OS87, but the same genotype was 
associated with reduced OS in Chinese breast cancer patients.92 Stage III colorectal cancer 
patients with the VEGF +936CC homozygote genotype had significantly shorter time to tumor 
recurrence compared to patients with at least one T allele.94 VEGF -2578CC homozygotic 
patients with renal cell carcinoma showed significantly lower cancer specific survival, compared 
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to patients with at least one variant allele.95 Another polymorphism VEGF -1498T>C showed 
poorer differentiation of colorectal carcinomas for the CC genotype.93 These conflicting and 
sometimes unexpected results concur with our current lack of full understanding of these 
polymorphisms on VEGF expression and function. 
Hypoxia-inducible factor 1a
Three polymorphisms have been described in exon 12 of the HIF-1α gene, HIF-1α Pro582Ser 
(1722C>T), HIF-1α Ala588Thr (1790G>A), HIF-1α Pro564Ala, and one in exon 13, which 
is a GT-repeat polymorphism.96;97 Genotypes coding for variant proteins showed higher 
transcription capacity in vitro, both under normoxic and hypoxic conditions, compared 
to wildtype.97;98 Expression of a Pro582Ser variant allele was associated with a significantly 
increased risk of ulcerative disease in colorectal cancer, although vascularization was not 
increased.99 Whereas both Pro582Ser and Ala588Thr were not associated with tumor grade or 
stage in transitional cell carcinoma, patients with at least one variant allele showed significantly 
worse disease-free and overall survival.100 
Discussion
So far, pharmacogenetic studies hold the promise of becoming a useful way of predicting 
results for chemotherapeutic treatment in colorectal carcinoma. Results from earlier trials 
have even lead to a label change for irinotecan, now advising dose reduction for UGT1A1*28 
homozygotic individuals. There are, however, some difficulties in interpreting study results.
Pharmacogenetic studies aim at understanding the influence of germline polymorphisms. 
This does not account for the potential bias of somatic mutations or loss of heterozygosity in the 
tumor, which is a frequent phenomenon with regard to the TYMS polymorphisms(26-54%).3;19 
Patients who have a 2R3R genotype, with tumoral 3R-loss might obtain significant benefit 
from 5-FU based chemotherapy, with a lower risk of toxicity. In addition, the frequent presence 
of linkage disequilibrium between variant alleles makes it difficult to ascertain which allele 
is essential in predicting chemosensitivity. Haplotype analysis may eventually overcome this 
problem.
Furthermore, ethnic differences in relative allele frequencies may want for different 
strategies for the respective populations. Substantial interethnic differences have been found 
for the allele frequencies of ERCC1 118, XRCC1 399 and XPD 751 polymorphisms, with African 
Americans carrying the wildtype allele more often than Americans of European descent.101 
Asian populations show only very limited expression of the beneficial TYMS 2R2R genotype, 
and a different spectrum of UGT1A1 polymorphisms, compared to Caucasians.102;103 
Another problem regarding pharmacogenetic results lies in the fact that some poly-
morphisms are not only predictive of chemotherapeutic efficacy, but also of general prognosis 
in cancer patients104 and may even have contributed to the development of colorectal 
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carcinoma105. This is especially true for components of DNA repair mechanisms. By impairing 
DNA repair polymorphic changes may predispose to carcinogenesis, whereas they may also 
improve response to chemotherapy when cancer has developed. 
In developing predictive pretreatment models for colorectal cancer therapy genetic and 
non-genetic factors with proven effect on outcome, such as performance status and tumor 
stage will need to be combined. This has proven effective in other fields, such as predicting 
MTX treatment efficacy rheumatoid arthritis.106 
Conclusion
In conclusion, pharmacogenetic studies in colorectal cancer therapy show promising results 
with regard to prediction of tumor response, survival and toxicity. Although further research 
is warranted, predictive models including genotypic testing will influence the choice for a 
chemotherapy regimen in the future.
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Background & aim: Results from different pharmacogenetic association studies in colorectal 
cancer are often conflicting. Both peripheral blood and formalin-fixed, paraffin-embedded (FFPE) 
tissue are routinely used as DNA source. This could cause bias due to somatic alterations in tumor 
tissue, such as loss of heterozygosity. We therefore compared genotypes in DNA from peripheral 
blood and FFPE colorectal tumor samples for SNPs with putative influence on the cytotoxicity of 
chemotherapy.
Materials & methods: Eleven SNPs in nine genes involved in anticancer drug metabolism or 
efficacy were determined in matched samples from blood and FFPE tissue of colorectal tumors by 
pyrosequencing and TaqMan® techniques. The k-statistic was calculated to assess concordance.
Results: A total of 149 paired FFPE tissue and EDTA blood DNA samples were available for compari-
son. Overall, 20 out of 1418 genotypes were discordant (1.4%); in ten cases, loss of heterozygosity 
could not be ruled out. Only GSTP1 showed significant discordance between FFPE tissue and blood 
genotype (k = 0.947; 95% CI: 0.896–0.998).
Conclusion: FFPE tissue-derived DNA can be used as a valid proxy for germline DNA for a selection 
of SNPs in (retrospective) pharmacogenetic association studies in colorectal cancer. However, for 
future studies, genotyping of blood-derived DNA is preferred.
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Introduction
The field of pharmacogenetics has developed rapidly over the last decade1;2, as have techniques 
for DNA isolation and SNP genotyping. Pharmacogenetic association studies have shown 
inconsistent results for candidate genes in many pharmacologic pathways. Among other 
variables, the source of DNA could be a confounding factor explaining these inconsistencies. 
The majority of studies use whole blood as a source of DNA, since it supplies genomic DNA 
and is easy to obtain in a clinical setting. Alternative sample types include buccal swabs or 
saliva, both of which are ideal for use in nonclinical settings and for shipping by mail.1;3
Tumor tissue as a source of DNA is of particular interest, as tumor biopsies and resection 
specimens of large patient populations have been archived and are potentially useful for 
retrospective pharmacogenetic studies.4;5 However, the quality of DNA isolated from formalin-
fixed, paraffin-embedded (FFPE) material is often inferior to DNA from peripheral blood 
leukocytes.5;6 As a result of chromosomal damage, DNA amplification and primer recognition 
may be hampered. Indeed, unpublished pilot experiments showed that genetic variations in the 
TYMS 28-bp repeat and UGT1A1*28, both spanning a larger number of base pairs, could not 
be determined in most of our FFPE samples due to low DNA quality.
Although these arguments make peripheral blood the preferred DNA source for most 
pharmacogenetic studies, blood samples are not always available, especially in retrospective 
studies. Indeed, many pharmacogenetic association studies in colorectal cancer (CRC) have 
used FFPE tissue specimens as the primary source of DNA.7–19 However, the use of FFPE 
tissue may lead to genotyping results that differ from the germline genotype, because tumor 
DNA harbors somatic alterations that are associated with carcinogenesis on top of germline 
characteristics. These may involve point mutations, copy number variations or, more frequently, 
loss of heterozygosity (LOH).
Concordance of germline drug metabolism pathway polymorphisms in DNA from 
peripheral blood and FFPE tissue has not been extensively investigated in colorectal carcinomas. 
It is therefore unknown whether results from studies using archived tumor samples as the 
primary source of DNA can be assessed alongside those from studies using blood-derived 
DNA. Therefore, the aim of the present study was to compare the genotypes of a large set of 
paired blood and FFPE samples in CRC patients for a selection of SNPs with putative influence 
on the cytotoxicity of commonly used chemotherapeutic drugs for CRC.20
Materials and methods
DNA was obtained from previously untreated metastatic CRC patients participating in the 
multicenter CAIRO trial of the Dutch Colorectal Cancer Group. The inclusion criteria and 
clinical results of this study have been published elsewhere.21 All included patients gave 
written informed consent before inclusion. EDTA–blood was stored at -20°C before DNA 
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isolation. FFPE colorectal tumor resection samples were collected from multiple pathology 
laboratories in The Netherlands and stored under standard conditions. Procedures for tissue 
collection and fixation are uniform across Dutch hospitals. Germline DNA was isolated from 
EDTA–blood with the MagNA Pure LC® (Roche Diagnostics, The Netherlands) according to 
the manufacturer’s instructions. Tissue DNA was obtained by macrodissection from FFPE 
samples of areas optically containing predominantly tumor tissue with QIAamp® DNA Mini 
Kit columns (Qiagen, The Netherlands).
SNP selection and genotyping assays
We selected polymorphisms in genes with putative influence on the pharmacokinetics or 
pharmacodynamics of fluoropyrimidines, oxaliplatin and irinotecan. SNPs in the following 
genes were included in our analyses: ABCB1, ABCG2, MTHFR, SLC91A1, ERCC1, ERCC2, 
XRCC1, GSTP1 and TP53. In addition to MTHFR, other genes have been associated with 
fluoropyrimidine cytotoxicity, including the genes TYMS, DPYD and TYMP. However, 
polymorphisms in these genes were not included in the present study. The TSER polymorphisms 
(rs34743033 and rs11540151) were not included because, in pilot experiments, genotyping for 
these SNPs failed in the majority of FFPE samples, presumably due to the extended length of 
the polymorphism (data not shown). DPYD*2A (rs3918290) was also excluded, because the 
very low minor allele frequency and expected low number of heterozygotes in our population 
(1–2%9;22) would preclude statistical analyses. Although TYMP expression has been linked to 
fluoropyrimidine cytotoxicity, very few studies have addressed the effect of genetic variation in 
this gene. It was therefore not included in this study. Regarding irinotecan pharmacogenetics, it 
would have been interesting to test UDP-glucuronosyltransferase polymorphisms, particularly 
UGT1A1*28. Unfortunately, genotyping was not successful in most FFPE samples, which led 
us to exclude this polymorphism from further analyses.
In order to maintain statistical power, we chose to limit the number of polymorphisms to 
be studied per gene. Because our intention was to validate results from earlier publications, we 
aimed to include the polymorphism that was cited most frequently in publications to date for 
each gene. Therefore, in these cases, we searched PubMed for the respective polymorphisms 
and their rs numbers and included the SNP with the highest number of citations.
The following SNPs were determined using the TaqMan® 7500 real-time PCR system 
(Applied Biosystems, The Netherlands) according to the manufacturer’s protocol: ABCB1 
rs1128503 and rs1045642; ABCG2 rs2231142; ERCC1 rs11615; MTHFR rs1801133; SLC19A1 
rs1051266; and ERCC2 rs1799793 and rs13181. To genotype ABCB1, ABCG2 and SLC19A1, we 
used custom-designed assays. To genotype ERCC1, MTHFR and ERCC2, we used predesigned 
assays. Additionally, GSTP1 rs1695, TP53 rs1042522 and XRCC1 rs25487 were determined 
using the Pyrosequencer 96MA™ (Isogen, The Netherlands). The pyrosequencing reactions 
were performed according to the manufacturer’s protocol. PCR primers, target sequences and 
the calculated dispensation orders for each SNP are listed in Table 1. Note that the lowercase 
nucleotides in the dispensation order are negative controls, which would not be incorporated 
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into the target DNA and consequently should not appear in the pyrogram.
The technicians performing the analyses were blinded with respect to sample identity. 
As a quality control in the pyrosequencing and TaqMan assays, at least 5% of samples were 
genotyped in duplicate, and water was used as a negative control. No inconsistencies were 
observed. In case of discrepancies between genotypes in tumor and blood DNA, the discordant 
pair was reanalyzed in one run. In this run, we included five randomly selected samples and 
water as controls.
SNP Target# Sequence 5’-3’ Modification
















Table 1. Primers and probes for pyrosequence analysis and fragment length analysis
# f = forward orientated, r = reverse orientated
 
Statistical analysis
Concordance of genotypes determined in DNA from EDTA–blood and FFPE samples was 
tested using the k-statistic, which tests the agreement between two paired results. A k-value 
larger than 0.95 was considered good agreement. We calculated 95% confidence intervals (95% 
CI) of the k-statistic. The null hypothesis was that there is no difference in genotyping results 
due to source of DNA, corresponding to a k of 1.00. The two-sided significance level was set at 




















































































































































































































































































































































































































































































































































































































































































































Both EDTA–blood and FFPE tissue samples were available for 149 patients with metastatic 
CRC who participated in the CAIRO trial. Paraffin tissue and peripheral blood genotypes were 
determined for a total of 11 SNPs from nine chromosomal regions. Depending on genotype, 
results were obtained in 87–100% of peripheral blood samples; FFPE tissue-derived genotypes 
were obtained in 77–97% of samples. Paired results for FFPE tissue and peripheral blood 
genotype were obtained for 77–95% of patients, depending on the studied SNP. Genotype 
distributions were in accordance with previously published results.9;23–25(Table 2) All genotypes 
were in Hardy–Weinberg equilibrium, with the exception of XRCC1 (both in EDTA–blood 
and FFPE tissue; χ2 = 4.999, p = 0.025 and χ2 = 3.997, p = 0.046, respectively), GSTP1 (EDTA–
blood only; χ2 = 3.896, p = 0.048) and ABCG2 (FFPE tissue only; χ2 = 4.520, p = 0.034).
Gene rs No Number of 
evaluable pairs  
(% of 149 pairs)
No of discordant 
pairs (%#)
κ statistic 95% Confidence interval$
ABCB1 1128503 131 (88%) 3 (2.3%) 0.963 0.921-1.00
ABCB1 1045642 137 (92%) 0 (0%) 1.00 -
ABCG2 2231142 134 (90%) 0 (0%) 1.00 -
ERCC1 11615 132 (89%) 2 (1.5%) 0.975 0.940-1.00
ERCC2 13181 124 (83%) 2 (1.6%) 0.974 0.914-1.00
ERCC2 1799793 124 (83%) 3 (2.4%) 0.960 0.915-1.00
GSTP1 1695 134 (90%) 4 (3.0%) 0.947 0.896-0.998
MTHFR 1801133 120 (81%) 2 (1.7%) 0.971 0.932-1.00
TP53 1042522 115 (77%) 2 (1.7%) 0.969 0.926-1.00
SLC19A1* 1051266 126 (85%) 1 (0.8%) 0.987 0.961-1.00
XRCC1 25487 141 (95%) 1 (0.7%) 0.987 0.961-1.00
 
Table 3. Concordance of genotypes between peripheral blood and formalin-fixed  
paraffin-embedded tissue 
* Also denominated: Reduced folate carrier (RFC). # Percentage of evaluable pairs that is discordant.
$ Ninety-five percent confidence interval for κ statistic.
 
Concordance of EDTA–blood & FFPE genotype
We found an excellent agreement between the peripheral blood genotypes and the genotypes 
determined in corresponding FFPE samples.(Table 3) With the exception of GTSP1 rs1695 
(95% CI for k-statistic: 0.896–0.998), all SNPs showed an agreement between samples that 
was not significantly different from 100%. The 95% confidence levels of genotype concordance 
ranged from 0.961–1.000 (XRCC1 rs25487) to 0.914–1.000 (ERCC2 rs1799793).
Description of discordant results
In total, 20 out of 1418 (1.4%) genotype pairs in 18 patients were discordant in our sample set. 
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For each individual SNP, no more than 3.0% of pairs showed dissimilar results. Table 4 shows 
the genotypes found in peripheral blood and FFPE tissue for all discordant pairs. A potential 
source of discordance is LOH. We assessed LOH using heterozygous genotypes from adjacent 
loci. Because LOH involves larger stretches of DNA, loss of an allele for one SNP should be 
accompanied by loss of an allele for neighboring loci.26 Using this approach, the number of 
mismatches potentially due to LOH was reduced to ten, including four sample pairs for GSTP1 











ABCB1 rs1128503 1 CC TT - - No
2 CC CT - - No
3 CT CC ABCB1 rs1045642 missing Possible
ERCC1 rs11615 4 TC TT XRCC1 rs5487 heterozygous No
5 TC CC ERCC2 rs13181 heterozygous No
ERCC2 rs13181 6 AC AA ERCC2 rs1799793 missing Possible
7 AC AA XRCC1 rs5487 heterozygous No
ERCC2 rs1799793 8 GA GG ERCC2 rs13181 missing Possible
5 GA AA ERCC2 rs13181 heterozygous No
9 GA AA ERCC2 rs13181 heterozygous No
GSTP1 rs1695 10 AG AA - - Possible
11 AG AA - - Possible
12 AG AA - - Possible
13 AG AA - - Possible
MTHFR rs1801133 2 CT CC - - Unlikely*
14 CT CC - - Possible
TP53 rs1042522 15 GC CC - - Possible
16 CC GC - - No
SLC19A1 rs1051266 17 AA GA - - No
XRCC1 rs25487 18 GA AA ERCC2 rs13181 heterozygous No
Table 4. Exploration of discordant pairs on the basis of genotype in adjacent loci
* Mix-up of samples is likely to have happened, given the genotyping results for ABCB1 rs1128503 for this 
patient.
LOH: loss of heterozygosity; Possible: loss of heterozygosity cannot be determined due to missing genotypes 
and/or no adjacent loci were genotyped. Other explanations for discordant pairs include patient mix-up, sample 
mix-up, genotype errors.
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Discussion
Although concordance of genotypes between colorectal tumor and adjacent normal mucosa 
has been studied by others, this is the first study in which the results of an extended set of 
genotypes were compared between peripheral blood DNA and archived FFPE tissue DNA 
from patients with metastatic CRC. The results of our study show that genotyping using 
material from FFPE tissue and EDTA–blood yields highly concordant results. Consequently, 
this implies that the findings from retrospective trials using archived FFPE tissue can be 
reliably compared with studies using peripheral blood leukocytes as the DNA source for a 
considerable number of SNPs.
Although for most SNPs no significant discordance between DNA derived from EDTA–
blood and FFPE tissue was found, a small discrepancy was found for GSTP1. This is of particular 
interest because of the possible role of GSTP1 in carcinogenesis. Knockdown experiments with 
a CRC cell line showed that GSTP1 function is essential for in vivo growth of xenografts27 and 
GSTP protein levels are frequently increased in colon cancer tissue.28 The enzyme is part of the 
JNK pathway and as such is involved in cell cycle regulation and apoptosis.29;30 The GSTP1 rs1695 
SNP leads to an amino acid substitution (Ile105Val) that lies within a JNK protein binding site, 
and may therefore have functional implications in carcinogenesis.31 Despite the high concordance 
rate between blood-derived and FFPE tissue-derived DNA, we cannot exclude the possibility that 
LOH occurs for this gene. Therefore, use of FFPE tissue from resection specimens for genotyping 
this SNP in pharmacogenetic association studies is possibly not advisable. Additionally, 
genotyping for TP53 failed in 23% of our FPPE tissue samples, thereby indicating that this SNP is 
also less suitable for genotyping in archived tumor tissue.
Only a few studies have compared genetic variations in malignant and normal tissues, 
and most did not include CRC patients. Marsh and coworkers compared genotypes of 
tumor and adjacent normal tissue in fresh-frozen tumor samples of 44 CRC patients for 28 
polymorphisms in 13 genes.32 Overall, 13 out of 1139 genotypes (1.1%) showed discordant 
results, similar to our findings. By contrast, Le Morvan and colleagues found considerable 
LOH in FFPE colorectal tumor samples for GSTP1 (five out of 25 samples) and ERCC2 (14 
out of 32 samples).16 These authors did not elaborate on the methods used for detecting LOH 
in their samples. A third study compared genotypes in EDTA–blood and FFPE rectal tumor 
samples for seven genes, including GSTP1, and found extensive discordance, with only 14 
out of 65 sample pairs showing no discrepancies.33 Explanations for these contrasting results 
include different rates of genotyping success and different tumor characteristics in colon and 
rectal tumors.
In a recent debate, the concordance between germline and tumor genotype has been 
questioned when using tumor samples in the determination of CYP2D6 genotype for breast 
cancer patients in large association studies of tamoxifen efficacy.34–37 Significant deviation 
from the Hardy–Weinberg equilibrium in tumor material was occasionally found for CYP2D6 
genotypes, possibly due to hemizygous chromosomal deletions. According to some authors, 
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this should preclude studies with pharmacodynamic end points using tumor material as a 
source of DNA.34
Indeed, LOH may explain discordance between genotype in DNA from EDTA–blood and 
FFPE tissue samples. However, in our study, we excluded LOH in ten out of 20 discordant cases, 
using heterozygous alleles in adjacent loci as a marker for chromosomal loss. This technique 
does not exclude hemizygous loss of very short chromosomal regions. Nevertheless, we believe 
that this is a valid method for evaluating the presence of LOH in our sample set, because LOH 
in colorectal carcinogenesis is thought to involve large stretches of chromosomal material in 
most cases.38 Minimal presence of LOH was also expected, since most of these SNPs have not 
been convincingly associated with colorectal carcinogenesis and therefore selection of somatic 
mutations in these genes is unlikely.
For cases in which LOH could not be excluded, copy number gain of one allele could also 
explain discordant results, as the strong signal from the amplified allele would obscure the 
signal from the other allele. However, copy number amplification for the selected genes is not a 
common event in colorectal carcinogenesis, and is therefore a less likely cause of discordance. 
Alternative explanations for discordance include patient mix-up, sample mix-up or repeated 
genotyping errors. Reanalyzing all discordant pairs reduced the chance that disagreements 
were induced by genotyping errors or sample mix-up, but does not rule out patient mix-up 
or technical problems in earlier stages of sample preparation. However, assuming that only 
one result in every discordant pair is incorrect, we observed a maximum error rate of 0.7% for 
all samples (20 out of 2836 assays). This is likely to reflect the actual practice in clinical trials, 
which, in our opinion, is an acceptable level of inaccuracy.
The almost complete concordance of genotypes between blood-derived and FFPE tissue-
derived DNA most likely reflects the actual absence of LOH in our tumor samples. However, our 
method may be hampered by the presence of stromal cells in our FFPE samples. In the presence 
of large amounts of non-cancerous stromal cells, FFPE tissue-derived genotypes may actually 
reflect germline genotypes, rather than tumor genotypes. Techniques for DNA extraction from 
FFPE tissues have been optimized in recent years and the use of microdissection instead of 
macrodissection would presumably have reduced the amount of stromal contamination in 
our samples. By contrast, most previously published articles have used macrodissection as the 
technique for DNA extraction.7–19 It was our aim to confirm that results from these studies 
can be reliably compared with those from studies using blood-derived DNA for genotyping. 
Whether the concordance when using macrodissection is a reflection of a large stromal 
component or of actual agreement between the germline and tumor genotype is therefore only 
of theoretical importance.
We showed excellent concordance for all studied genetic variations. Unfortunately, it is 
unknown whether this concordance can be extrapolated to other genes or genetic variations 
of interest, or other types of cancer. The current study does not account for other genetic 
variations, such as amplification, methylation and copy number variation, which could be 
pharmacogenetically relevant. Taking these limitations into consideration, our results show 
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that FFPE tissue-derived DNA can be used as a valid proxy for germline DNA in CRC when 
blood samples are not available. However, even with the expanding possibilities of DNA 
collection from archived material, we believe peripheral blood should be the preferential 
source of DNA for future prospective pharmacogenetic studies.
Future perspectives
The field of pharmacogenomics is rapidly evolving. Most oncological clinical trials now include 
pharmacogenetic side-studies, for which peripheral blood samples are routinely collected. 





1. Swen JJ, Huizinga TW, Gelderblom H et al. 
Translating pharmacogenomics: challenges on the 
road to the clinic. PLoS Med. 4(8), e209 (2007). 
2. Swen JJ, Wilting I, de Goede AL et al. 
Pharmacogenetics: from bench to byte. Clin. 
Pharmacol. Ther. 83(5), 781–787 (2008). 
3. Andrisin TE, Humma LM, Johnson JA. Collection 
of genomic DNA by the noninvasive mouthwash 
method for use in pharmacogenetic studies. 
Pharmacotherapy 22(8), 954–960 (2002). 
4. Casparie M, Tiebosch AT, Burger G et al. Pathology 
databanking and biobanking in The Netherlands, 
a central role for PALGA, the nationwide 
histopathology and cytopathology data network 
and archive. Cell. Oncol. 29(1), 19–24 (2007). 
5. Coura R, Prolla JC, Meurer L, Ashton-Prolla P. 
An alternative protocol for DNA extraction from 
formalin fixed and paraffin wax embedded tissue.  
J. Clin. Pathol. 58(8), 894–895 (2005). 
6. Santos MC, Saito CP, Line SR. Extraction of 
genomic DNA from paraffin-embedded tissue 
sections of human fetuses fixed and stored in 
formalin for long periods. Pathol. Res. Pract. 
204(9), 633–636 (2008). 
7. Afzal S, Jensen SA, Vainer B et al. MTHFR 
polymorphisms and 5-FU-based adjuvant 
chemotherapy in colorectal cancer. Ann. Oncol. 
20(10), 1660–1666 (2009). 
8. Afzal S, Gusella M, Jensen SA et al. The association 
of polymorphisms in 5-fluorouracil metabolism 
genes with outcome in adjuvant treatment of 
colorectal cancer. Pharmacogenomics 12(9), 1257–
1267 (2011). 
9. Braun MS, Richman SD, Thompson L et al. 
Association of molecular markers with toxicity 
outcomes in a randomized trial of chemotherapy 
for advanced colorectal cancer: the FOCUS trial. J. 
Clin. Oncol. 27(33), 5519–5528 (2009). 
10. Castillo-Fernandez O, Santibanez M, Bauza 
A et al. Methylenetetrahydrofolate reductase 
polymorphism (677 C>T) predicts long time to 
progression in metastatic colon cancer treated with 
5-fluorouracil and folinic acid. Arch. Med. Res. 
41(6), 430–435 (2010). 
11. Chua W, Goldstein D, Lee CK et al. Molecular 
markers of response and toxicity to FOLFOX 
chemotherapy in metastatic colorectal cancer. Br. J. 
Cancer 101(6), 998–1004 (2009). 
12. Etienne MC, Formento JL, Chazal M et al. 
Methylenetetrahydrofolate reductase gene 
polymorphisms and response to fluorouracil-based 
treatment in advanced colorectal cancer patients. 
Pharmacogenetics 14(12), 785–792 (2004). 
13. Fernandez-Peralta AM, Daimiel L, Nejda N, 
Iglesias D, Medina Arana V, Gonzalez-Aguilera JJ. 
Association of polymorphisms MTHFR C677T and 
A1298C with risk of colorectal cancer, genetic and 
epigenetic characteristic of tumors, and response to 
chemotherapy. Int. J. Colorectal Dis. 25(2), 141–151 
(2010). 
14. Garcia-Aguilar J, Chen Z, Smith DD et al. 
Identification of a biomarker profile associated with 
resistance to neoadjuvant chemoradiation therapy 
in rectal cancer. Ann. Surg. 254(3), 486–492 (2011). 
15. Gordon MA, Gil J, Lu B et al. Genomic profiling 
associated with recurrence in patients with 
rectal cancer treated with chemoradiation. 
Pharmacogenomics 7(1), 67–88 (2006). 
16. Le Morvan V, Smith D, Laurand A et al. 
Determination of ERCC2 Lys751Gln and GSTP1 
Ile105Val gene polymorphisms in colorectal cancer 
patients: relationships with treatment outcome. 
Pharmacogenomics 8(12), 1693–1703 (2007). 
17. Nobili S, Napoli C, Landini I et al. Identification 
of potential pharmacogenomic markers of clinical 
efficacy of 5-fluorouracil in colorectal cancer. Int. J. 
Cancer 128(8), 1935–1945 (2011). 
18. Panczyk M, Balcerczak E, Piaskowski S, Jamroziak 
K, Pasz-Walczak G, Mirowski M. ABCB1 gene 
polymorphisms and haplotype analysis in 
colorectal cancer. Int. J. Colorectal Dis. 24(8), 
895–905 (2009). 
19. Suh KW, Kim JH, Kim do Y, Kim YB, Lee C, Choi 
S. Which gene is a dominant predictor of response 
during FOLFOX chemotherapy for the treatment of 
metastatic colorectal cancer, the MTHFR or XRCC1 
gene? Ann. Surg. Oncol. 13(11), 1379–1385 (2006). 
20. Pander J, Gelderblom H, Guchelaar HJ. Insights 
into the role of heritable genetic variation in the 
pharmacokinetics and pharmacodynamics of 
anticancer drugs. Expert Opin. Pharmacother. 8(9), 
1197–1210 (2007).
21. Koopman M, Antonini NF, Douma J et al. 
Sequential versus combination chemotherapy 
with capecitabine, irinotecan, and oxaliplatin in 
advanced colorectal cancer (CAIRO):  
a Phase III randomised controlled trial. Lancet 
370(9582), 135–142 (2007). 
22. Salgado J, Zabalegui N, Gil C, Monreal I, 
Rodriguez J, Garcia-Foncillas J. Polymorphisms in 
the thymidylate synthase and dihydropyrimidine 
dehydrogenase genes predict response and toxicity 
to capecitabine– raltitrexed in colorectal cancer. 
Oncol. Rep. 17(2), 325–328 (2007). 
23. Cecchin E, Agostini M, Pucciarelli S et al. Tumor 
response is predicted by patient genetic profile in 
rectal cancer patients treated with neo-adjuvant 
chemo-radiotherapy. Pharmacogenomics J. 11(3), 
214–226 (2011). 
24. Cote JF, Kirzin S, Kramar A et al. UGT1A1 
polymorphism can predict hematologic toxicity in 
patients treated with irinotecan. Clin. Cancer Res. 
13(11), 3269–3275 (2007). 
25. de Jong FA, Marsh S, Mathijssen RH et al. 
ABCG2 pharmacogenetics: ethnic differences in 
allele frequency and assessment of influence on 
irinotecan disposition. Clin. Cancer Res. 10(17), 
5889–5894 (2004). 
Genotype concordance between peripheral blood and colorectal tumor tissue
49
26. Zheng HT, Peng ZH, Li S, He L. Loss of 
heterozygosity analyzed by single nucleotide 
polymorphism array in cancer. World J. 
Gastroenterol. 11(43), 6740–6744 (2005). 
27. Dang DT, Chen F, Kohli M, Rago C, Cummins JM, 
Dang LH. Glutathione S-transferase pi1 promotes 
tumorigenicity in HCT116 human colon cancer 
cells. Cancer Res. 65(20), 9485–9494 (2005).
28. Ranganathan S, Tew KD. Immunohistochemical 
localization of glutathione S-transferases alpha, 
mu, and pi in normal tissue and carcinomas from 
human colon. Carcinogenesis 12(12), 2383–2387 
(1991). 
29. Adler V, Yin Z, Fuchs SY et al. Regulation of JNK 
signaling by GSTp. EMBO J. 18(5), 1321–1334 
(1999). 
30. Sidler D, Brockmann A, Mueller J et al. Thiazolide-
induced apoptosis in colorectal cancer cells is 
mediated via the Jun kinase– Bim axis and reveals 
glutathione-S-transferase P1 as Achilles’ heel. 
Oncogene 31(37), 4095–4106 (2012). 
31. Adler V, Pincus MR. Effector peptides from 
glutathione-S-transferase-pi affect the activation of 
jun by jun-N-terminal kinase. Ann. Clin. Lab. Sci. 
34(1), 35–46 (2004). 
32. Marsh S, Mallon MA, Goodfellow P, McLeod 
HL. Concordance of pharmacogenetic markers 
in germline and colorectal tumor DNA. 
Pharmacogenomics 6(8), 873–877 (2005). 
33. Balboa E, Duran G, Lamas MJ et al. 
Pharmacogenetic analysis in neoadjuvant 
chemoradiation for rectal cancer: high incidence of 
somatic mutations and their relation with response. 
Pharmacogenomics 11(6), 747–761 (2010). 
34. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, 
Kroetz DL, Flockhart DA. Re: CYP2D6 genotype 
and tamoxifen response in postmenopausal women 
with endocrine-responsive breast cancer: the Breast 
International Group 1–98 trial. J. Natl Cancer Inst. 
104(16), 1264–1268 (2012).
35. Pharoah PD, Abraham J, Caldas C. Re: 
CYP2D6 genotype and tamoxifen response 
in postmenopausal women with endocrine-
responsive breast cancer: the Breast International 
Group 1–98 trial and Re: CYP2D6 and UGT2B7 
genotype and risk of recurrence in tamoxifen-
treated breast cancer patients. J. Natl Cancer Inst. 
104(16), 1263–1264 (2012). 
36. Regan MM, Leyland-Jones B, Bouzyk M et al. 
CYP2D6 genotype and tamoxifen response 
in postmenopausal women with endocrine-
responsive breast cancer: the Breast International 
Group 1–98 trial. J. Natl Cancer Inst. 104(6), 
441–451 (2012). 
37. Stanton V. Re: CYP2D6 genotype and tamoxifen 
response in postmenopausal women with 
endocrine-responsive breast cancer: the Breast 
International Group 1–98 trial. J. Natl Cancer Inst. 
104(16), 1265–1266 (2012). 
38. Thiagalingam S, Laken S, Willson JK et al. 
Mechanisms underlying losses of heterozygosity 
in human colorectal cancers. Proc. Natl Acad. Sci. 
USA 98(5), 2698–2702 (2001). 

4
MTHFR polymorphisms and 
capecitabine-induced toxicity 
in patients with metastatic 
colorectal cancer
Lieke H. van Huis-Tanja, Hans Gelderblom, 
Cornelis J.A. Punt, Henk-Jan Guchelaar




Objective: The availability of current chemotherapeutic options for metastatic colorectal cancer 
(mCRC) has increased survival, but it is also accompanied by considerable morbidity. Fluoro-
pyrimidines are the mainstay of systemic therapy. Germline pharmacogenetic markers involved in 
5-fluorouracil pharmacodynamics could provide individualized pretreatment tools for predicting 
toxicity. Research on methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and 
fluoro pyrimidine treatment outcome has focused on intravenous 5-fluorouracil and has yielded 
inconclusive results. The literature on pharmacogenetics in capecitabine-based chemotherapy is 
scarce. Therefore, we analyzed the association of MTHFR gene polymorphisms and the occurrence 
of serious toxicity of first-line capecitabine monotherapy and combination therapy.
Methods: One hundred and twenty-seven patients treated with first-line monotherapy capecitabine 
and 141 patients on capecitabine–irinotecan combination therapy were recruited from the 
CAIRO trial, an open-label phase III randomized trial, comparing sequential versus combination 
chemotherapy with capecitabine, irinotecan and oxaliplatin in mCRC. All patients were genotyped 
for MTHFR 1298A > C and 677C > T polymorphisms and analyzed in both cohorts separately for 
the association between the MTHFR genotype and incidence of grade 3–4 overall toxicity and 
specific adverse events, as well as efficacy parameters.
Results: MTHFR 1298A > C and 677C > T genotypes were not associated with grade 3–4 overall 
toxicity, febrile neutropenia or hand–foot syndrome. MTHFR 1298CC homozygotes showed a 
borderline significantly higher incidence of grade 3–4 diarrhea compared with MTHFR 1298AC or 
AA individuals (25 vs. 5%, P = 0.041) in the monotherapy cohort. No significant association was 
found between the MTHFR genotypes and efficacy parameters in either treatment cohort.
Conclusion: MTHFR polymorphisms are not associated with toxicity or efficacy in mCRC patients 
treated with capecitabine-based chemotherapy. 
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Introduction
In recent years, chemotherapeutic options for the treatment of metastatic colorectal cancer 
(mCRC) have expanded and have improved overall survival (OS) considerably.1;2 Fluoro-
pyrimidines, such as 5-fluorouracil (5-FU) and the oral pro-drug capecitabine, are still the 
mainstay of systemic treatment. However, despite the significant progress made with systemic 
therapy, the prognosis for mCRC remains relatively poor, with a median OS time of 19–22 
months after diagnosis.3;4 At the same time, chemotherapeutic regimens used in mCRC 
may result in toxicity, causing morbidity and occasionally even mortality, and frequently 
necessitating dose reductions. Unfortunately, predictors for adverse drug events in mCRC are 
scarce. In addition to clinical parameters, such as age and sex5, germline pharmacogenetic 
markers could provide pretreatment information on the risk of toxicity.6;7
Several pharmacogenetic studies examining genetic variants related to 5-FU therapy, such 
as methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase (TS), have been 
published, but without conclusive results. Although polymorphisms in the gene coding for 
dihydropyrimidine dehydrogenase, the main catabolic enzyme of 5-FU, are linked to increased 
toxicity, the low allele frequency of the most common polymorphism in this gene limits its 
clinical usefulness. In addition, the role of pharmacogenetic biomarkers in predicting the 
toxicity and efficacy of capecitabine is as yet largely unexplored.
Fluoropyrimidines act in two different ways.8 First, 5-FU is incorporated into RNA, 
precluding protein synthesis, the preferential mode of action for 5-FU bolus infusion. In 
addition, when administered as a continuous infusion, 5-FU binds to TS. This prevents the 
conversion of 2’-deoxyuridine-5’-monophosphate into 2’-deoxythymidine-5’-monophosphate, 
the latter of which is an essential precursor for DNA synthesis. In forming this ternary complex, 
5,10-methylenetetrahydrofolate (5,10-MTHF) is required as an essential cofactor. MTHFR 
catalyzes the irreversible conversion of 5,10-MTHF into 5-methyltetrahydrofolate, thereby 
reducing the amount of 5,10-MTHF available for binding to TS.
Although over 60 germline polymorphisms in the MTHFR gene have been described, only 
two have shown functional effects on enzyme activity.9 A non-synonymous single nucleotide 
polymorphism (SNP) at base pair 677 (C>T, Ala222Val) and a second SNP at base pair 1298 
(A>C, Glu428Ala) both reduce MTHFR enzyme activity.10;11
Functional polymorphisms have also been described for TS, including a variable 
number of tandem repeats (VNTR) polymorphism in the enhancer region (TSER) in the 
5’-untranslated region and an SNP G > C at bp12 of the second repeat of this VNTR.12;13 In 
addition, a polymorphic locus is found in the TS 3’-untranslated region, consisting of a 6 bp 
deletion at position 1494.12;14
It is hypothesized that by reducing enzyme activity, MTHFR polymorphisms enhance the 
stable formation of the TS/fluorodeoxyuridine monophosphate complex, thereby resulting 
in both greater effect and toxicity of fluoropyrimidines. Higher intratumoral TS-levels 
are considered to hinder cytotoxicity. These assumptions have been studied extensively for 
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intravenous 5-FU therapy, but with contradictory results.(Table 1) In both the adjuvant and 
the metastatic setting of CRC, capecitabine is often replacing 5-FU, both in monotherapy 
and in combination therapy. A schematic overview of the capecitabine pharmacodynamics 
is presented in Figure 1. To our knowledge, only one previous pharmacogenetic study of 
capecitabine monotherapy in mCRC patients has been published.16
Figure 1. Schematic overview of enzymes involved in the cellular response of capecitabine
5-FU: 5-fluoro-uracil; DHF: dihydrofolate; dTMP: deoxythymidine monophosphate; dUMP: deoxyuridine 
monophosphate; FdUMP: fluoro- deoxyuridine monophosphate; MTHF: methylene hydrofolate; MTHFR: 
methylene tetrahydrofolate reductase; TYMS: thymidylate synthase. Figure based on: Thorn C.F., et al.15 
Therefore, in this multicenter study, we aimed to determine the effect of the germline 
polymorphisms MTHFR 677C > T and MTHFR 1298A > C on the toxicity and efficacy profile 
of capecitabine in patients with mCRC who started first-line palliative chemotherapy. Patients 
treated with two frequently used treatment schedules were studied: a cohort of patients treated 
with capecitabine monotherapy and a second cohort of patients treated with a combination 
therapy of capecitabine and irinotecan. Genetic variants in the gene encoding for TS were 
included as covariates.
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In total, 127 patients who were treated with capecitabine monotherapy as the first-line 
treatment for mCRC were prospectively included in the study. In addition, a second cohort 
including 141 patients treated with first-line capecitabine–irinotecan combination therapy was 
studied. Patients were recruited from the CAIRO study, a multicenter open-label randomized 
phase III trial, comparing sequential versus combination chemotherapy with capecitabine, 
irinotecan and oxaliplatin in a total of 803 patients with mCRC.17
Patients with mCRC were enrolled in the CAIRO study between January 2003 and 
December 2004 by the Dutch Colorectal Cancer Group in 74 hospitals in the Netherlands. 
The study flowchart and number of patients available for analysis are shown in Figure 2. As 
this pharmacogenetic substudy was initiated later than the CAIRO clinical trial and not all 
study centers participated, the number of patients included in the pharmacogenetic analyses 
is limited to a total of 268 patients. The inclusion criteria were a WHO performance score of 
0–2 and adequate renal, hepatic and bone marrow function. A history of previous adjuvant 
chemotherapy was allowed only if the last administration was 6 months before randomization. 
The main exclusion criteria were as follows: serious concomitant disease preventing the safe 
administration of chemotherapy and other malignancies in the past 5 years. Capecitabine (1250 
mg/m2, twice daily) was administered on days 1–14 in the monotherapy group every 3 weeks. 
In the combination therapy group, capecitabine (1000 mg/m2, twice daily) was administered 
on days 1–14, and irinotecan (250 mg/m2) on day 1, in a 3-weekly cycle. Tumor response was 
assessed by computed tomography scan, every 9 weeks, using the response evaluation criteria 
for solid tumors (version 1.0). Toxicity during first-line therapy was assessed at each visit by 
determining the patient’s history, physical examination and hematology and biochemical 
laboratory tests. Toxic effects were classified following the US National Cancer Institute 
Common Toxicity Criteria, version 2.0. The CAIRO study protocol provided guidelines for 
dose modification in case of serious toxicity.
The study was approved both by the Central Committee on Research involving Human 
Subjects (CCMO) and by the local ethics committees of all participating centers. All patients 
included provided written informed consent before inclusion in the main study and the 
pharmacogenetic side study.
Genotyping data
Peripheral EDTA-blood samples were collected and stored at – 20°C before DNA isolation. 
Germline DNA was extracted with the Magnapure LC (Roche Diagnostics, Almere, the 
Netherlands) according to the manufacturer’s instructions. MTHFR rs1801133 (677C > T) 
and MTHFR rs1801131 (1298A > C) genotypes were determined with TaqMan 7500 (Applied 
Biosystems, Nieuwerkerk aan de Ijssel, the Netherlands) according to the manufacturer’s 
protocol using a predesigned assay. The call rate for the MTHFR genotypes was greater than 
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98%. Five per cent of samples were analyzed in duplicate, with 100% concordance. In addition, 
negative controls using water were included. To exclude confounding by other known pharma-
cogenetic determinants in 5-FU-based chemotherapy, we also assessed the TYMS genotype. 
The VNTR polymorphism in the TYMS 5’-untranslated region (TSER, rs34743033), including 
the additional G/C SNP in the second base pair for 3-repeat individuals (rs11540151), was 
determined by direct sequencing. The TYMS 1494del6bp polymorphism in the 3’-untranslated 
region (rs11280056) was determined with TaqMan 7500 (Applied Biosystems) according to 
the prescribed protocol. DPYD*2A (IVS14 + 1G > A) was not included because of low expected 
population allele frequency.
Data and statistical analysis
The primary endpoints of this study were overall toxicity (i.e. grade 3 or higher) on first-line 
therapy, and specific adverse events, including hand–foot syndrome (HFS), diarrhea and 
febrile neutropenia. Toxicity was assessed for all patients who started treatment. The secondary 
endpoints were progression-free survival (PFS), OS and response rate. PFS was calculated from 
the date of randomization until the first observation of disease progression or death from any 
cause. OS was calculated as the interval from randomization until death from any cause or 
until the date of last follow-up. Survival data have been updated since the publication of the 
original CAIRO trial. Best response was assessed in all patients who completed at least three 
cycles of treatment. Clinical benefit was defined as either a complete or a partial response, or 
stable disease.
Genotype distributions were tested for agreement with those expected under Hardy–
Weinberg equilibrium using the χ2-test. The association between genotype or diplotype and 
the presence of overall toxicity of at least grade 3, specific toxicity parameters of at least grade 
3 and clinical benefit were determined using a χ 2-test. Kaplan– Meier survival analysis and 
the log-rank test were used to test the relationship between genotype and OS/PFS. For TYMS 
polymorphisms, patients were further subdivided into three groups according to the expected 
level of TS expression: low (2R/2R or 2R/3RC or 3RC/3RC), intermediate (2R/3RG or 3RC/3RG) 
or high (3RG/3RG). MTHFR genotypes were grouped as follows: wild-type homozygote versus 
all other genotypes or variant-type homozygote versus all other genotypes. The association of 
genotype and OS or PFS was determined using the Mann–Whitney test. Fisher’s exact test was 
used to determine the effect of grouped genotype on toxicity and clinical benefit. Multivariate 
analysis was carried out with TYMS genotype and sex. Because of the linkage disequilibrium 
between both MTHFR genotypes, we did not carry out multivariate analyses including both 
polymorphisms as independent covariates, but rather carried out separate analyses for MTHFR 
1298A > C and 677C > T genotypes. On the basis of reports finding a difference in the effect 
of MTHFR genotype on 5-FU efficacy according to sex, subgroup analysis was carried out. 
Subgroup analysis was also carried out by subdividing patients according to previous adjuvant 
therapy. Patients with missing genotyping data were excluded from analysis. A two-sided 
significance level of P less than 0.01 was accepted for all analyses to compensate for multiple 
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The baseline characteristics of the studied patients are listed in Table 2. The median age at 
randomization for all patients was 61 years, ranging from 27 to 81 years. Patients were 









Age at randomization,  
median (range)
61 years (27-81) 61 years (27-78) 62 years (37-81)
Sex
Male 163 (62%) 77 (61%) 86 (62%)
Female 101 (38%) 49 (39%) 52 (38%)
Performance status
PS 0 152 (58%) 77 (61%) 75 (54%)
PS 1 96 (36%) 42 (33%) 54 (40%)
PS 2 16 (6%) 7 (6%) 9 (6%)
LDH at randomization
Normal 173 (66%) 82 (65%) 91 (66%)
>Upper limit of normal 91 (34%) 44 (35%) 47 (34%)
Site of primary tumor
Colon 146 (55%) 73 (58%) 73 (53%)
Rectosigmoid 96 (37%) 40 (32%) 56 (41%)
Rectum 20 (8%) 11 (9%) 9 (6%)
Multiple tumors 1 (<1%) 1 (<1%) 0
Unknown 1 (<1%) 1 (<1%) 0
Predominant localization  
of metastases
Liver 179 (68%) 83 (66%) 96 (70%)
Extra-hepatic 81 (31%) 39 (31%) 42 (30%)
Unknown 4 (1%) 4 (3%) 0
Previous adjuvant therapy
Yes 31 (12%) 13 (10%) 18 (13%)
No 233 (88%) 113 (90%) 120 (87%)
 
Table 2. Baseline characteristics. 
LDH, lactate dehydrogenase
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Genotype frequencies
Genotype frequencies are listed in Table 3. Genotyping for MTHFR polymorphisms was 
successful for 126 of the 127 (99%) patients in the capecitabine monotherapy group. For the 
MTHFR 677C > T locus, we found that 51 (41%) patients were homozygote wild type, 14 (11%) 
were homozygote variant type and 61 (48%) were heterozygote. For MTHFR 1298A > C, 58 
(46%) patients were homozygote wild type, 12 (10%) were homozygote variant type and 56 
(44%) patients were heterozygote.
Genotyping was successful for 138 of the 141 (98%) patients in the combination therapy 
group. For MTHFR 677C > T, in this group 55 (40%) patients were homozygote wild type, 
13 (9%) were homozygote variant type and 70 (51%) heterozygote. For MTHFR 1298A > C, 
57 (42%) patients were homozygote wild type, 13 (9%) were homozygote variant type and 68 
(49%) were heterozygote.
Allele frequencies for MTHFR 677C > T and for MTHFR 1298A > C in both groups were 
consistent with Hardy–Weinberg equilibrium (χ2-test: P > 0.05). Genotype frequencies are 
similar to those reported by other authors.18–20 No patients were found to be homozygous for 
both loci, consistent with the linkage disequilibrium between both polymorphisms described 
elsewhere.11
Genotyping for TYMS was successful for 112 (88%) patients in the monotherapy group 
and for 120 (85%) patients in the combination therapy group. In the capecitabine monotherapy 
group, TSER-genotype frequencies were 26 (23%) 2R2R, 31 (28%) 3R3R and 55 (49%) 2R/3R. 
A predicted low TS-expression genotype was present in 70 (62%) patients, an intermediate-
expression genotype in 33 (30%) and a high-expression genotype in nine (8%) patients (see 
the Methods section for definition of expression level in individual genotypes). For the TYMS 
1494del6bp genotype, 13 (12%) patients had the del/del genotype, 40 (36%) had the del/ins 
genotype and 59 (52%) had the ins/ins genotype.
In the combination therapy group, TSER genotypes were as follows: 28 (23%) 2R2R, 37 
(31%) 3R3R and 55 (46%) heterozygote. TS expression genotypes were predicted to be low in 
65 (54%) patients, intermediate in 46 (38%) and high in nine (8%) patients. The TYMS 1494 
del/del genotype was found in 11 (9%) patients; 57 (48%) patients were heterozygote and 52 
(43%) were ins/ins homozygote. The TSER genotype for patients in the monotherapy group 
was not consistent with the Hardy–Weinberg equilibrium (χ 2 = 12.2, P < 0.001). However, 
because no deviation from the equilibrium was found (χ 2-test: P > 0.05) in the total population 
and in the combination therapy group, it is likely that this inconsistency was derived by chance. 
All other genotype frequencies were as expected under the Hardy– Weinberg equilibrium.
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Genotype Total Capecitabine monotherapy CapIri combination therapy
N= 264 126 138
MTHFR 677C>T
677CC 106 (40%) 51 (41%) 55 (40%)
677CT 131 (50%) 61 (48%) 70 (51%)
677TT 27 (10%) 14 (11%) 13 (9%)
MTHFR 1298A>C
1298AA 115 (44%) 58 (46%) 57 (42%)
1298AC 124 (47%) 56 (44%) 68 (49%)
1298CC 25 (9%) 12 (10%) 13 (9%)
Diplotype
1298AA/677CC 26 (10%) 15 (12%) 11 (8%)
1298AA/677CT 64 (24%) 31 (25%) 33 (24%)
1298AA/677TT 25 (10%) 12 (10%) 13 (9%)
1298AC/677CC 57 (22%) 26 (21%) 31 (23%)
1298AC/677CT 65 (25%) 28 (22%) 37 (27%)
1298AC/677TT 2 (<1%) 2 (2%) 0
1298CC/677CC 23 (9%) 10 (8%) 13 (9%) 
1298CC/677CT 2 (<1%) 2 (2%) 0
1298CC/677TT 0 0 0
Table 3. MTHFR genotype and diplotype frequencies
 
Correlation between MTHFR and TYMS genotypes/ diplotypes and toxicity
The results for toxicity analyses are listed in Table 3. No correlation was found between genotype 
and overall toxicity of at least grade 3 for the MTHFR 677C > T genotype and 1298A>C 
in patients treated with capecitabine monotherapy. Grouping genotypes according to the 
presence or absence of variant alleles did not show any statistically significant association with 
the incidence of severe overall toxicity. Diplotype analysis was carried out grouping patients 
according to the number of variant alleles (gene score). This did not result in a significant 
association between any gene score and overall toxicity of at least grade 3 (P = 0.838).
In addition, we carried out association analyses for the MTHFR genotype and specific 
adverse events. No significant association was found for the MTHFR 1298A > C genotype, 
the MTHFR 677C > T genotype or the MTHFR diplotype and the incidence of HFS of at least 
grade 3 or febrile neutropenia of at least grade 3. However, a trend towards a higher incidence 
of diarrhea of at least grade 3 was observed for MTHFR 1298CC homozygotes (AA and AC vs. 
CC: 5 vs. 25%, P = 0.041). No episodes of febrile neutropenia of at least grade 3 were observed 
in the capecitabine monotherapy group.
Next, all analyses were repeated for patients in the combination treatment arm. No 
associations were found between MTHFR 677C > T and 1298A > C genotypes and severe 
overall toxicity. These results remained similar after grouping genotypes according to the 
presence or absence of variant alleles. In terms of the effect of MTHFR polymorphisms on 
specific adverse events, we found no association for diarrhea or febrile neutropenia. MTHFR 
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1298CC individuals experienced a significantly higher incidence of HFS in the combination 
therapy group (MTHFR 1298AA 7% vs. AC 5% vs. CC 31%, P = 0.006; 1298AA and AC vs. CC: 
6 vs. 31%, P = 0.011). No toxic deaths were observed in either treatment cohort.
The TSER genotype was found not to be associated with the incidence of overall toxicity 
of at least grade 3, diarrhea of at least grade 3 or febrile neutropenia of at least grade 3 in either 
treatment cohort (data not shown). However, a trend towards a protective effect of the TSER 2R 
allele on the incidence of HFS of at least grade 3 was found in the capecitabine monotherapy 
group (2R/2R 8% vs. 2R/3R 11% vs. 3R/3R 29%, P = 0.041; 2R2R and 2R/ 3R vs. 3R/3R: 10 vs. 
29%, P = 0.019). This association was not found in the combination therapy group (2R/2R and 
2R/3R vs. 3R/3R: 11 vs. 5%, P = 0.499). In both groups, no effect was found of the G > C SNP or 
the TYMS 1494 del6bp genotype on the incidence of overall or specific toxicity (data not shown).
TSER and TYMS 1494 del6bp genotypes were not associated with a difference in PFS or 
OS, and no significant interaction was found after combining TSER genotypes according to 
the expected level of TS expression on the basis of the G > C SNP. In addition, no association 
was found between clinical benefit and the TYMS 1494 del6bp or TSER (including G > C SNP) 
polymorphisms (data not shown). These results were found in both treatment groups. Only in 
the monotherapy group was there a non-significant trend towards a longer PFS for high TS-
expression (3RG/3RG) individuals (3RG/3RG vs. all other genotypes, 10.2 vs. 6.2 months, P = 
0.022), as well as for TYMS 1494del/del individuals (1494del/del vs. del/ins and ins/ins: 10.2 
vs. 6.1 months, P = 0.017).
Subgroup and multivariate analysis
Multivariate analyses including the MTHFR genotype, TYMS genotype and sex as covariates 
did not yield any significant results. No patients with the MTHFR 1298CC genotype in first-
line capecitabine monotherapy had received previous adjuvant chemotherapy. This is probably 
because of chance (χ2-test: P = 0.453). In either treatment group, very few MTHFR 677TT 
individuals had received previous chemotherapy. Therefore, multivariate analysis for the 
association of MTHFR genotype with efficacy and toxicity parameters according to previous 
adjuvant treatment could not be carried out.
Subdividing our population according to sex showed no significant association between 
the incidence of adverse events and any MTHFR genotype or diplotype (data not shown). Male 
patients with the MTHFR 1298AA genotype had slightly, but non-significant, shorter PFS than 




















Overall 37% 7% 16% 0%
MTHFR 677C>T
MTHFR 677CC 40% 12% 29% -
MTHFR 677CT 33% 5% 7% -
MTHFR 677TT 43% 0.649 0% 0.193 24% 0.018 - n.a.
MTHFR 677CC 40% 12% 24% -
MTHFR 677CT + 
677TT
35% 0.574 4% 0.154 11% 0.079 - n.a.
MTHFR 677CT + 
677CC
36% 8% 14% -
MTHFR 677TT 43% 0.770 0% 0.596 29% 0.237 - n.a.
MTHFR 1298A>C
MTHFR 1298AA 37% 7% 19% -
MTHFR 1298AC 34% 4% 11% -
MTHFR 1298CC 50% 0.578 25% 0.033 25% 0.309 - n.a.
MTHFR1298AA 37% 7% 19% -
MTHFR 1298AC + 
1298CC
37% 1.000 7% 1.000 13% 0.464 - n.a.
MTHFR 1298AC + 
1298AA
35% 5% 15% -
MTHFR1298CC 50% 0.355 25% 0.041 25% 0.406 - n.a.
MTHFR diplotype*
No variant alleles 43% 14% 36% -
One variant allele 33% 5% 12% -
Two variant alleles 38% 8% 14% -
Three variant alleles 50% 0.838 0% 0.630 25% 0.170 - n.a.
 
Table 4. MTHFR genotype and adverse events of first-line chemotherapy 
HFS, hand-foot syndrome
*No variant alleles, 1298AA/677CC; one variant allele, 1298AC/677CC or 1298AA/677CT; two variant alleles, 
1298CC/677CC or 1298AA/677TT or 1298AC/677CT; three variant alleles, 1298CC/677CT or 1298AC/67TT.





















Overall 50% 23% 8% 6%
MTHFR 677C>T
MTHFR 677CC 47% 22% 11% 4%
MTHFR 677CT 51% 27% 6% 7%
MTHFR 677TT 54% 0.862 8% 0.297 8% 0.581 8% 0.665
MTHFR 677CC 47% 22% 6% 4%
MTHFR 677CT + 
677TT
52% 0.728 24% 0.838 11% 0.348 7% 0.475
MTHFR 677CT + 
677CC
50% 25% 8% 6%
MTHFR 677TT 54% 1.000 8% 0.298 8% 1.000 8% 0.560
MTHFR 1298A>C
MTHFR 1298AA 54% 16% 7% 7%
MTHFR 1298AC 44% 29% 5% 6%
MTHFR 1298CC 62% 0.355 23% 0.199 31% 0.006 0% 0.621
MTHFR1298AA 54% 16% 7% 7%
MTHFR 1298AC + 
1298CC
47% 0.489 28% 0.103 9% 0.762 5% 0.719
MTHFR 1298AC + 
1298AA
49% 23% 6% 7%
MTHFR1298CC 62% 0.562 23% 1.000 31% 0.011 0% 1.000
MTHFR diplotype*
No variant alleles 36% 0% 9% 0%
One variant allele 53% 27% 5% 8%
Two variant alleles 49% 24% 11% 5%








PFS in months 
(95%CI)





Overall 6.3 (5.8-6.9) 19.5 (16.7-22.2) 85%
MTHFR 677C>T
MTHFR 677CC 6.6 (5.1-8.2) 19.5 (15.6-23.3) 90%
MTHFR 677CT 6.1 (5.1-7.1) 18.1 (12.8-23.4) 78%
MTHFR 677TT 6.6 (5.5-7.7) 0.148 24.0 (19.9-28.1) 0.857 100% 0.067
MTHFR 677CC 6.6 (5.1-8.2) 19.5 (15.6-23.3) 90%
MTHFR 677CT + 
677TT
6.1 (5.3-6.9) 0.190 19.5 (13.1-25.8) 0.609 82% 0.310
MTHFR 677CT + 
677CC
6.3 (5.7-6.8) 19.2 (16.3-22.0) 83%
MTHFR 677TT 6.6 (5.5-7.7) 0.807 24.0 (19.9-28.1) 0.270 100% 0.127
MTHFR 1298A>C
MTHFR 1298AA 6.1 (5.7-6.5) 19.4 (11.4-27.4) 93%
MTHFR 1298AC 6.9 (5.0-8.8) 19.8 (12.1-27.4) 78%
MTHFR 1298CC 6.5 (4.2-8.8) 0.610 18.7 (17.6-19.8) 0.534 83% 0.097
MTHFR1298AA 6.1 (5.7-6.5) 19.4 (11.4-27.4) 93%
MTHFR 1298AC + 
1298CC
6.7 (5.1-8.4) 0.582 19.5 (15.4-23.5) 0.957 79% 0.042
MTHFR 1298AC + 
1298AA
6.3 (5.8-6.8) 18.7 (17.6-19.8) 86%
MTHFR1298CC 6.5 (4.2-8.8) 0.904 19.5 (13.5-25.4) 0.758 83% 0.691
MTHFR diplotype*
No variant alleles 6.3 (5.8-6.8) 21.0 (13.5-28.6) 100%
One variant allele 6.7 (4.7-8.6) 19.4 (10.9-27.9) 87%
Two variant alleles 6.0 (4.5-7.5) 19.1 (17.2-21.1) 78%
Three variant alleles 8.3 (6.2-10.5) 0.470 21.4 (12.6-30.2) 0.942 100% 0.157
 
Table 5. MTHFR genotype and efficacy of first-line chemotherapy
 CI, confidence interval; OS, overall survival; PFS, progression-free survival.
*No variant alleles, 1298AA/677CC; one variant allele, 1298AC/677CC or 1298AA/677CT; two variant alleles, 
1298CC/677CC or 1298AA/677TT or 1298AC/677CT; three variant alleles, 1298CC/677CT or 1298AC/67TT.





PFS in months 
(95%CI)





Overall 8.3 (7.6-9.1) 20.0 (16.9-23.1) 93%
MTHFR 677C>T
MTHFR 677CC 9.2 (7.9-10.5) 19.8 (14.1-25.4) 94%
MTHFR 677CT 7.8 (6.6-8.9) 20.0 (16.0-24.0) 93%
MTHFR 677TT 6.3 (3.5-9.1) 0.047 23.1 (12.4-33.8) 0.923 92% 0.964
MTHFR 677CC 9.2 (7.9-10.5) 19.8 (14.1-25.4) 94%
MTHFR 677CT + 
677TT
7.8 (6.5-9.0) 0.052 20.5 (16.7-24.3) 0.888 93% 1.000
MTHFR 677CT + 
677CC
8.3 (7.5-9.1) 20.0 (16.6-23.4) 93%
MTHFR 677TT 6.3 (3.5-9.1) 0.625 23.1( 12.4-33.8) 0.994 92% 1.000
MTHFR 1298A>C
MTHFR 1298AA 7.1 (5.8-8.4) 17.9 (15.0-20.9) 94%
MTHFR 1298AC 8.8 (7.9-9.7) 22.3 (18.8-25.9) 92%
MTHFR 1298CC 9.4 (5.8-13.0) 0.107 22.4 (14.9-29.9) 0.529 90% 0.848
MTHFR1298AA 7.1 (5.8-8.4) 17.9 (15.0-20.9) 94%
MTHFR 1298AC + 
1298CC
9.0 (8.1-10.0) 0.033 22.4 (18.9-25.8) 0.148 92% 0.735
MTHFR 1298AC + 
1298AA
8.3 (7.7-8.9) 20.0 (16.6-23.4) 93%
MTHFR1298CC 9.4 (5.8-13.0) 0.425 22.4 (14.9-29.9) 0.916 90% 0.531
MTHFR diplotype*
No variant alleles 6.5 (5.7-7.3) 14.4 (6.9-21.9) 90%
One variant allele 8.4 (7.7-9.2) 19.8 (15.3-24.2) 97%
Two variant alleles 8.3 (7.1-9.6) 22.3 (18.9-25.8) 90%






The present study is the second and the largest to address MTHFR pharmacogenetics of 
capecitabine-based therapy in mCRC. No significant association was found between the 
MTHFR 677C > T or the 1298A > C genotype or diplotype and the incidence of severe 
chemotherapy-induced adverse events for either monotherapy or combination therapy with 
capecitabine. MTHFR 1298CC homozygotes showed a non-significant increase in grade 3–4 
diarrhea when treated with capecitabine monotherapy, in accordance with our hypothesis. No 
effect was found of these genotypes on clinical response or survival statistics in our populations.
Because of the prospective accrual of patients in the CAIRO study, there is homogeneity in 
the treatment protocol for all patients, thereby obviating the risk of confounding by dosage or 
mode of 5-FU administration. Publications to date, including many clinical trials3;18;19;21–39 and 
two recent meta-analyses40;41, could not show a convincing effect of MTHFR polymorphisms 
on fluoropyrimidine-induced toxicity or treatment benefit in mCRC. However, whereas all 
these studies have focused on intravenous 5-FU therapy, capecitabine is increasingly being 
incorporated into the first-line treatment for mCRC, making the existing literature on 5-FU 
pharmacogenetics less relevant. Although capecitabine has comparable efficacy to 5-FU as 
monotherapy or in combination therapy1, toxicity profiles differ. Capecitabine leads to a higher 
incidence of HFS than a 5-FU bolus injection.42 This side effect is also found more frequently in 
5-FU continuous infusion and suggests a difference in 5-FU pharmacodynamics depending on 
the mode of administration.5 As a result, polymorphisms involved in the folate pathway may 
have a different effect on efficacy and toxicity according to the treatment schedule and mode of 
administration, and pharmacogenetic studies with 5-FU cannot be extrapolated to capecitabine. 
Only one previous small clinical trial studying pharmacogenetics of capecitabine monotherapy 
in mCRC patients has been published.16 In this study, MTHFR 677TTand MTHFR 1298AA 
genotypes were associated with a lower incidence of grade 2–3 toxicity. Although the results for 
MTHFR 1298AA individuals confirm the hypothesis that MTHFR polymorphisms enhance 
capecitabine cytotoxicity, the results for MTHFR 677TT are contrary to what was expected. As 
there is no obvious pharmacological explanation for this incongruence, the results may have 
been affected by the small sample size. By choosing a stricter significance level, we reduced 
the risk of false-positive results because of multiple testing and found no association of the 
MTHFR genotype and capecitabine-induced adverse events. Furthermore, we focused only on 
the occurrence of severe toxicity (i.e. grade 3 or 4) because the goal of pretreatment testing is 
the prevention of serious adverse events. Indeed, an increase in grade 2 toxicity will not lead to 
pre-emptive dose reduction and therefore may not be considered clinically relevant. 
As capecitabine cytotoxicity is the result of many interdependent enzymatic reactions, not 
only including MTHFR but also TS, the effects of one aberrant enzyme may be obscured by those 
of another. Therefore, addressing only polymorphisms in one gene may be an oversimplification 
of reality and this was the motivation to also include genetic variants in TYMS and TSER. 
The importance of the variants is supported by two studies, showing that patients with TYMS 
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3R/3R and either the MTHFR 1298CC or the 677TT genotype had a higher response rate 
to 5-FU-based chemotherapy, and longer OS or time to progression.18;34 We univariately and 
multivariately evaluated the contributing effect of TYMS polymorphisms, without any effect 
on study outcome. We then identified the patients in our cohort carrying the TYMS 3R/3R 
genotype and a homozygote variant genotype for at least one of the MTHFR polymorphisms, 
in an attempt to replicate the two above-mentioned studies. In our population, however, only 
a few patients carried the TYMS 3R/3R-MTHFR 677TT or TYMS 3R/3R-MTHFR 1298CC 
genotype (five and four patients in the monotherapy group, respectively). Although we found 
no significant associations of these genotypes and the clinical outcome parameters, analyses 
are limited by the small number of affected patients (data not shown).
In early phase I trials, capecitabine was combined with oral leucovorin. This addition 
showed no effect on capecitabine pharmacokinetics, but appeared to reduce the maximum 
tolerable dose.43;44 Currently, capecitabine therapy is not combined with leucovorin, in contrast 
to intravenous 5-FU therapy and tegafur. It can be hypothesized that in case of high serum 
levels of active folate, either by diet or by administration of leucovorin, the effects of MTHFR 
polymorphisms are masked. Folate intake and serum folate levels differ according to the 
geographical location of the population.45;46 The folate levels in a Dutch population are on 
average lower than those for other European populations.45 Therefore, in our population, folate 
level does not seem to explain the lack of effect of MTHFR polymorphisms.
In many modern chemotherapy regimens, capecitabine is combined with other 
chemotherapeutic agents, such as irinotecan or oxaliplatin. In combination therapy, toxicity 
caused by one of the agents may lead to dose reduction, and this may affect the possible 
pharmacogenetic associations of the other drugs. Our study is unique in the fact that it 
studies MTHFR pharmacogenetics in both capecitabine monotherapy and combined therapy. 
In the combination therapy group, however, the results may have been biased by the known 
pharmacogenetic effects of UGT1A1. Indeed, in Caucasians, the incidence of diarrhea and 
specifically febrile neutropenia because of irinotecan have been shown to be influenced by 
UGT1A1*28 genotype.6;31 We found no significant association between MTHFR genotypes and 
the incidence of febrile neutropenia or diarrhea in the combination treatment cohort. Therefore, 
inclusion of the UGT1A1 genotype in multivariate analysis was not deemed contributory. To 
fully exclude an interference of the UGT1A1 genotype, we carried out toxicity analyses for 
all patients in the combination therapy cohort responding to the UGT1A1 homozygote wild-
type genotype. In this subgroup of 57 patients, we found a preventive effect of the MTHFR 
677TT genotype on the occurrence of severe diarrhea. None of eight patients with the MTHFR 
677TT genotype developed grade 3 or 4 diarrhea, versus 11 out of 49 patients with the MTHFR 
677CT or TT genotype (0 vs 22%, P = 0.009, data not shown). As no statistically significant 
effect was found in the monotherapy group, these results would suggest an effect of MTHFR 
677C > T on irinotecan toxicity, for which there is no obvious pharmacologic explanation. 
Furthermore, introducing additional subgroup analysis should lead to the acceptance of an 
even stricter significance level, thereby making the outcome statistically non-significant. 
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Therefore, we conclude that this remarkable result was because of multiple testing, rather than 
a pharmacogenetic effect.
In a recent study involving neoadjuvant chemoradiation treatment for rectal carcinoma, 
MTHFR polymorphisms were predictive of grade 3–4 diarrhea and mucositis in patients 
receiving 5-FU monotherapy, but not in patients receiving 5-FU in combination with 
irinotecan.20 However, because patients were prospectively assigned to either 5-FU 
monotherapy or 5-FU/irinotecan on the basis of the TYMS genotype, it cannot be excluded 
that the difference between the two groups was caused by the TYMS genotype, rather than the 
addition of irinotecan.
It has been proposed that the conflicting results of pharmacogenetic studies with 5-FU 
in mCRC are related to sex differences. Zhang et al.39 reported a better OS for the MTHFR 
1298AA genotype only for women in a heavily pre-treated cohort of mCRC patients. Another 
study found that MTHFR 1298AC heterozygote women had a shorter OS.47 However, a sex-
specific effect could not be confirmed by others.21;25–27;48 Our data show a slightly, albeit non-
significant, shorter PFS for male patients with the MTHFR 1298AA genotype. In our opinion, 
these conflicting data suggest that the difference between sexes may be the result of multiple 
testing in increasingly small groups.
Interestingly, epigenetic changes may act in concert with genetic variations. Cancer 
cell lines expressing the MTHFR 1298CC homozygous genotype show a higher number of 
methylated genes compared with heterozygotes or wild-type homozygotes.49 The MTHFR 
1298C allele was associated with a longer doubling time in cancer xenografts, with the shortest 
doubling time for 1298AA homozygotes, independent of 5-FU.50
Conversely, colorectal cancer cells and xenografts transfected with variant MTHFR 
677T showed an accelerated growth rate compared with non-transfected cells, but were also 
inhibited more effectively by 5-FU plus leucovorin.51 MTHFR polymorphisms may therefore 
be a prognostic, rather than a predictive marker. Indeed, Fernandez-Peralta et al.29 found that 
the MTHFR 1298C variant allele was associated with shorter OS in sporadic colorectal cancer 
patients, even in the absence of 5-FU-containing chemotherapy.
Although we studied a larger group of patients on capecitabine monotherapy than any 
previous study, our sample size remains relatively small. The small number of homozygote 
variant individuals in our population limits the statistical power of this study to detect small 
effects of pharmacogenetics on clinical outcome. However, if MTHFR genotypes were strongly 
associated with toxicity or efficacy parameters, these effects would have been found even in a 
relatively small cohort. Other polymorphisms have been described for MTHFR. It cannot be 
excluded that a full haplotype analysis, including all known MTHFR polymorphisms, would 
show an effect on fluoropyrimidine toxicity. However, as MTHFR 677C > T and MTHFR 
1298A > C are the polymorphisms showing functional importance, we believe that the chances 
of finding an effect on 5-FU or capecitabine toxicity are small. Therefore, we conclude that 
MTHFR 677C > T and 1298A > C polymorphisms are not related to the occurrence of severe 
toxicity (and efficacy) of capecitabine-based chemotherapy in mCRC.
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Background & aim: Pharmacogenetic studies continue to search for pretreatment predictors of 
chemotherapeutic efficacy and toxicity in metastatic colorectal cancer (mCRC). Both genome wide 
association (GWA) studies and candidate gene studies have yielded potential genetic markers for 
chemosensitivity. We conducted a clinical association study, validating the effect of specific genetic 
markers cited in recently published papers on the efficacy of the oral 5-FU pro-drug capecitabine.
Patients & methods: Germline DNA was collected for 268 mCRC patients from the CAIRO trial, 
a multicenter phase III trial, randomizing between combined or sequential first-line treatment with 
capecitabine, irinotecan and oxaliplatin. Genotyping was performed for eight single nucleotide 
polymorphisms (SNPs), using high resolution melting curves. Four SNPs are located in the MTRR 
gene, and another four SNPs showed significant association with 5-FU cytotoxicity in a recent in 
vitro GWA study. Primary endpoint was progression free survival (PFS); secondary endpoints were 
objective response and overall survival (OS).
Results: In patients receiving capecitabine monotherapy, rs4702484, located in ADCY2 and close 
to MTRR, was associated with slightly reduced PFS for homozygous wildtype patients (CC 6.2 
vs. CT 8.0 months, P = 0.018). For the other selected genetic markers, we found no association 
with PFS, OS or radiologic response upon treatment with capecitabine, either in the total study 
population, or the capecitabine monotherapy subgroup.
Conclusion: With the exception of rs4702484, we found no evidence of an effect on capecitabine 
chemosensitivity of any of the studied SNPs. More specifically, variants in MTRR are not likely 
associated with capecitabine efficacy.
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Background
Colorectal cancer is the third leading cause of cancer death worldwide.1 Survival is strongly 
dependent on disease stage.2 For patients presenting with distant irresectable metastases, 
systemic therapy is indicated with the objective of prolongation of survival and sometimes 
cure if downsizing permits secondary resection of metastases. Fluoropyrimidines, including 
the oral pro-drug capecitabine, remain the cornerstone of chemotherapeutic treatment, 
although treatment options have expanded and now include oxaliplatin and irinotecan, as 
well as the monoclonal vascular endothelial growth factor (VEGF) inhibitor bevacizumab 
and the endothelial growth factor receptor (EGFR) blockers panitimumab and cetuximab.3 
Despite the fact that systemic therapy significantly improves median survival, a substantial 
portion of patients do not benefit from this. Chemotherapy is sometimes accompanied by 
severe adverse events, which can delay or even abrogate further treatment. There is an urgent 
need to preemptively identify patients who will both tolerate and benefit from a specific 
chemotherapeutic schedule. Up until now, no germline molecular markers have been identified 
that may predict for the efficacy of chemotherapy.4 Pharmacogenetics may provide such a tool, 
by identifying genetic predictors for both efficacy and toxicity.5 
Up to now, most studies searching for pretreatment genetic markers in colorectal cancer 
have used a pathway-based approach. This has led to the identification of UGT1A1*28 as a 
risk factor for increased toxicity (specifically neutropenia) after treatment with irinotecan6, 
and DPYD*2A as a risk factor for severe and sometimes lethal toxicity in response to 
fluoropyrimidine therapy.7 However, this candidate gene approach is limited by our a priori 
knowledge of the genes involved in the pathway, and is therefore unable to identify novel 
markers in genes not previously associated with the drug under investigation. Recently, a 
genome wide association (GWA) study applying a hypothesis free approach was published, 
identifying single nucleotide polymorphisms (SNPs) with putative influence on cytotoxicity 
of capecitabine in human lymphoblastoid cell lines (LCL).8 The most significant marker was 
located near the gene encoding for 5-methyltetrahydrofolate-homocysteine methyltransferase 
reductase (methionine synthase reductase, MTRR). As part of the methionine-folate pathway, 
MTRR is involved in fluoropyrimidine cytotoxicity. (Figure 1) Furthermore, variation in this 
gene has been implicated in colorectal carcinogenesis.9 
The number of genes and polymorphisms that are being implicated as pretreatment 
biomarkers has expanded rapidly, necessitating validation of reported results.
In this study, we tested eight single nucleotide polymorphisms (SNPs), selected for their 
location within the MTRR-gene or their significance in the recent GWA paper by O’Donnell 
and co-workers8, for their association with progression free survival (PFS) in a clinical trial 
population of 268 metastatic colorectal cancer (mCRC) patients who were treated with first-
line capecitabine-based chemotherapy. 
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Figure 1. Schematic overview of pathways involved in cellular response of fluoropyrimidines
5-FU, 5-fluoro-uracil; DHF, dihydrofolate; dTMP, deoxythymidine monophosphate; dUMP, deoxyuridine 
monophosphate; FdUMP, fluoro-deoxyuridine monophosphate; MTHF, methylene tetrahydrofolate; MTHFR, 
methylene tetrahydrofolate reductase; MTR, methionine synthase; MTRR, methionine synthase reductase; 
SAH, S-adenosyl homocysteine; SAM S-adenosyl methionine; THF, tetrahydrofolate. Figure based on: M. 
Whirl-Carrillo, et al.31 
Patients and methods
Clinical association study
Patients were recruited from the CAIRO trial, a multicenter open label randomized phase 
III clinical trial, comparing sequential versus combination chemotherapy with capecitabine, 
irinotecan, and oxaliplatin in a total of 803 mCRC patients.10 A total of 268 patients were included 
in this pharmacogenetic study, of whom 127 received first-line capecitabine monotherapy, and 
141 patients received first-line capecitabine plus irinotecan combination therapy. Patients with 
mCRC were enrolled in the CAIRO study between January 2003 and December 2004, by the 
Dutch Colorectal Cancer Group (DCCG) in 74 hospitals in The Netherlands. Inclusion criteria 
were a WHO performance score of 0-2 and adequate renal, hepatic and bone marrow function. 
A history of previous adjuvant chemotherapy was allowed, only if the last administration was 
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given six months prior to randomization. Main exclusion criteria were: serious concomitant 
disease preventing the safe administration of chemotherapy and other malignancies in the past 
five years. Capecitabine (1250 mg/m2, bid) was administered on day 1-14 in the monotherapy 
group, every three weeks. In the combination therapy group, capecitabine (1000 mg/m2, bid) 
was given on day 1-14, and irinotecan (250 mg/m2) on day 1, in a three weekly cycle. Tumor 
response was assessed by computed tomography (CT)-scan, every nine weeks, using Response 
Evaluation Criteria for Solid Tumors (RECIST, version 1.0). 
The CAIRO study was approved both by the Central Committee on Research involving 
Human Subjects (CCMO) and by the local ethics committees of all participating centers. 
As sample collection for this pharmacogenetic substudy was initiated later than the CAIRO 
clinical trial and not all study centers participated, the number of patients included in the 
pharmacogenetic analyses is limited to 268 patients. All included patients gave written 
informed consent before inclusion for the main study and the pharmacogenetic side study.
SNP selection and genotyping
Four SNPs were selected from the results of a recently published in vitro GWA study8 (rs4702484, 
rs8101143, rs576523 and rs11722476), based on their genome-wide significance levels in 
meta-analysis. A fifth SNP (rs361433) showed near genome-wide significance in this study. 
Unfortunately, no primers could be designed for this marker and it was therefore not included 
in our analyses. The GWA study suggested involvement of MTRR in capecitabine cytotoxicity. 
Although the MTRR gene has been suggested to be involved in colorectal carcinogenesis11, 
current knowledge on the effect of MTRR polymorphisms on efficacy of fluoropyrimidine 
treatment in colorectal carcinoma is limited to one publication. In that study, no association 
of MTRR genotype with PFS was found.12 To further investigate the predictive effect of MTRR 
polymorphisms in colorectal cancer treatment, four additional SNPs were selected based on 
their location in the this gene and citation in recent pharmacogenetic papers (rs1801394, 
rs10380, rs162036 and rs1532268). Variants in MTHFR (rs1801133 and rs1801131) and 
TYMS (rs34743033, rs11540151 and rs11280056) were also included as covariates, because an 
effect on capecitabine efficacy has been suggested for these polymorphisms.11;13;14 DPYD*2A 
(IVS14+1G>A) was not included as a covariate in the model, because of the low estimated 
population frequency (minor allele frequency 0.00316). Furthermore, it was previously shown 
that individual SNPs in DPYD, including DPYD*2A, did not influence treatment efficacy in 
our patient group.7
Peripheral EDTA-blood samples were collected and stored at -20°C before DNA isolation. 
Germline DNA was extracted with the Magnapure LC (Roche Diagnostics, Almere, The 
Netherlands) according to manufacturer’s instructions. 
A short amplicon high resolution melting (HRM) assay was designed for each SNP and 
genotype allocations were confirmed by conventional Sanger sequencing. Genotype calls were 
made using the Call-IT 2.0 software. Oligonucleotide sequences and annealing temperatures 
are available on request. As quality control, all HRM assays were validated on a panel of DNA 
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from 18 healthy individuals. In addition, negative controls (water) were included in each 
run. Samples failing initial genotyping were repeated and in this run samples with confirmed 
genotypes were included as positive controls. By repeating HRM and sequencing samples, more 
than 5% of samples were genotyped in duplicate. MTHFR rs1801133 (677C>T) and MTHFR 
rs1801131 (1298 A>C) genotypes were determined using commercially available Taqman 
genotyping assays and analyzed on 7500 realtime PCR system (Lifetechnologies, Bleiswijk, 
The Netherlands) according to manufacturer’s protocol. The VNTR polymorphism in the 
TYMS 5’-untranslated region (TSER, rs34743033), including the additional G/C SNP in the 
second base pair for 3-repeat individuals (rs11540151), was determined by direct sequencing. 
The TYMS 1494del6bp polymorphism in the 3’-untranslated region (rs11280056) was also 
determined using a pre-designed Taqman genotyping assay.
Data and statistical analysis
The primary endpoint of this study was progression free survival (PFS), which was calculated 
from the date of randomization until the first observation of disease progression or death from 
any cause. Secondary endpoints were overall survival (OS), objective response and clinical 
benefit. OS was calculated as the interval from randomization until death from any cause or until 
the date of last follow-up. Response to chemotherapy was assessed in all patients who completed 
at least 3 cycles of treatment. Objective response was determined as either complete or partial 
response. Clinical benefit was determined as stable disease, complete or partial response.
We chose not to include analyses for SNP effects on treatment toxicity. In vitro experiments, 
such as performed by O’Donnell and co-workers8, are useful in examining cytotoxic effects of 
chemotherapeutic drugs, but do not take into account the multitude of patient-related factors 
that influence adverse events in clinical practice. We therefore believe that these in vitro results 
cannot be extrapolated to predict fluoropyrimidine-induced toxicity. 
Differences in PFS and OS according to genotype were determined by Kaplan-Meier 
survival curves and log-rank testing. Multiple regression analysis was performed assessing the 
effect of genotype on PFS and OS by Cox regression analysis, treating gender, age, treatment 
arm and LDH at baseline as covariates. Variants in MTHFR (rs1801133 and rs1801131) and 
TYMS (rs34743033, rs11540151 and rs11280056) were also included as covariates, because 
these polymorphisms have been associated with efficacy of fluoropyrimidine therapy by 
others.11;13;14 Although we previously showed that these SNPs did not affect treatment efficacy 
in our patient group15, they were nonetheless included to minimize bias. Data are expressed 
as medians and 95 percent confidence intervals (95% CI). Additionally, the ten percent of all 
patients showing the longest PFS times and the ten percent of patients showing the shortest 
PFS times were selected and genotype distributions were compared between these groups by 
the Chi-squared test. The association of objective response and clinical benefit with genotypes 
was determined by cross tabulation and the Chi-squared test. All analyses were performed 
for the treatment population as a whole and for patients in the capecitabine monotherapy 
group separately. Conservative Bonferroni-correction for multiple testing would lead to the 
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adoption of a significance level of α = 0.05/8 = 0·00625, if all genetic markers are assumed to be 
unrelated. Earlier research has shown that there is a moderate amount of linkage disequilibrium 
between MTRR polymorphisms11, and these SNPs are therefore not completely independent. 
We confirmed the presence of linkage disequilibrium between these polymorphisms in our 
population, using Haploview. (Figure 2A and B) A more lenient correction was therefore 
adopted, with a significance level of α = 0.05/5 = 0·01. 
Genotype distributions were tested for agreement with those expected under Hardy-
Weinberg equilibrium using the Chi-squared test, with a statistical cut-off value of χ2 ≥ 3.84. 
All statistical analyses were performed using SPSS software, version 20.0 (IBM Corp., 




Figure 2. Linkage disequilibrium analyses for polymorphisms located in the gene encoding  
for 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR)
A. Numbers in squares represent D’ values between the respective SNPs. D’ for rs10380 and rs162036, as well as 













Age at randomisation, 
median (range)
62 (27-81) 61 (27-78) 62 (37-81)
Sex 0.90
Male 161 (61%) 76 (60%) 85 (61%)
Female 104 (39%) 50 (40%) 54 (39%)
Performance status 0.57
PS 0 153 (58%) 77 (61%) 76 (55%)
PS 1 96 (36%) 42 (33%) 54 (39%)
PS 2 16 (6%) 7 (6%) 9 (6%)
LDH at randomisation 0.89
Normal 174 (66%) 82 (65%) 92 (66%)
>Upper limit of normal 91 (34%) 44 (35%) 47 (34%)
Previous adjuvant therapy 0.70
Yes 235 (89%) 113 (90%) 122 (88%)
No 30 (11%) 13 (10%) 17 (12%)
Table 1. Baseline characteristics
LDH, Lactate dehydrogenase




Baseline characteristics are shown in Table 1. Baseline characteristics were not significantly 
different between both treatment groups. The majority of patients (61%) were male and median 
age at randomization was 62 years (range 27-81 years). Baseline characteristics were evaluated 
for their relationship with SNP-genotypes, and no associations were found (data not shown). 
Genotyping data
Genotyping was successful for all SNPs in 248 of 268 patients (93%). Three samples failed 
genotyping for three or more SNPs, and these were excluded from the statistical analysis. For 
individual SNPs, genotyping results ranged from 96% for rs1081394 to 100% for rs1532268. 
Genotype frequencies are shown in Table 2. Genotype distributions were consistent with 
Hardy Weinberg equilibrium (HWE), except for rs11722476 (c2 = 4.38) and rs4702484 (c2 = 
4.86). However, allele frequencies are consistent with those reported by others16 and HWE 
would have been met in both cases with the addition of even one homozygous variant-type 
sample.
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rs576523 1q23.3 159012700 intergenic A>G 0.01 / 0.07 98.9 – 1.1 – 0 
rs11722476 4q22.3 95389862 SMARCAD1 G>A 0.40 / 0.45 33.0 – 54.2 – 12.9
rs4702484 5p15.31 7702860 ADCY2 C>T 0.12 / 0.15 76.1 – 23.9 – 0 
rs1801394 5p15.31 7923973 MTRR G>A 0.42 / 0.38 34.8 – 46.8 – 18.4
rs1532268 5p15.31 7931179 MTRR G>A 0.38 / 0.26 37.7 – 48.0 – 14.3 
rs162036 5p15.31 7938959 MTRR A>G 0.14 / 0.23 74.8 – 21.8 – 3.4 
rs10380 5p15.31 7950191 MTRR C>T 0.09 / 0.19 81.7 – 18.3 – 0 
rs8101143 19p12 21747976 intergenic A>G 0.29 / 0.18 51.5 – 38.6 – 9.9
 
Table 2. Genotype frequencies
ADCY2, adenylate cyclase type 2; MAF, minor allele frequency; MTRR, 5-methyltetrahydrofolate-homocysteine 
methyltransferase reductase; SMARCAD1, SWI/SNF-related, matrix-associated actin-dependent regulator of 
chromatin, subfamily A, containing DEAD/H box 1; SNP, single nucleotide polymorphism.
* Observed minor allele frequencies in our population. Expected minor allele frequencies, based on those 
reported in: Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for 
Biotechnology Information, National Library of Medicine.(dbSNP Build ID: 36.3). http://www.ncbi.nlm.nih.
gov/SNP/.
# Genotype frequencies are displayed as percentages homozygous wildtype – heterozygous – homozygous 
variant type.
Association with capecitabine efficacy
Association with PFS
Updated PFS data were available for all but three patients. Updated OS data were available for 
243 patients. In the remaining cases censored data were used for the analyses. Results for the 
association analyses are shown in Table 3. 
Considering the total study population, we found no difference in PFS according to genotype 
for any of the SNPs. Also, when comparing genotypes between patients with the longest and 
those with the shortest PFS times, no significant differences in genotype distributions were 
found for any of the SNPs (P = 0.183 for rs1801394, to P = 1.000 for rs576523, data not shown). 
For rs4702484, PFS for homozygous wildtype patients was 7.5 months (95% CI: 6.4-8.5 
months), versus 7.8 months (95% CI: 5.9-9.6 months) for heterozygous patients (P = 0.351), 
with no patients carrying the rs4702484 homozygous variant genotype. However, when 
patients in the capecitabine monotherapy group were considered separately, a borderline 
significant effect of rs4702484 genotype was seen. (Table 4 and Figure 3A) PFS for patients 
with the homozygous wildtype genotype was 6.2 months (95% CI: 5.6-6.7), versus 8.0 months 
(95% CI: 6.2-9.8) for heterozygous patients (P univariate = 0.018). This result did not remain 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































None of the genetic markers showed interaction with OS in our data set. OS for rs4702484 was 
19.5 months for homozygote wildtype (95% CI: 17.1-21.8 months) and 19.8 months (95% CI: 
14.0-25.5 months) for heterozygotes (P = 0.759) in the total study population; and 19.2 (95% 
CI: 11.9-27.0) versus 22.1 months (95% CI: 15.6-28.6) for the capecitabine monotherapy group 
(P univariate = 0.457, P multivariate = 0.096; Figure 3B).
When the capecitabine monotherapy group was evaluated separately, results for PFS and 
OS remained similar.(Table 4)
Association with radiologic response
Regarding radiologic response to capecitabine, no association with genotype was found for any 
of the selected SNPs. No effect of genotype was present, whether objective response was used 
as the outcome measure, or clinical benefit.(Table 3) 
A trend toward significant results was found for the association with clinical benefit of 
rs1533268 (GG vs. GA vs. AA: 84% vs. 91% vs. 97%; P = 0.054) and of rs162036 (AA vs. AG 
vs. GG: 91% vs. 85% vs. 67%; P = 0.039). When both treatment arms were evaluated separately, 
results remained statistically significant for patients receiving capecitabine-irinotecan 
combination treatment (rs1533268: GG vs. GA vs. AA: 85% vs. 97% vs. 100%; P = 0.023; and 
rs162036: AA vs. AG vs. GG: 96% vs. 85% vs. 50%; P = 0.001, data not shown), but not for 
patients receiving capecitabine monotherapy (rs1533268: GG vs. GA vs. AA: 82% vs. 86% vs. 
93%; P = 0.612; and rs162036: AA vs. AG vs. GG: 86% vs. 85% vs. 80%; P = 0.943).
Figure 3. Kaplan-Meijer survival curves for patients receiving capecitabine first-line 
monotherapy, according to genotype for rs4702484
A. Progression free survival; B. Overall survival.
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Discussion
We designed this clinical pharmacogenetic association study to validate if a specific selection of 
SNPs implicated in recent pharmacogenetic papers was associated with efficacy of capecitabine 
in a large cohort of mCRC patients, treated with first-line capecitabine-based chemotherapy. 
The genetic markers were carefully chosen based on reports from previous studies.8;11 In our 
evaluation of eight selected SNPs, we found a small, borderline significant effect of rs4702484 
on PFS in a subgroup of patients treated with capecitabine monotherapy. However, none of the 
other genetic variants showed significant association with capecitabine efficacy, neither in the 
total study population, nor in patients receiving capecitabine monotherapy. 
Rs4702484, located intronic in the gene encoding for adenylate cyclase type 2 (ADCY2) 
and 200kbp upstream of MTRR, was first implicated in capecitabine chemosensitivity in a 
recent GWA report by O’Donnell and co-workers.8 Consistent with their results, we found 
PFS for patients carrying the rs4702484 heterozygous genotype was marginally better than 
for patients carrying the homozygous wildtype genotype, but only if they were treated with 
capecitabine monotherapy. As this did not translate, however, into a statistically significant 
overall survival benefit, the clinical implications of these findings remain uncertain. 
Despite the positive result for rs4702484, we could not confirm an effect on capecitabine 
chemosensitivity for the other SNPs from the GWA study in our patient population. Replication 
of GWA results is subject to statistical difficulty. Genome wide studies tend to overestimate 
the effect of the associated SNPs and these extreme results will be closer to the average when 
replicated in a second measurement.17 To replicate these inflated results, large population sizes 
are necessary. Our patient sample is relatively small and lack of power may explain our inability 
to replicate the results found by O’Donnell et al.8 For most SNPs, however, median values and 
confidence intervals are almost identical between genotype groups, without a trend towards an 
effect for the genetic markers. We therefore believe that increasing population size would not 
have led to substantially different results. 
Furthermore, although the use of cell lines allows for analyses that would be unethical 
or infeasible in humans, it has certain disadvantages. Many pharmacokinetic influences, both 
genetic and non-genetic, are excluded. To partly circumvent this problem, the capecitabine 
metabolite 5’-deoxy-5-fluorouridine (5’DFUR) was used for the cited in vitro GWA study.8 
Although the impact of genetic variation in carboxylesterase (CES) and cytidine deaminase 
(CDD), both involved in the conversion of capecitabine to 5’DFUR in vivo, is still unclear18;19, 
this may also partly explain the lack of replication in our patient group. In addition, tissue 
specific and tumor specific characteristics are eliminated when non-malignant cell lines, such 
as LCLs, are used. 
We also studied four SNPs within MTRR. This gene has been implicated in the development 
of colorectal cancer11 and is located in proximity to rs4720484. In our population of mCRC 
patients, the selection of four MTRR polymorphisms was not associated with capecitabine 
efficacy, which is consistent with results of another study showing no relation to efficacy of 
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adjuvant treatment with 5-FU in colorectal cancer patients.20 Although a trend towards a 
significant effect was found for the association of rs1532268 and rs162036 with clinical benefit 
of capecitabine in combination therapy, this is probably due to statistical error associated with 
the small number of patients carrying the minor allele and with bias induced by multiple 
testing. Furthermore, since the effect is only present in patients treated with capecitabine-
irinotecan combination therapy, this would imply an effect of this SNP on irinotecan, rather 
than capecitabine efficacy.
In designing this study, we hypothesized that MTRR could be important in capecitabine 
efficacy for two reasons. Firstly, MTRR as part of the folate pathway is involved in 
fluoropyrimidine pharmacodynamics (see also Figure 1). However, the relationship of 
fluoropyrimidine sensitivity to genetic variation in other components of this pathway, such 
as methylene tetrahydrofolate reductase (MTHFR), has not been confirmed12;15;21, making an 
effect of MTRR genetic variation questionable. Secondly, polymorphisms in MTRR have been 
associated with colorectal carcinogenesis and as such may also influence disease prognosis. 
Whereas some authors described that cancer susceptibility genes show prognostic or predictive 
value in colorectal cancer patients22;23, most studies found no correlation between these genes 
and survival of colorectal cancer patients, whether they were treated with chemotherapy24 
or not.25;26 Furthermore, although two MTRR variants (MTRR A66G, rs1801394; and MTRR 
C1793T, rs10380) were associated with increased colorectal cancer risk in a case control 
study11, these results were not replicated consistently in meta-analyses.9;27 Based on these 
considerations, we believe our results should be seen as evidence that variation in MTRR is not 
essential in capecitabine chemosensitivity. 
Genetic effects on drug metabolism have been recognized for decades.28 Nevertheless, in 
today’s practice, only few genetic markers have been integrated in algorithms for therapeutic 
control. The Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association 
has provided pharmacogenetics-based therapeutic recommendations for 53 drugs, related to 
eleven genes.29;30 Before implementation into clinical practice, extensive validation of genetic 
markers in varied patient groups is warranted. Validation studies like the present contribute to 
the conscientious transfer of basic research results into clinical practice. Although we believe 
the selected markers are not useful as pretreatment biomarkers of capecitabine efficacy in 
colorectal cancer, we cannot exclude an effect of some of these SNPs in other types of cancer 
and with other 5-FU derivatives. Further research therefore remains necessary.
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Effects of genetic variation 
in organic cation transporters (OCT) 
on oxaliplatin-induced neurotoxicity
Lieke van Huis-Tanja, Tahar van der Straaten, Hans Gelderblom, 




Background: Although the addition of oxaliplatin to fluoropyrimidine treatment leads to increased 
progression free survival in metastatic colorectal cancer (mCRC), its use is hampered by the 
frequent occurrence of peripheral sensory neuropathy. Based on pre-clinical studies, it has been 
assumed that organic cation transports (OCTs) are involved in the neurotoxic effects of oxaliplatin. 
We hypothesized that polymorphisms in the genes encoding for OCT1 and OCT2, as well as for 
the human multidrug and compound extrusion protein 1 (hMATE1), influence the incidence and 
severity of oxaliplatin-induced neurotoxicity.
Methods: Patients with mCRC were recruited from the CAIRO2 study, a multicenter trial 
randomizing between first-line treatment with capecitabine-oxaliplatin-bevacizumab (CAPOX-B) 
versus CAPOX-B plus cetuximab. Patients were divided into three phenotype groups, dependent on 
the extent of neurotoxicity. A total of nine SNPs in SLC22A1, SLC22A2 and SLC47A1, encoding for 
OCT1, OCT2 and hMATE1, respectively, were selected based on literature search. Genotyping was 
performed on germline DNA, derived from EDTA-blood samples collected at baseline.
Results: 419 patients who completed at least 4 cycles of oxaliplatin and had available clinical and 
genotyping data were included in the analyses. We found SLC22A1 Arg61Cys univariately and 
multivariately associated with neurotoxicity phenotype, with a protective effect for homozygote 
variant genotype carriers. None of the other selected markers showed an association with 
neurotoxicity in our patient group. 
Conclusion: SLC22A1 Arg61Cys is a potential predictive marker for decreased risk of oxaliplatin-
induced neurotoxicity in mCRC patients. This marker may select a group of patients capable of 
tolerating a higher dose of oxaliplatin, or with a lower risk of neurotoxicity at standard dose.
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Introduction
First-line treatment for metastatic colorectal cancer (mCRC) often consists of a fluoropyri-
midine and oxaliplatin, combined with bevacizumab. In the adjuvant setting, oxaliplatin 
was introduced for the combination with 5-FU, after publication of the MOSAIC-trial.1 
Oxaliplatin was shown to have synergistic effects when combined with 5-FU2, and its 
addition to fluoropyrimidine-therapy in standard first-line treatment of mCRC has resulted 
in an improvement of progression free survival.3 However, treatment is hampered by the 
development of peripheral sensory neuropathy, which can persist for months to years after the 
last dose of oxaliplatin or even throughout life.4 This can have a substantial effect on quality 
of life with persistent handicaps, including pain and loss of sensory or motor nerve function. 
Phase I studies of oxaliplatin showed that neurotoxicity is the main dose-limiting side effect.5 
Many strategies have been applied in an attempt to reduce its incidence, including altered 
infusion schedules6, administration of carbamazepine7, and calcium/magnesium infusions.8 
However, chronic neurotoxicity remains an important cause of dose-modifications and 
treatment discontinuation in patients treated with oxaliplatin. 
In current practice, it cannot be reliably predicted which patients will experience severe 
neuropathic side-effects. Clinical patient characteristics have been associated with increased 
neurotoxicity, such as anemia, hypoalbuminemia and alcohol consumption.9 The interpatient 
variation may also be explained by differences in metabolism, cellular uptake and excretion of 
oxaliplatin, or by a different effect on neuronal cellular components. Genetic variants in genes 
encoding for oxaliplatin metabolizing enzymes (such as GSTP110;11 and AGXT12), for membrane 
efflux proteins (such as ABCC212) and for voltage-gated sodium channels (such as SCN4A and 
SCN10A13) have been evaluated for their effect on oxaliplatin-induced neurotoxicity, with 
varying results. 
Organic cation transporters type 1 and 2 (OCT 1 and OCT2, respectively) are involved in 
the cellular uptake of platinum-compounds. OCT1/OCT2 negative cells show impaired uptake 
of oxaliplatin, as well as increased cell survival upon incubation with oxaliplatin, compared 
to OCT transfected cells.14 Pre-clinical studies showed that the accumulation of platinum is 
higher in dorsal root ganglia than most other tissues.15;16 OCTs have been detected in dorsal 
root ganglia, and are therefore potential determinants of oxaliplatin-induced neurotoxicity.17 
In addition, the human multidrug and compound extrusion protein 1 (hMATE1) appears to 
play a functional role in cellular uptake of oxaliplatin.18 
Genetic variation in the genes encoding for these cellular transporters may interfere with 
oxaliplatin uptake, and therefore influence its cytotoxic effects. Multiple single nucleotide 
polymorphisms (SNPs) have been described for each of these genes. In this clinical association 
study, we evaluated the effect of SNPs in the genes encoding for OCT1 (SLC22A1), OCT2 
(SLC22A2) and hMATE1 (SLC47A1) on the incidence and severity of oxaliplatin-induced 




Patients for this clinical association study were recruited from the CAIRO2 trial19, a multicenter 
phase III trial of the Dutch Colorectal Cancer Group (DCCG), which randomized between 
first-line treatment for mCRC with capecitabine-oxaliplatin-bevacizumab (CAPOX-B) versus 
CAPOX-B plus cetuximab. Patients were enrolled between June 2005 and December 2006 in 
79 hospitals across the Netherlands. All patients received capecitabine 1000mg/m2 b.i.d. orally 
on days 1-14 in a three weekly cycle. Oxaliplatin 130mg/m2 was administered intravenously 
on day 1 of each treatment cycle, with a maximum of 6 treatment cycles. Bevacizumab 7.5mg/
m2 was administered intravenously on day 1 of each cycle. For patients randomized to the 
CAPOX-B plus cetuximab group, cetuximab was administered intravenously at a loading 
dose of 400mg/m2 on the first treatment day, followed by 250mg/m2 once weekly thereafter. 
Treatment was continued until disease progression, unacceptable toxicity or death, whichever 
occurred first. 
Patient eligibility criteria and guidelines for response assessment in the CAIRO2 trial 
have been described in detail elsewhere.19 The trial protocol provided guidelines for dose-
modifications in case of serious toxicity. In case of persistent paresthesia, temporary painful 
paresthesia or functional impairment, a 25% dose reduction of oxaliplatin was ordered. If 
painful paresthesia or functional impairment persisted for more than two weeks, oxaliplatin 
was omitted until recovery and was then initiated again at a reduced dose of 50% of the initial 
dose. If despite 50% dose reduction neurotoxicity recurred, patients went off-study. In case of 
dose reduction, dose delay, or discontinuation of treatment, the reason for the adjustment was 
noted in the patient file.
All included patients gave written informed consent before inclusion for the main study 
and the pharmacogenetic side study. 
SNP selection and genotyping
A Pubmed literature search was performed to find relevant citations of SNPs in SLC22A1, 
SLC22A2, and SLC47A1. Keywords used were: (oxaliplatin, or platinum); (“organic cation 
transporter”, or OCT; OCT1, or SLC22A1); (OCT2, or SLC22A2); (MATE1, or hMATE1, or 
“multidrug and toxin extrusion”, or SLC47A1); (pharmacogenetics, or pharmacogenomics, or 
polymorphism, or SNP, or mutation).
SNPs with a minimum of three citations in Pubmed, of which at least one had to report 
on functional effects, were evaluated for selection. This criterion was adopted to limit the SNP 
selection to established markers. Only polymorphisms with a minor allele frequency (MAF) 
in Caucasians of 0.04 or higher were considered for inclusion. This led to the selection of four 
SNPs in SLC22A1 (rs34059508, rs12208357, rs35167514, rs628031), two SNPs in SLC22A2 
(rs316019, rs145405955), and one SNP in SLC47A1 (rs2289669). 
In addition, three SNPs in SLC47A1 (rs77630697, rs76645859, rs35395280) were selected. 
Although these SNPs did not fulfill the pre-set criteria, they were nonetheless included, because 
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they were specifically reported to influence cellular oxaliplatin uptake in a recent report.18 
Peripheral EDTA-blood samples were collected at baseline and germline DNA was 
extracted with the Magnapure LC (Roche Diagnostics, Almere, The Netherlands) according 
to manufacturer’s instructions. An Open Array technique (Lifetechnologies) was applied 
for genotyping of all SNPs, using predesigned assays for rs34059508 (SLC22A1 Gly465Arg), 
rs12208357 (SLC22A1 Arg61Cys), rs628031 (SLC22A1 Met408Val), rs316019 (SLC22A2 
Ala270Ser), rs2289669 (SLC47A1intronic), and rs3595280 (SLC47A1 Cys497Phe). Custom 
assays were designed for the genotyping of rs145450955 (SLC22A2 Thr201Met), rs76645859 
(SLC47A1 Val480Met), rs77630697 (SLC47A1 Gly64Asp). Unfortunately, no assay could 
be designed for rs35167514 (SLC22A1 Met420del) for this technique, and this marker was 
therefore not included in the analyses. Negative controls (water), as well as positive controls 
with known genotypes were included in all runs. For further quality control, a proportion of 
the samples was analysed in duplicate. Because of technical difficulties, more samples were 
re-analysed than initially planned. In total, 280 analyses were performed in duplicate, with no 
inconsistencies. Samples in which five or more SNPs failed to genotype were excluded from 
the analyses. 
Statistical analyses
Toxicity was assessed at each visit by taking the patients history, physical examination, and 
hematology and biochemical laboratory tests. Toxic effects were classified following the US 
National Cancer Institute Common Toxicity Criteria (CTC), version 2.0. Neurotoxicity was 
scored based on patient report only. 
Symptoms of neurotoxicity were only included if developed during the first 6 courses of 
chemotherapy (i.e. during administration of oxaliplatin). For statistical reasons, the extent of 
neuropathic symptoms was categorized in three distinct phenotype groups: no neurotoxicity 
(patients who did not experience peripheral sensory neuropathy during any of the first 6 
treatment cycles), severe neurotoxicity (patients who either experienced grade 3 neuropathy, 
or who had oxaliplatin dose reduction or treatment discontinuation because of neuropathy) 
and intermediate phenotype (all other patients). The development of oxaliplatin-induced 
neurotoxicity is thought to be dependent on cumulative dosage.20 Therefore, patients with early 
treatment discontinuation (i.e. during the first three cycles), whether due to adverse events, 
disease progression or other factors, were excluded from the analyses. 
Association of genotype with neurotoxicity phenotype group was then assessed by 
crosstabulation and the Chi-squared test. An additive effect of variant alleles was assumed. 
A significance threshold of P<0.05 was adopted for this exploratory study. Multivariate 
linear regression analysis was performed for the association of genotype with neurotoxicity 
phenotype, including cumulative dose of oxaliplatin per square meter, treatment arm and age 
at inclusion as covariates.
Genotype distributions were tested for agreement with those expected under Hardy-
Weinberg equilibrium (HWE) using the Chi-squared test, with a threshold of P<0.05. Because 
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the selection of patients who completed a minimum of four cycles of oxaliplatin may have 
inadvertently led to the selection of patients with a specific genotype, adherence to HWE was 
calculated in the total population of patients for whom genotyping was successful for at least 
half of the SNPs. 




In the CAIRO2 study, in total 755 patients were randomized between first-line treatment with 
CAPOX-B or CAPOX-B with cetuximab. Four hundred and nineteen patients who completed 
a minimum of four cycles of oxaliplatin and had successful genotyping for at least five of the 
selected SNPs were included in the analyses.(Figure 1)
Baseline characteristics for the included patients are shown in Table 1. Distributions 
across baseline characteristics were similar for the patients included in the pharmacogenetics 






61.3 (27.6-83.6) 62 (27-84)
Gender 
Male 249 (59.4%) 59.5%
Female 170 (40.6%) 40.5%
Treatment arm
CAPOX-B 214 (51.1%) 50.0%
CAPOX-B plus C 205 (48.9%) 50.0%
LDH at baseline
Normal 234 (55.8%) 56.7%
Above ULN 185 (44.2%) 43.3%
PFS
0 263 (62.8%) 62.5%
1 150 (35.8) 37.5%
unknown 6 (1.4%)
Prior chemotherapy
No 361 (86.2%) 84.9%
Yes 58 (13.8%) 15.1%
 
Table 1. Baseline characteristics
CAPOX-B, capecitabine, oxaliplatin and bevacizumab; CAPOX-B plus C, capecitabine, oxaliplatin and 
bevacizumab plus cetuximab; LDH lactate dehydrogenase; PFS, performance score; PGx, pharmacogenetics; 
ULN, upper limit of normal.
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Figure 1. Schematic presentation of patient numbers included in pharmacogenetic analyses 
Association of clinical parameters with neurotoxicity
Patients included in the pharmacogenetic analyses were separated into three phenotype 
groups, as described in the methods section. We found 47 (11.2%) patients experienced no 
neurotoxicity during the first six courses of chemotherapy, 66 (15.8%) patients had severe 
neurotoxicity, and the remaining 306 (73.0%) patients had an intermediate phenotype. 
Cumulative doses of oxaliplatin, expressed as milligrams per square meter of body surface 
area (BSA) were calculated for all included patients and rounded to the nearest ten. Mean 
cumulative doses of oxaliplatin were significantly lower for patients with severe neurotoxicity 
(688 mg/m2, 95% confidence interval [95% CI] 644-691mg/m2), than for patients without 
neurotoxicity (727 mg/m2, 95% CI 701-754mg/m2), and for those with the intermediate 
phenotype (739 mg/m2, 95% CI 730-749mg/m2) (Kruskal-Wallis test, P = 0.000). Consistent 
with these results, a significantly higher number of patients with the severe neurotoxicity 
phenotype had a dose reduction of oxaliplatin in any cycle (50/66, 92%), compared to patients 
with either no neurotoxicity (6/47, 13%) or the intermediate phenotype (54/306, 18%) (Chi-
square test, P = 0.000). However, there were no differences between the phenotype groups 
in the administered number of cycles of oxaliplatin per patient, or in delays in oxaliplatin-
administration (data not shown). 
Patients with severe neurotoxicity had a slightly higher mean age (63.8 years, 95% CI 61.5-
66.1 years), than patients without neurotoxicity (60.7 years, 95% CI 57.9-63.4 years) or those 
with the intermediate phenotype (61.0 years, 95% CI 60.0-62.1 years), but the difference was 
non-significant (one way ANOVA, P = 0.088). The extent of neurotoxicity was not associated 
with patient gender (P = 0.255), LDH at baseline (P = 0.322), WHO performance score (P = 
0.709) or prior adjuvant chemotherapy (P = 0.724).
There was an overrepresentation of patients treated with CAPOX-B plus cetuximab in the 
“no neurotoxicity” phenotype group. In other words, patients who were treated with CAPOX-B 
alone had a slightly higher chance of at least intermediate phenotype neurotoxicity, compared 




Genotyping was successful for all nine polymorphisms in 274 of the 419 included patients 
(65.4%). Call rates for individual polymorphisms varied from 77.1% (323/419 patients) for 
SLC47A1 Cys497Phe to 99.3% (416/419 patients) for SLC47A1 Gly46Asp.
Genotype distributions followed Hardy-Weinberg equilibrium for all selected SNPs, accept 
for SLC22A1 Arg61Cys (χ2 = 9.77) and SLC22A1 Met408Val (χ2 = 6.08), but allele frequencies 
are consistent with those reported in literature.21 Four of the selected SNPs were monoallelic in 
our population (SLC22A2 Thr201Met, SLC47A1 Val480Met, SLC47A1 Gly64Asp, and SLC47A1 
Cys497Phe). Genotype distributions for all patients in whom genotyping was successful and 
for those included in the pharmacogenetic analyses are described in Table 2. 
Association of genotype with neurotoxicity
Polymorphic SNPs (SLC22A1 Gly465Arg, SLC22A1 Arg61Cys, SLC22A1 Met408Val, SLC22A2 
Ala270Ser, and SLC47A1 non-coding) were univariately assessed for their association with 
neurotoxicity phenotype. Results for these analyses are shown in Table 3.
SLC22A1 Arg61Cys (rs12208357) showed a statistically significant association with 
neurotoxicity phenotype. None of the patients carrying the homozygote variant genotype 
experienced severe neurotoxicity, compared to 8.5% of heterozygote patients and 17.8% of 
patients carrying the homozygote wildtype genotype (P = 0.011). 
The association of genotype with neurotoxicity phenotype was then explored in 
multivariate analysis, treating age, treatment arm and cumulative oxaliplatin dose per BSA as 
covariates. The association of SLC22A1 Arg61Cys genotype with the extent of neurotoxicity 
was preserved in multivariate analysis (P multivariate = 0.015). This effect was also seen when 
patients who discontinued oxaliplatin treatment during the first 3 courses were included in the 
analysis (P = 0.045, data not shown). None of the other polymorphisms were associated with 
neurotoxicity phenotype in univariate or multivariate analysis.
 
SNP number Variation Call rate Total population* PGx analyses 
population*
N = 556 N = 419
SLC22A1 Gly465Arg rs34059508 1393G>A 94.5% 0.97-0.03-0.00 0.96-0.04-0.00
SLC22A1 Arg61Cys rs12208357 181C>T 85.2% 0.85-0.13-0.02 0.85-0.13-0.02
SLC22A1 Met408Val rs628031 1222G>A 85.4% 0.35-0.44-0.21 0.35-0.43-0.22
SLC22A2 Ala270Ser rs316019 808C>A 87.8% 0.80-0.18-0.02 0.80-0.18-0.02
SLC22A2 Thr201Met rs145450955 602C>T 98.3% 1.00-0.00-0.00 1.00-0.00-0.00
SLC47A1 non-coding rs2289669 G>A 96.4% 0.33-0.51-0.16 0.34-0.50-0.16
SLC47A1 Gly64Asp rs77630697 191G>A 99.3% 1.00-0.00-0.00 1.00-0.00-0.00
SLC47A1 Val480Met rs76645859 1438G>A 99.0% 1.00-0.00-0.00 1.00-0.00-0.00
SLC47A1 Cys497Phe rs35395280 1490G>C 77.1% 1.00-0.00-0.00 1.00-0.00-0.00
 
Table 2. Genotype distributions
SNP, Single nucleotide polymorphism; PGx, pharmacogenetics.
* Genotype distributions are shown as: homozygote wildtype – heterozygote – homozygote variant type.













SLC22A1 Gly465Arg GG 11.0% 73.0% 16.0%
0.365 0.627
 GA 21.4% 57.1% 21.4%
SLC22A1 Arg61Cys CC 9.5% 72.8% 17.8%
0.011 0.015 CT 12.8% 78.7% 8.5%
 TT 50.0% 50.0% 0.0%
SLC22A1 Met408Val GG 9.7% 77.4% 12.9%
0.728 0.331 GA 9.0% 75.0% 16.0%
 AA 11.5% 69.2% 19.2%
SLC22A2 Ala270Ser CC 12.2% 72.1% 15.6%
0.280 0.321 CA 3.0% 80.6% 16.4%
 AA 14.3% 71.4% 14.3%
SLC47A1 intron GG 12.6% 70.4% 17.0%
0.843 0.851 GA 10.3% 73.4% 16.3%
 AA 10.6% 77.3% 12.1%
Table 3. Univariate analyses for the association of genotype with extent of oxaliplatin-induced 
neurotoxicity
Discussion
Organic cation transporters are proposed determinants of oxaliplatin-induced neurotoxicity. 
We investigated the effect of germline genetic variation in genes encoding for OCT1 (SLC22A1), 
OCT2 (SLC22A2), and hMATE1 (SLC47A1) on the incidence and severity of neurotoxicity in 
419 mCRC patients treated with oxaliplatin-containing chemotherapy. We found that SLC22A1 
Arg61Cys was significantly associated with the extent of oxaliplatin-induced peripheral 
sensory neuropathy, with a protective effect for carriers of the homozygote variant genotype. 
None of the other selected polymorphisms showed an association with neurotoxicity in our 
study population.
To our knowledge, this is the first study to address the effect of polymorphisms in these 
genes on oxaliplatin-induced neurotoxicity. Pharmacogenetic research so far has led to the 
identification of other potential predictors for neurotoxicity. Polymorphisms in the gene 
encoding for the metabolic enzyme alanine glyoxylate transferase (AGXT)12, as well as variation 
in SCN4A and SCN10A, encoding for voltage gated sodium channels13, have been associated 
with the incidence of oxaliplatin-induced neuropathy. Earlier, germline genetic variation in 
the detoxifying enzyme glutathione S-transferase π1 (GSTP1), was identified as a possible 
predictor of neurotoxicity caused by oxaliplatin22, but this result could not be replicated by our 
own studygroup.10 Additionally, a genome wide association study in Korean colorectal cancer 
patients identified five SNPs that were not previously associated with oxaliplatin-induced 
neurotoxicity.23 However, all of these results have not been sufficiently validated, and cannot be 
incorporated into clinical practice at present.
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Based on the assumptions that peripheral neuropathy is an important complication of 
oxaliplatin-treatment5;20, that platinum-uptake is increased in dorsal root ganglia15;16, and that 
OCT2 is present as a transporter in dorsal root ganglia17, we proposed that the influence of 
OCT-function on oxaliplatin-induced neurotoxicity should be further evaluated. Indeed, 
OCT1 and -2, as well as hMATE1, are involved in transportation of oxaliplatin into cells 
expressing these transporters24, and OCT-transfected cells are over 20 times more sensitive 
to oxaliplatin than empty-vector cells.14 Likewise, cells completely lacking hMATE1 are more 
chemoresistent to oxaliplatin than hMATE1 positive cells.18 Noteworthy, colorectal cancer cells 
express a high level of organic cation transporter type 3 (OCT3)25, but not OCT217, which may 
explain the lack of correlation between anti-cancer effect and the development of neuropathy 
on oxaliplatin-based chemotherapy. 
In vivo experiments showed that, after a single administration of oxaliplatin, OCT1/2 
positive mice experienced increased sensitivity to cold and mechanical stimulation, compared 
to OCT1/2 knock-out mice17. Concurrent administration of cimetidine, a known competitive 
inhibitor of OCT1 and -214, resulted in complete protection from cold-sensitivity in OCT1/2 
positive mice.17 These preclinical results confirm the relationship between OCT1/2 function 
and oxaliplatin-induced neuropathy.
A multitude of germline genetic polymorphisms have been described for OCT1, 
OCT2 and hMATE1, and selected variants have shown functional effects on compound 
transport.26-29 We hypothesized that functional polymorphisms in SLC22A1, SLC22A2 and 
SLC47A1 are associated with the incidence and severity of oxaliplatin-induced neurotoxicity. 
Indeed, SLC22A1 Arg61Cys is a missense variant located in exon 1, on the first large loop of 
the protein, and the residue change results in reduced mRNA expression and loss of OCT 
protein function.21;30-36 Our results, showing a protective effect of the Cys/Cys homozygote 
variant genotype on neuropathic complaints after oxaliplatin-administration, are in line with 
the aforementioned data. This SNP may therefore be a predictive marker for a decreased risk 
of oxaliplatin-induced neurotoxicity. Since neurotoxicity is the main dose-limiting event in 
oxaliplatin-treatment, patients carrying the protective genotype may actually be able to endure 
a higher dose of oxaliplatin than determined in phase I trials.
Despite this promising result, our study is subject to several difficulties, both in clinical 
and technical aspects. Oxaliplatin-induced neurotoxicity appears in two distinct forms: acute 
and chronic neuropathy. Acute neuropathy occurs in the vast majority of patients, during 
hours or days after infusion of oxaliplatin.12 It is characterized by dysesthesias and paresthesias 
in the oropharyngeal region and extremities, which are induced or aggravated by cold.37 These 
sensory symptoms are presumably caused by neuromyotonic discharges, consistent with 
peripheral nerve hyperexcitability.7 In contrast, chronic neurotoxicity develops in the course 
of treatment. It was originally thought to occur in less than a quarter of patients12, and only 
after a cumulative dosage of 500mg/m2 oxaliplatin.20 However, newer studies have shown 
that almost 85 percent of patients treated with oxaliplatin experience some degree of chronic 
neurotoxicity.38 This phenomenon is caused by progressive loss of sensory fibers, thereby 
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inducing sensory axonal neuropathy.39 There appears to be a correlation between the amount 
of acute neuropathic symptoms and the severity of chronic oxaliplatin-induced neuropathy.40 
Different scoring systems are used for assessing the intensity of oxaliplatin-induced neuropathy. 
Most studies use the National Cancer Institute-Common Toxicity Criteria (NCI-CTC). An 
oxaliplatin-specific scale has been described by Levi et al41, which takes into account the 
duration of symptoms, as well as the intensity. In our patient population, no distinction was 
made between acute and chronic neuropathy. 
As described above, it is suggested that there is a difference in the etiology of chronic 
versus acute oxaliplatin-induced neurotoxicity.7;39 Pre-clinical studies so far have only shown 
an effect of OCT2 on acute neurotoxicity in mice.17 No data are available for OCT effects on 
chronic oxaliplatin-induced neurotoxicity. Our results may therefore have been clouded by the 
inclusion of patients in whom neurotoxic symptoms, whether acute or chronic, were mediated 
by systems other than OCT.
Another clinical pitfall is our lack of complete information on other determinants of 
neurotoxicity, such as alcohol consumption or co-medication. For instance, uptake efficacy of 
hMATE1 is influenced by many other drugs, such as omeprazole and antibiotics.42 Interestingly, 
its transport capacity may also be inhibited by irinotecan.43 If any of the co-administered 
medications impair oxaliplatin uptake by OCT1, OCT2 or hMATE1, they may have lowered 
the incidence of neurotoxicity in patients taking these drugs independent of the investigated 
genotypes, thereby obscuring our results. 
Technical difficulties may also weaken the validity of our results. Genotyping failed for 
five or more SNPs in 60 patients, almost 10% of our population. Even after elimination of 
these samples, genotyping was successful for all markers in less than half of the patients. The 
exclusion of samples based on missing genotypes may have induced bias in our analyses. We 
also excluded patients who completed only 1 to 3 cycles of oxaliplatin. However, baseline-
characteristics in the selected population are similar to those for the total CAIRO2 population 
(Table 1), and allele frequencies are comparable between the selected population and all 
genotyped patients.(Table 2) We therefore believe this clinical selection did not confound the 
analyses. 
We found that four out of nine SNPs were monoallelic in our population. Frequency data 
on these SNPs in all ethnicities are scarce and minor allele frequencies may differ between 
populations.21 In addition, SLC22A1 Arg61Cys is not in strong linkage disequilibrium with 
the other selected SNPs in Caucasians, but a haplotype block including this SNP and SLC22A1 
Met408Val was identified in Asian subjects.26;44 It is therefore not certain that results for 
SLC22A1 Arg61Cys can be extrapolated to other populations, or that this is the best predicting 
SNP in the chromosomal region.
Although the evidence supporting our hypothesis seems solid, there are some incon-
sistencies. Whereas one study found both OCT1 and OCT2 are involved in cellular uptake 
and cytotoxicity of oxaliplatin14, others found that OCT2, but not OCT1 was essential for 
oxaliplatin transport into the cell.17;24;45 Furthermore, contrasting results have been published 
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for the effect of the selected polymorphisms on OCT function. Whereas some studies report 
on the cellular uptake of different substances46-48, others have used more elaborate endpoints, 
such as drug efficacy or renal clearance.49-53 This may in part explain the contradicting results.
In conclusion, in our population of mCRC patients treated with CAPOX-B either with or 
without cetuximab, a SNP in the gene encoding for OCT1 (SLC22A1 Arg61Cys) associated 
with the absence of severe oxaliplatin-induced neurotoxicity. This result needs to be validated 
in independent patient cohorts. In these validation studies, neurotoxicity should be assessed by 
an oxaliplatin-specific scale, or physical diagnostic tests, to better grade the extent of sensory 
neuropathy and to distinguish acute from chronic neurotoxicity. Because of the potential 
interaction with other drugs, treatment regimen should ideally be uniform across all patients 
and co-medication meticulously monitored. 
Because peripheral sensory neuropathy is the main dose-limiting toxicity in oxaliplatin-
based chemotherapy, this SNP may select a group of patients capable of tolerating a higher than 
average dose of oxaliplatin, perhaps leading to an increment in treatment efficacy. 
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Aims: ERCC1 is involved in the repair of oxaliplatin-induced DNA damage. Studies for the 
association of the C118T SNP with clinical response to treatment with platinum drugs have 
rendered inconsistent results. We investigated the ERCC1 C118T SNP with respect to overall and 
progression-free survival in patients with advanced colorectal cancer (ACC) treated with oxaliplatin 
and in vitro DNA repair capacity after oxaliplatin exposure. In addition we discuss discrepancies 
from other studies concerning ERCC1 C118T.
Materials & methods: Progression-free survival was determined in 145 ACC patients treated 
with oxaliplatin-based chemotherapy in a phase 3 trial. For the in vitro studies regarding ERCC1 
functionality, we transfected an ERCC1 negative cell line with 118C or 118T ERCC1. Cellular sensi-
tivity and DNA repair capacity after exposure to oxaliplatin was examined by Sulphorodamine B 
growth inhibition assay, COMET assay and Rad51 foci staining.
Results: We found no association between ERCC1 C118T and progression-free or overall survival. 
In addition, transfection of either 118C or 118T restores DNA-repair capacity of UV20 cells to the 
same level and chemosensitivity to oxaliplatin was similar in ERCC1 118C and 118T transfected 
cells.
Conclusion: This study shows that the ERCC1 C118T variants are not associated with survival in 
ACC patients treated with oxaliplatin or the in vitro sensitivity and DNA-repair capacity in 118C and 
118T transfected cell lines. Therefore, ERCC1 C118T genotyping seems of no value in individualizing 
oxaliplatin based chemotherapy in ACC.
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Introduction
The third-generation platinum analogue oxaliplatin is a widely used chemotherapeutic agent, 
especially in the treatment of colorectal cancer. The antitumor effect of oxaliplatin results from 
intercalation of diaminocyclohexane (DACH)-platinum (Pt) in the DNA helix, causing Pt-
DNA cross-links, and ultimately leading to programmed cell death. However, several cellular 
DNA repair mechanisms are capable of repairing damage from Pt-DNA adducts, such as the 
Nucleotide Excision Repair (NER) system.1 Within the NER system, ERCC1 is involved in 
the excision of DNA adducts, which are then replaced by a new piece of DNA strand that is 
synthesized in situ. As a result, NER and ERCC1 function may influence cellular sensitivity 
towards platinum analogues.
Absolute ERCC1 defects in humans are rare2 and were found lethal in mice.3 Most 
information about ERCC1 protein function is therefore based on observations in cell lines with 
NER defects, such as the UV-light sensitive CHO mutant UV20 cell line.4;5 Removal of cisplatin-
induced Pt-adducts in ERCC1 deficient UV20 CHO cells appeared to be low compared to its 
wild type counterpart AA8 cell line6, stressing the importance of the NER system in cellular 
platinum sensitivity. The overall rate and efficiency of the NER process was found comparable 
for cisplatin and oxaliplatin7, and lack of ERCC1 function is thought to influence oxaliplatin 
sensitivity as well.8
A common single nucleotide polymorphism (SNP) in the ERCC1 gene (C118T, rs11615) 
changes the common AAC codon into the infrequently expressed AAT, both coding for 
asparagine (Asn).9 The consequences of this synonymous substitution are not fully understood, 
but there is evidence that the 118T allele may be associated with lower ERCC1 expression 
caused by a difference in translational efficiency for this codon.10;11 Differences in translation 
kinetics may also give rise to conformational changes of the ERCC1 protein, thereby causing a 
change in function.12 Consequently, it has been hypothesized that this SNP influences clinical 
response to oxaliplatin chemotherapy.
Although many authors have studied the association between ERCC1 C118T genotype 
and treatment outcome of oxaliplatin-based chemotherapy in colorectal cancer, only one 
previous study tried to determine if this SNP is causally involved in oxaliplatin resistance.8 It 
was shown that the polymorphism does not alter cellular sensitivity to platinum treatment, 
but no attempt was made to clarify its influence on DNA repair capacity. Because of the 
contradictory results of clinical association studies for this SNP, we investigated the potential 
association of ERCC1 C118T with overall and progression free survival in advanced colorectal 
cancer (ACC) patients treated with oxaliplatin based chemotherapy in the phase 3 CAIRO 
trial of the Dutch Colorectal Cancer Group (DCCG).13 In addition, we performed functional 
in vitro tests using ERCC1 transfected cells, to study the involvement of these genetic variants 
not only in oxaliplatin sensitivity, but also on cellular DNA repair mechanisms.
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Patient DNA for the clinical association study was isolated from venous EDTA blood, collected 
as part of the CAIRO study (previously described in detail).13;14 The study flowchart and number 
of patients available for analysis are shown in Figure 1. As this pharmacogenetic substudy was 
initiated later than the CAIRO clinical trial and not all study centers participated, the number 
of patients included in the pharmacogenetic analyses is limited to a total of 268 patients. 
Baseline characteristics and stratification parameters were not different between our subset of 
patients and the total CAIRO population (data not shown). Tumor response to treatment was 
assessed every 9 weeks by computed tomography (CT) scanning using Response Evaluation 
Criteria In Solid Tumors (RECIST 1.0).15 All included patients gave written informed consent 
before inclusion for the main study and the pharmacogenetic side study.
Genotyping ERCC1 C118T
DNA was isolated from whole blood with the total MagnaPure Total Nucleic Acid Isolation 
Kit I on the MagnaPure LC (Roche Diagnostics, Mannheim, Germany). Chromosomal DNA 
was quantified using the Nanodrop (Isogen, IJsselstein, The Netherlands) and diluted to a 
concentration of 10 ng/ l. TaqMan assay was purchased from Applied Biosystems (Nieuwerkerk 
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aan den IJssel, The Netherlands). The ERCC1 C118T SNP was determined on Realtime PCR 
system 7500 (Applied Biosys-tems, Nieuwerkerk aan den IJssel, The Netherlands) according to 
their instructions. PCR primer sequences are available on request.
Cell lines/plasmids
Wildtype CHO (AA8) and ERCC1 negative CHO (UV20) cells4 were used for in vitro 
transfection experiments. All cells were grown in DMEM supplemented with 5% FCS and G418 
when required, at 37°C and 5% CO2 conditions. All reagents were obtained from Invitrogen 
(Breda, The Netherlands).
Transfection of ERCC1 C118T in UV20-cells
Bicistronic plasmids expressing the open reading frame of wild type or mutant ERCC1 allele 
at codon 118, and expressing Green Fluorescent Protein (GFP) for selection of transfected 
cells, were created by Gateway technology (Invitrogen, Breda, The Netherlands). Briefly, the 
ERCC1 gene was PCR amplified from human cDNA, which was genotyped as heterozygous 
for ERCC1 C118T, with attB-flanked primers p121 and p122.(Table 1) The PCR product was 
recombined in pDONR201. The PCR product in the resulted entry vector was sequenced to 
confirm genotype. Second, the entry vector was recombined with destination vector pExp-
IRES-GFP (Clontech, Oxford, UK) that had been made gateway compatible using the Gateway 
Conversion system (Invitrogen, Breda, The Netherlands). The resulting plasmids were 
designated pTS401 and pTS402 and were used to transfect UV20 cells with GeneJuice (VWR, 
Amsterdam, The Netherlands). Transfected cells were selected by cellsorting, and plasmid 
expression was maintained by growth under selection by G418 (Sigma-Aldrich, Zwijndrecht, 
The Netherlands). The derived cell lines were designated UV20+118C (transfected with 
pTS401) and UV20+118T (transfected with pTS402). UV20 cells were also transfected with 
blank plasmid, and designated UV20-GFP.
Cell lines Characteristics Origin/Reference
AA8 wildtype CHO-cells ATCC
UV20 ERCC1 deficient CHO- cells Thompson (1980)
UV20+118C UV20 expressing ERCC1-118C and GFP this study
UV20+118T UV20 expressing ERCC1-118T and GFP this study
UV20-GFP UV20 expressing GFP this study
Plasmids
pDONR201 donor vector Invitrogen
pEXP-IRES-GFP destiny vector Clontech
TS401 pERCC1:118C-ires-GFP this study
TS402 pERCC1:118T-ires-GFP this study
Table 1. Plasmids and cell lines used in the ERCC1 transfection experiment.
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Sulphorodamine B growth inhibition assay
Oxaliplatin cytotoxicity was assessed using the Sulphorodamine B (SRB) growth inhibition 
assay described by Skehan et al.16 A total of 1.2 × 103 cells (AA8, UV20, UV20-GFP, UV20+118C, 
UV20+118T) were seeded into 96-well plates in a volume of 150 µl and incubated at 37°C 
overnight. Oxaliplatin concentrations were prepared in culture medium immediately before 
use. To the cells, 50 µl of drug-medium mixture was added. Triplicates were used for each 
drug concentration. Plates were incubated for 24 h at 37°C. Following drug treatment, the 
medium was replaced with 200 µl of fresh complete medium, and the plates were incubated 
for 3 days at 37°C. The growth medium in the wells was removed, and 50 µl of ice-cold 50% 
(w/v) trichloroacetic acid was added to fix the cells for 1 h at 4°C. Then, cells were washed six 
times with water, and stained with 50 µl of 0.4% (w/v) SRB-1% acetic acid for 20 min at room 
temperature. Unbound dye was removed by washing six times with 1% acetic acid, and plates 
were dried. The dye was solubilized by the addition of 150 µl of 10 mM Tris-base into each 
well. Plates were left at room temperature for 20 min, and the optical density (OD) at 570 nm 
was measured.
Clonogenic assay
The clonogenic assay was performed as described by Franken et al.17 Briefly, a total of 50 
exponentially growing cells (AA8, UV20, and transfected cells UV20+118C, UV20+118T and 
UV20-GFP) were plated in triplicate in 6-wells plates and incubated for 24 h to allow for cellular 
attachment. Attached single cells were treated with different concentrations of oxaliplatin (195 
nM, 781 nM and 3125 nM) for 24 h at 37°C in medium. Cells were washed and incubated for 
7–9 days until visible colonies of more than 50 cells were obtained. Cells were then stained with 
1% Giemsa and the number of colonies in each dish was counted.
Modified COMET assay
DNA damage was studied by the modified COMET assay.18;19 Exponentially growing cells 
were exposed to oxaliplatin 195 nM or 3125 nM for 1 h. The cells were washed and incubated 
overnight at 37°C and 5% CO2. Next, the cells were trypsinized and resuspended in 1 ml 
culture medium. To induce DNA damage, the cells were treated with 30 M H2O2 (peroxide) for 
10 min at 4°C. After spinning down, the degraded DNA was resuspended in 1% low melting 
point agarose (Promega, Leiden, The Netherlands) put on a microscope slide. The slides were 
soaked in lysisbuffer (100 mM EDTA, 10 mM Tris, 2.5 M NaCl, 1% Triton and 10% DMSO) 
for at least 90 min. In order to denature the DNA, the slides were air-dried and incubated in 
electrophoresis buffer (1 M EDTA, 300 mM NaOH pH 13) for 40 min. Next, the DNA was 
electrophoresed at 25 V and 250 mA for 30 min. After electrophoresis, the slides were washed 
at least three times with 0.4 M Tris pH 7.5 prior to staining with ethidiumbromide (20 g/l) 
(Promega, Leiden, The Netherlands) for 5 min.
Comet tails were visualized using FITC filtered fluorescent microscopy and visually 
scored as described elsewhere.20 In these experiments, cells with high amounts of oxaliplatin-
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induced cross-links have shorter tails compared to cells in which cross-links have been repaired 
effectively. This is explained by the fact that unrepaired platinum-induced DNA cross-links 
will stay together after DNA degradation by H2O2, resulting in larger DNA fragments. Mean 
difference in tail olives moment (and tail areas) between treated and untreated cells indicates 
the presence of DNA damage due to exposure to oxaliplatin. The damage level is expressed 
according to the formula: (unexposed cells − oxaliplatin exposed cells) tail olives moment/tail 
olives moment of unexposed cells.
Rad51 foci staining
Rad51 foci, indicative of DNA damage, were shown as follows.21 Exponentially growing cells 
(AA8, UV20, and transfected cells UV20+118C, UV20+118T and UV20-GFP) were exposed 
to oxaliplatin and incubated as described in section 2.5. Next day, cells were washed with PBS 
and fixated with 2% formaldehyde for 15 min at room temperature. To enhance permeability, 
cells were incubated in 0.1% Triton for 10 min. To prevent non-specific binding of Rad51 
antibody, the cells were washed with PBS+ (PBS containing 0.15% glycine (Biorad, Veenendaal, 
The Netherlands) and 0.5% BSA (Sigma–Aldrich, MO, USA)). Rabbit-anti-Rad51 antibody 
(Sigma–Aldrich, MO, USA) diluted in PBS+ was added to the cells and incubated at room 
temperature for 90 min under dark and humid conditions. Alexa488 conjugated goat-anti-
rabbit antibody (Molecular Probes, Leiden, The Netherlands) was used to visualize Rad51 foci 
using FITC filtered fluorescent microscopy. Rad51 expression was quantified by counting the 
number of cells that have more than 5 foci. A representative image of the Rad51 foci staining 
used for analysis is shown in Figure 2.
Statistical methods
DNA from venous blood and tumor samples was obtained from a subset of patients participating 
in the previously described CAIRO study.13
One-way ANOVA with LSD-t test was used to compare the results of the SRB assay. A 
Cox proportional hazard model was used to investigate the association between ERCC1 status 
and death and/or progression. PFS for second-line treatment was defined as the time from 
randomization until first progression reported after the start of second-line treatment and, 
if a patient did not start second-line treatment, the date of first progression reported after 
randomization or death or last follow-up. Likewise, PFS for third-line treatment was defined 
as the time from randomization until first progression, death, or last follow-up after the start 
of third-line treatment. OS was calculated as the interval from the date of randomization 
until death from any cause or until the date of last follow-up. Overall and progression-free 
survival curves were estimated with the Kaplan–Meier method and compared with the Log-
Rank test. Association between survival and ERCC1 status were analyzed by a univariate Cox 
proportional hazards model.
All tests were two-sided and p values of less than 0.05 were considered statistically 
significant. All data received before February 2008, with a median follow-up of 40.6 months 
Chapter 7
120
(range 0.3; 53 months), are included in this report.
Figure 2. Representative picture used for assessment of Rad51 foci of oxaliplatin treated cells. 
All cells have been incubated with 3125nM oxaliplatin, during 24 hours. 
A: AA8 (wildtype CHO cells); B: UV20 (ERCC1-/- CHO cells); C: UV20+118C (UV20 cells transfected with 
ERCC1-118C allele); D: UV20+118T (UV20 cells transfected with ERCC1-118T allele).
Results
ERCC1 C118T is not associated with survival in ACC patients treated with 
oxaliplatin
Genotyping was successful in 251 out of 268 patients, and genotype frequencies were 118TT 92 
(37%), 118TC 129 (51%), 118CC 30(12%). The genotype frequencies were in Hardy–Weinberg 
equilibrium (HWE) and comparable with those reported in Caucasians.22;23
A total of 145 patients treated with capecitabine and oxaliplatin were evaluated for analysis 
of PFS and OS. The C118T genotype was not correlated with PFS (p = 0.145 and p = 0.614 
for second-and third-line treatment, respectively) or with OS (second-line therapy: p = 0.121; 
third-line therapy: p = 0.331). Similar results were obtained when patients of both regimens 
receiving second-and third line treatment were analyzed together. (Table 2)













Overall survival (months) median 10.0 12.1 10.8 11.0 p= 0.186
95% CI (8.7-11.8) (10.3-14.4) (6.9-13.7) (9.8-12.1)
PFS (months) median 4.2 4.2 4.5 4.2 p= 0.190
95% CI (3.1-4.9) (3.4-6.1) (1.9-5.2) (3.8-4.9)
Oxaliplatin 2nd line
Number of patients
31 48 10 89
Overall survival (months) median 9.6 13.2 12.5 11.6 p= 0.121
95% CI (7.4-12.0) (10.6-15.3) (8.2-18.9) (9.6-13.6)
PFS (months) median 4.1 4.1 4.5 4.1 p= 0.145
Oxaliplatin 3rd line
Number of patients
28 24 4 56
Overall survival (months) median 10.7 10.4 7.6 10.3 p= 0.331
95% CI (8.1-13.0) (6.4-12.7) (1.5-13.6) (8.3-12.1)
PFS survival (months) median 4.3 4.5 3.2 4.4 p= 0.614
95% CI (2.8-5.5) (2.1-5.9) (0.0-7.4) (2.8-5.4)
95% CI (2.1-5.8) (3.7-6.7) (1.9-5.2) (3.8-5.1)
Table 2. ERCC1 C118T genotypes and clinical outcome after treatment with CAPOX
CAPOX, capecitabine-oxaliplatin; CI, confidence interval; ERCC1, Excision Repair Cross-Complementation 
group 1 (ERCC1); OS, overall survival; PFS, progression free survival.
Figure 3. Sulphorodamine B (SRB) assay determined oxaliplatin sensitivity in parental AA8, 
UV20 (ERCC1-/-), and transfected cells UV20+118C, UV20+118T and UV20-GFP. 
Growth inhibition was determined using the SRB assay and the percentage of surviving cells was calculated as 
described. All results are the mean of at least three independent experiments and error bars show the standard 
deviation of the mean.
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ERCC1, but not C118T genotype, influences cellular sensitivity to oxaliplatin in vitro
To test whether C118T genetic variants are causally related to cellular sensitivity to oxaliplatin, 
we conducted transfection experiments with ERCC1 negative CHO cells. Figure 3 shows 
the sensitivity to oxaliplatin of AA8 (wildtype CHO), ERCC1 defective CHO mutant UV20 
and the three transfected cell lines (UV20+118C, UV20+118T and UV20-GFP). The drug 
concentrations to inhibit cell growth by 50% (IC50 values) in the ERCC1-defective cells (UV20 
and UV20-GFP) are approximately 16-fold lower than for their parental cell line (AA8). UV20 
and UV20-GFP showed similar IC50 values, indicating that the transfection of GFP had no effect 
on cell growth. In contrast, the ERCC1 overexpressing cells, UV20+118C and UV20+118T, 
show substantial resistance to oxaliplatin. IC50 values for these cells were approximately 32-fold 
higher compared to the UV20 cell line (p-value < 0.005, paired Student’s t-test). No difference 
was found in IC50 values between UV20+118C and UV20+118T. These results indicate that 
ERCC1 influences cellular sensitivity to oxaliplatin, and that chemosensitivity is not different 
between ERCC1 118C and 118T expressing variants.
We repeated these experiments using the clonogenic assay. Consistent with the results 
from the SRB assay, all ERCC1 expressing cells (AA8, UV20+118C and UV20+118T) showed 
significant numbers of surviving colonies after treatment with oxaliplatin. However, ERCC1 
negative UV20 cells and cells transfected with the empty vector (UV20-GFP) showed no 
colony formation after treatment with oxaliplatin. A schematic representation of these results 
is shown in Figure 4.
Figure 4. Clonogenic assay determined oxaliplatin sensitivity in parental AA8, UV20  
(ERCC1-/-), and transfected cells UV20+118C, UV20+118T and UV20-GFP.
Number of visible colonies of more than 50 exponentially growing cells, after 24h treatment with different 
concentrations of oxaliplatin (195nM, 781nM and 3125nM) and subsequent incubation during 7-9 days
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ERCC1, regardless of C118T genotype, is essential for oxaliplatin-induced  
DNA-damage in vitro
To validate whether the high susceptibility of UV20 cells to oxaliplatin is caused by a defect 
in DNA repair, we evaluated oxaliplatin-induced DNA damage using the COMET assay, in 
wild-type AA8 cells, ERCC1 defective UV20, and the transfected variants UV20+118C and 
UV20+118T. As expected, tails of the ERCC1 deficient UV20 cell line are smaller than AA8 
tails. The comet tails in UV20+118C and UV20+118T are comparable with AA8. These results 
indicate that DNA repair activity in ERCC1 deficient UV20 is fully restored by introducing 
ERCC1 and that this is equally the case for ERCC1 118C and 118T transfected cells.(Figure 5) 
A representative image of the modified COMET assay used for data analysis is shown in Figure 6.
Figure 5. Difference in comet tail length after exposure to oxaliplatin of parental AA8, UV20 
(ERCC1-/-), and transfected cells UV20+118C and UV20+118T.
A large decrease in comet-tail olives moment is indicative of higher amounts of residual DNA-cross links caused 
by oxaliplatin. Results are the mean of 100 comets and error bars show the standard deviation of the mean. 
Because ERCC1 is also considered to be involved in homologous recombinational repair 
(HRR)24;25, we stained for Rad51 foci in oxaliplatin treated cells. Rad51 is important for 
recognition of DNA damage in HRR26 and impaired ERCC1 function leads to constant 
expression of Rad51 at the site of the lesion. Results for these analyses are shown in Figure 7. 
The data shown are the means of at least three experiments. After 24 h, the amount of foci 
per cell was more abundant in UV20 compared to AA8 (Figures 2B and A, respectively) or 
ERCC1 complemented cells.(Figures 2C and D) In UV20 ERCC1 negative cells, on average 61% 
of cells showed more than five Rad51 foci, versus only 27% for AA8 wildtype cells. In the ERCC1 
overexpressing cells (UV20+118C, UV20+118T) very few Rad51 foci positive cells were present, 
irrespective of their codon 118 genotype (13% versus 11% for 118C and 118T, respectively). 
These results indicate that HRR pathway is less active in the ERCC1 deficient cell line and can be 
restored to wildtype activity by ectopic expression of ERCC1 118C, as well as 118T.
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(Opposite page) Figure 6. Representative image of the modified COMET assay  
used for interpretation of remaining DNA damage after treatment with oxaliplatin.
A: AAV8, not treated with oxaliplatin; B: AAV8 treated with oxaliplatin 3125nM; C: UV20, not treated with 
oxaliplatin; D: UV20, treated with oxaliplatin 3125nM; E: UV20-118C, not treated with oxaliplatin; F: UV20-
118C, treated with oxaliplatin 3125nM; G: UV20-118T, not treated with oxaliplatin; H: UV20-118T, treated with 
oxaliplatin 3125nM.
 
Figure 7. Change is Rad51 foci staining after treatment with increasing oxaliplatin 
concentrations, for parental AA8, UV20 (ERCC1-/-), and transfected cells UV20+118C  
and UV20+118T.
Results are means of at least three experiments.
Discussion
Despite numerous publications in recent years, there has been ongoing debate on the role 
of ERCC1 and the common SNP at codon 118 of this gene regarding chemosensitivity to 
oxaliplatin in colorectal carcinoma. This is the most comprehensive study of ERCC1 C118T 
functionality in the repair of oxaliplatin-induced DNA-damage to date. We investigated the 
association of ERCC1 genotype with PFS and OS after oxaliplatin-containing chemotherapy in 
ACC and found no effect of the C118T SNP. We did, however, confirm ERCC1 functionality in 
the repair of oxaliplatin-induced DNA-damage, using a modified COMET assay and staining 
of Rad51. Most importantly, we excluded an effect of the ERCC1 C118T SNP on cellular 
sensitivity to oxaliplatin and on DNA-repair efficacy in oxaliplatin-induced DNA damage, by 
using cellular transfection experiments.
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Publications regarding the effect of ERCC1 C118T in platinum therapy have been both 
extensive and contradictory. Consistent with our results, several authors reported no effect 
of the SNP on clinical efficacy of oxaliplatin-based chemotherapy in colorectal carcinoma 
patients.23;27–30 Other studies, however, found shorter survival times for the ERCC1 118T allele 
in ACC patients treated with oxaliplatin-containing schedules.10;11;31–33 Contrarily, a smaller 
number of authors found an adverse effect of the C allele.34–36 It should be noted that our study 
population, as most other clinical pharmacogenetic association studies, lacks statistical power 
to definitively rule out an effect of the ERCC1 C118T polymorphism on oxaliplatin efficacy. 
However, our results concur with those from a meta-analysis published in 2011, showing that 
PFS following oxaliplatin-based chemotherapy for colorectal cancer patients carrying the 
ERCC1 118C allele was not influenced by rs11615 genotype in Caucasian populations.37
Based on the results of our clinical association study, we questioned the functional 
relevance of the ERCC1 SNP C118T. By in vitro experiments, transfecting UV20 cells with 
either 118C or 118T, we showed that the SNP does not have functional consequences for 
either in vitro sensitivity to oxaliplatin, DNA-repair capacity, or HRR. Previously, Gao et al. 
followed a similar approach and also found no differences in viability upon platinum treatment 
between ERCC1 118C and 118T expressing cells.8 Seetharam et al. found that ERCC1 mRNA 
and protein expression were upregulated upon oxaliplatin in resistant CRC cell lines, but not 
in oxaliplatin sensitive cell lines. In addition, silencing of ERCC1 by siRNA led to an increase 
in chemosensitivity in previously oxaliplatin-resistant cell lines.38
Given our results and those by Gao and co-workers, it remains striking that many 
authors found an effect of the ERCC1 C118T polymorphism on oxaliplatin efficacy. Several 
explanations can be offered for this discrepancy. Firstly, it should be noted that many of the 
previous pharmacogenetic association studies did not correct adequately for multiple testing 
and positive results may therefore have arisen by chance. Secondly, differences in genotype 
frequencies between populations may have caused accidental statistical associations, especially 
in populations with mixed ethnicities. Whereas the 118C allele is the minor allele in Caucasians, 
it is the common variant found in people from Asian descent.22 Notably, a positive effect of 
the ERCC1 118C allele was pre-dominantly found in Asian populations.11;31;32 An alternative 
hypothesis is that the C118T SNP is indirectly functional due to its linkage disequilibrium with 
another SNP in the ERCC1 gene. The C118T SNP was found to be in a tight haplotype block 
with other SNPs in both coding and non-coding regions of the ERCC1 gene.27;34;39;40 Consistent 
with this hypothesis, a haplotype containing both ERCC1 C118T and a SNP in the 3’-UTR of 
ERCC1 (C8092A, rs3212986) was recently shown to associate with decreased DNA damage 
repair capacity for patients carrying ERCC1 8092A.20;41 In addition, with the redefinition of 
the gene concept, cis- or trans-acting elements and genetic variations could also be located 
distantly in the genome.42;43
It can be argued that our analyses did not include other loci with putative influence on 
oxaliplatin efficacy. Although some authors found an effect of glucuronyl-S-transferase pi 
(GSTP1) on oxaliplatin toxicity44;45, we previously showed that this polymorphism did not 
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influence chemosensitivity in our CAIRO population.46 However, it cannot be excluded that 
results for the ERCC1 polymorphism were confounded by the effect of another coinciding 
polymorphism or haplotype.
Although the use of in vitro data and transfection experiments offers important infor-
mation on the molecular physiology of oxaliplatin DNA damage repair, it is subject to 
limitations. Protein and mRNA expression in transfected cells are plasmid-derived and are no 
longer regulated by epigenetic systems, leading to supernatural levels of protein. This limits 
functional analyses in these transfected cells in general and impairs extrapolation of in vitro 
results to epidemiologic populations.47 However, in the case of ERCC1, protein functionality 
and, consequentially, the level of DNA repair are dependent on the concomitant expression of 
ERCC4.48;49 Higher ERCC1 protein levels due to unregulated plasmid derived transcription will 
therefore not lead to more effective DNA repair. Therefore, we believe our transfection model 
provides a valid proxy for the analysis of the in vivo effect of the ERCC1 C118T polymorphism 
on DNA repair after treatment with oxaliplatin.
Overall, our results show that ERCC1 activity is essential in response or resistance to 
oxaliplatin in colorectal cancer. However, it remains unclear if inter-individual variations in 
ERCC1 activity influence chemosensitivity. More importantly, it is not known how ERCC1 
activity can reliably be measured in a clinical setting. Many studies have used ERCC1 
staining in correlation to oxaliplatin efficacy.38;50;51 However, a recently published article 
highly questions the validity of ERCC1 staining, stressing that only one ERCC1 isoform is 
functionally active, whereas staining methods cannot differentiate between functional and 
non-functional iso-forms.52 Others have used ERCC1 mRNA expression, but results have been 
equally diverse.38;53–57 Nonetheless, pretreatment indicators of ERCC1 activity are warranted, 
before its use as a biomarker is possible.
Conclusion
In summary, we showed that ERCC1 function is essential in repair of oxaliplatin-induced 
DNA damage and thereby influences oxaliplatin cytotoxicity in vitro. However, we found 
no evidence for functional differences of ERCC1 C118T variants in the cellular response to 
oxaliplatin exposure. This coincides with our findings that this genetic variant is not associated 
with clinical outcome in ACC patients treated with oxaliplatin. Further research should focus 
on elucidating the optimal method for assessing ERCC1 activity and the search for genetic 
variation in other loci of ERCC1, or epigenetic regulation affecting the gene, since it is evident 
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Purpose: Despite expanding options for systemic treatment, survival for metastatic colorectal cancer 
(mCRC) remains limited and individual response is difficult to predict. In search of pretreatment 
predictors, pharmacogenetic research has mainly used a candidate gene approach. Genome wide 
association (GWA) studies offer the benefit of simultaneously analyzing a large number of SNPs, 
in both known and still unidentified functional regions. Using a GWA approach, we searched for 
genetic markers affecting progression free survival (PFS) in mCRC patients treated with first-line 
capecitabine, oxaliplatin and bevacizumab (CAPOX-B), with or without cetuximab.
Patients & methods: 755 patients were included in the CAIRO2-trial, a multicenter phase III 
trial, randomizing between first-line treatment with CAPOX-B versus CAPOX-B plus cetuximab. 
Germline DNA and complete clinical information was available from 553 patients and genome 
wide genotyping was performed, using Illumina’s OmniExpress beadchip arrays, with 647,550 
markers passing all quality checks. Another 2,202,473 markers were imputated by using HapMap2. 
Association with PFS was analyzed using a Cox proportional hazards model.
Results: One marker, rs885036, associated significantly with PFS (P = 2.17x10-8) showing opposite 
effects on PFS depending on treatment arm. The minor allele was associated with increased PFS in 
patients receiving cetuximab. A cluster of markers located on chromosome 8 associated with PFS, 
irrespective of treatment arm (P-values of 2.30x10-7 to 1.04x10-6). 
Conclusion: This is the first GWA study to find SNPs affecting PFS in mCRC patients treated 
with CAPOX-B, either with or without cetuximab. Rs885036 is a potential predictive marker for 
cetuximab efficacy. These markers need to be validated in independent treatment cohorts.
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Background
Colorectal cancer is among the most prevalent forms of cancer worldwide, with the estimated 
number of new diagnoses in the United States for 2013 exceeding 142,000 cases.1 Combination 
chemotherapy including a fluoropyrimidine plus the monoclonal agent bevacizumab and 
either oxaliplatin or irinotecan is generally recommended for first-line treatment of metastatic 
colorectal carcinoma (mCRC).2 Unfortunately, even with these modern-day treatment options, 
median survival is limited and variation in response is largely unpredictable. Optimal selection 
of patients who will benefit from these extensive treatment schedules is warranted, both from 
the individual aspect of preventing needless burden of toxicity, and from a population-based 
aspect of optimal cost-effectiveness. 
Germline genetic variation has been shown to predict differences in response to many 
chemotherapeutic drugs.3 Until now, most research has focused on genetic alterations in 
genes encoding for known target or metabolic enzymes. A disadvantage of this candidate-
gene approach is the limited knowledge of the exact mechanism of action for many drugs. 
Considering the immense amount of single nucleotide polymorphisms (SNPs) the human 
genome harbors, it is likely that many SNPs with potential effect on drug efficacy have not 
yet been detected. Circumventing the limitations of a candidate gene approach, genome wide 
association (GWA) studies offer the possibility of simultaneously analyzing a large number 
of SNPs, even in regions that have not previously been associated with the drug under 
investigation. This type of study has been applied to identify risk factors for multiple types 
of cancers, including colorectal carcinoma.4;5 Moreover, in pharmacogenetic GWA studies, 
an increasing number of SNPs associated with treatment response in cancer are identified. 
A recent GWA study in colorectal cancer patients identified SNPs that were associated with 
adverse drug reactions in response to treatment with 5-FU and oxaliplatin.6 
Here, we present the results of the first clinical GWA study to find SNPs that are associated 
with progression free survival (PFS) of first-line combination chemotherapy for mCRC with 
capecitabine, oxaliplatin and bevacizumab (CAPOX-B), either with or without cetuximab.
Patients and methods
Germline DNA was obtained from 553 of 755 previously untreated mCRC patients, who 
were recruited from the CAIRO2 trial, a multicenter phase III trial of the Dutch Colorectal 
Cancer Group (DCCG), which randomized between first-line treatment with CAPOX-B 
versus CAPOX-B plus cetuximab.7 All patients received three-weekly cycles of capecitabine 
1000mg/m2 b.i.d. orally on days 1-14 plus oxaliplatin 130mg/m2 (maximum of 6 cycles) and 
bevacizumab 7.5mg/m2, both intravenously on day 1 of each treatment cycle. From cycle 7 the 
capecitabine dosage was increased to 1250mg/m2. For patients randomized to treatment with 
CAPOX-B plus cetuximab, cetuximab was administered intravenously at a loading dose of 
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400mg/m2 on the first treatment day, followed by 250mg/m2 once weekly thereafter. Treatment 
was continued until disease progression, unacceptable toxicity or death, whichever occurred 
first. Patient eligibility criteria and guidelines for response assessment have been described in 
detail elsewhere.7 The study was approved by the Committee on Research involving Human 
Subjects Arnhem-Nijmegen and by all local institutional ethics boards. All subjects gave 
written informed consent. 
 
Figure 1. Cairo2 study flow-chart
Genotyping
Whole blood was collected at baseline and germline DNA was isolated from peripheral 
leukocytes using MagnaPure Compact (Roche diagnostics, Almere, The Netherlands). Geno-
typing was performed on Human OmniExpress v12 BeadChip arrays containing 733,202 
markers (Illumina, San Diego, CA, USA). Genotype calls were set using GenomeStudio software 
(Illumina). All products were used according to manufacturer’s prescriptions. The following 
cut-off values were used to filter out incorrectly called genotypes: GenCall ≥ 0.85; ClusterSep 
≥ 0.3; CallFreq >0.85; AB T-mean 0.2-0.8, resulting in the exclusion of 3172 markers (0.43%). 
Statistical analysis
Quality control
Quality control was performed using R, version 3.0.1 (http://www.r-project.org/), and plink.8 
Markers were excluded based on a minor allele frequency (MAF) threshold of 0.01 (1636 
excluded markers; 0.3%) and missingness threshold of 0.05 (no excluded markers). Hardy-
Weinberg equilibrium (HWE) was evaluated per marker, using a χ2 goodness-of-fit statistic 
with a cut-off P-value of ≤10-7 (36 excluded markers). After these quality checks, 647,550 
markers remained in the analysis.
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Individuals were excluded based on missingness > 2% (no excluded individuals).
Multidimensional scaling (MDS) was used to investigate possible stratification and outliers. 
After removal of outliers MDS did not show clustering. Association analysis was performed 
with and without the first four MDS coordinates as covariates. Ranking and P-values of the top 
30 SNPs were almost identical and only analyses without MDS coordinates are shown. In total 
33 patients were excluded due to low genotyping quality. Complete information, including 
genotype, was available for 520 patients. The study flowchart is shown in Figure 1.
Imputation
Additionally, non-measured genotypes were imputated using HapMap2, to further enhance 
SNP density. A minimum imputation accuracy of R2>0.40 was applied to select reliably 
imputed SNPs. In total 2,202,473 imputed markers were used in this analysis.
Association model
For each marker, the association with PFS was calculated with a Cox-proportional hazards 
model using R package survival. Age, gender, treatment arm were included as covariates. A 
first model contained each SNP as variable of interest (marginal model) and a second model 
tested the interaction SNP*arm as variable of interest while controlling for the main SNP effect 
(interaction model). Markers were evaluated using an additive genetic model in all analyses. 
The inflation factor for association models was calculated based on the χ2 -quantiles for the 
P-values of the evaluated models. Formal significance for a marker was assumed for a two-
sided P < 5x10-8 to correct for multiple testing, as has been described by others.9–11 




(n = 264 )
CAPOX-B plus 
cetuximab 
(n = 256 )
Age in years
Median (range)
63.2 (27.6-83.6) 62.9 (27.6-83.6) 63.9 (33.2-80.0)









LDH at baseline – no (%)*
Normal






















10.3 (0.1 – 44.7) 10.6 (0.4 – 44.7) 10.0 (0.1 – 40.8)
 
Table 1. Baseline patient characteristics
* According to cut-off values of each individual center





Baseline patient characteristics are described in Table 1. Median PFS was 10.3 months for all 
patients included in the analyses (range 0.1 – 44.7 months). At the time of analysis the primary 
endpoint PFS was reached by 487 of 520 patients (93.7%). 
Genome-wide association analysis including effect of treatment arm
Initially, analyses were performed including the interaction term of genetic markers with 
treatment arm as a covariate. The Manhattan plot for these analyses is shown in Figure 2 and 
details for the ten most significant markers are provided in Table 2. Markers with a differential 
effect according to treatment arm may actually reflect predictive markers for cetuximab efficacy. 
One marker (rs885036, position 98671226) on chromosome 2q12 showed a highly significant 
interaction with treatment arm (P = 2.17x10-8). In a stratified analysis, this SNP proved to have 
a contrasting effect in both treatment arms. Kaplan-Meyer survival curves for PFS according to 
genotype are shown in Figure 3. For patients treated with CAPOX-B, the G allele associated with 
shorter PFS (AA 13.47 months [95%CI 12.16-16.43]; AG 12.22 months [95%CI 9.17-14.32]; 
GG 9.00 months [95%CI 7.56-10.68]). For patients treated with CAPOX-B plus cetuximab, the 
G allele associated with increased PFS (AA 7.31 months [95%CI 6.53-10.05]; AG 10.05 months 
[95%CI 8.83-12.16]; GG 12.35 months [95%CI 10.35-15.44]).
Marker Chr Position Gene A0 A1 Allele 
frequency
R2 # Allele HR*
(95% CI)
P-value
rs885036 2 98671226 GnT- IVa A G 0.533 1.000 0.47 (0.36-0.61) 2.17x10-8
rs3769689 2 98660129 GnT- IVa A G 0.327 0.975 0.49 (0.37-0.65) 6.99x10-7
rs3769688 2 98660242 GnT- IVa A G 0.329 0.980 0.50 (0.38-0.66) 1.02x10-6
rs17448420 2 98664315 GnT- IVa C T 0.329 0.983 0.50 (0.38-0.66) 1.06x10-6
rs17448190 2 98656831 GnT- IVa C T 0.325 0.972 0.50 (0.38-0.66) 1.06x10-6
rs17448211 2 98657628 GnT- IVa A T 0.325 0.973 0.50 (0.38-0.66) 1.07x10-6
rs17448085 2 98653118 GnT- IVa C T 0.328 0.974 0.50 (0.38-0.67) 1.49x10-6
rs17514013 2 98653226 GnT- IVa A G 0.672 0.974 1.99 (1.50-2.64) 1.49x10-6
rs10199926 2 98658908 GnT- IVa C T 0.656 0.982 1.96 (1.49-2.60) 1.87x10-6
rs2309434 2 98672936 GnT- IVa C T 0.340 0.987 0.51 (0.39-0.68) 2.46x10-6
 
Table 2. Ten SNPs with lowest P-values for association with PFS
Abbreviations: HR, Hazard ratio; Chr, chromosome; CI, confidence interval; GnT-IVa: mannosyl (alpha-1,3)-
glycoprotein beta-1,4-N-acetylglucosaminyltransferase isozyme A; R2: imputation accuracy. A0: reference allele 
according to hapmap2, A1: alternate allele.
* HR assuming an additive effect depending on dosage of the alternate alleles, obtained with multivariate Cox-
proportional hazards model, including age, gender, treatment arm, and the interaction treatment arm* marker 
as covariates.
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Figure 2. Manhattan plot of –log10 (P-value) of the Cox-proportional hazards model
Adjusted for age, gender and treatment arm and the interaction of marker with treatment arm.
The horizontal line represents the formal genome-wide significance level of 5x10-8.
Figure 3. Kaplan-Meyer survival curves according to rs885036 genotype
A. Survival curves for patients in arm A, treated with CAPOX-B in first-line chemotherapy. B. Survival curves 
for patients in arm B, treated with CAPOX-B plus cetuximab in first-line chemotherapy. 
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Overall genome-wide association analysis results
The Manhattan plot for the overall GWA analysis is shown in Figure 4. No marker reached 
the pre-determined formal significance level. A cluster of markers, located on chromosome 8, 
showed the lowest P-values (P = 2.30x10-7 to P = 1.04x10-6, respectively). The inflation factor for 
this analysis was modest (λ 1.02), indicating there was no evidence of population stratification 
or other bias in the analysis. The ten most significant markers are described in Table 3. 
Figure 4. Manhattan plot of –log10 (P-value) of the Cox-proprotional hazards model
 Adjusted for age, gender and treatment arm. The horizontal line represents the formal genome-wide significance 
level of 5x10-8. The topmost significant markers are circled, i.e. rs2936519, rs2928608, rs2928609, rs2912024, 
rs2978926, rs2928607.





rs2936519 8 6626650 n.a. A G 0.90 1.00 0.53 (0.43-0.67) 2.30x10-7
rs2928608 8 6626434 n.a. C T 0.90 0.99 0.54 (0.43-0.67) 2.33x10-7
rs2928609 8 6626528 n.a. C T 0.90 0.99 0.54 (0.43-0.67) 2.36x10-7
rs2912024 8 6626309 n.a. C T 0.10 1.00 1.86 (1.49-2.32) 2.60x10-7
rs2978926 8 6626835 n.a. A G 0.10 0.98 1.86 (1.49-2.33) 2.67x10-7
rs2928607 8 6626120 n.a. C G 0.10 0.97 1.86 (1.49-2.33) 2.79x10-7
rs11997869 8 6625874 n.a. C G 0.10 0.97 1.84 (1.47-2.30) 4.32x10-7
rs2978931 8 6625491 n.a. A C 0.91 1.00 0.55 (0.44-0.69) 1.04x10-6
rs2073016 6 41128900 n.a. C T 0.83 0.72 1.62 (1.31-2.00) 3.70x10-6
rs4377367 2 131441375 ARHGEF4 C T 0.86 0.99 0.63 (0.52-0.76) 6.47x10-6
Table 3. Ten SNPs with lowest P-values for overall association with PFS
Abbreviations: HR, Hazard ratio; Chr, chromosome; CI, confidence interval; n.a., marker is not localized within 
a gene. ARHGEF4: Rho guanine nucleotide exchange factor 4.
* R2: imputation accuracy. A0: reference allele according to hapmap2, A1: alternate allele.
# HR assuming an additive effect depending on dosage of the alternate alleles, obtained with multivariate Cox-
proportional hazards model, including age, gender, treatment arm, and the interaction treatment arm* marker 
as covariates.
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Discussion
This is the first prospective GWA study to find SNPs that predict efficacy of first-line 
chemotherapy with CAPOX-B, with or without cetuximab, in mCRC patients in a clinical trial 
setting. One marker on chromosome 2, rs885036, was significantly associated with PFS, with 
a contrasting effect in both treatment arms. This SNP may therefore be a potential predictive 
marker for efficacy of cetuximab containing chemotherapy. Additionally, a cluster of SNPs on 
chromosome 8 influenced PFS with a similar effect in both treatment arms, almost reaching 
genome wide significance. 
A genome wide significant effect on PFS was found for rs885036, when treatment arm was 
taken into consideration. Interestingly, we found opposite effects of genotype on PFS in both 
treatment arms. This suggests that this polymorphism may have a deleterious prognostic effect 
on survival per se, but this effect is no longer seen after the addition of cetuximab to standard 
treatment with CAPOX-B. 
Rs885036 is located in the gene encoding for mannosyl (alpha-1,3)-glycoprotein beta-
1,4-N-acetylglucosaminyltransferase isozyme A, GnT-IVa (also denominated MGAT4A), as 
are all ten most significant markers from these analyses. The top region of most significant 
markers exhibits long ranging linkage disequilibrium (LD), extending >50kb in both directions 
(HapMap3 data, data not shown), which also covers the candidate gene GnT-IVa. Of note, 
rs885036 is a directly measured SNP.
GnT-IV encodes for a glycosyltransferase, which is involved in the biosynthesis of 
oligosaccharides and has previously been associated with tumor behavior. In one study, GnT-
IV mRNA was upregulated in metastatic colorectal tumors, as opposed to non-metastatic 
primary colorectal tumors.12 Strong expression of GnT-IVa mRNA and enzyme activity was 
also found in drug-resistant hepatocellular carcinoma cells.13 
The rs885036 SNP constitutes a C>T nucleotide change in the second intron of GnT-
IVa, and is located within a predicted binding site for the highly conserved microRNA-34A 
(miR-34a).14;15 MicroRNAs play an important role in post-transcriptional silencing of genes, 
as their interference with RNA leads to repressed translation or cleavage of RNA.16 Expression 
of miR-34a itself is regulated by p53 expression.17 Cytotoxic stress induced by chemotherapy 
or irradiation markedly increases miR-34a levels in the presence of p5318, emphasizing its 
importance in response to anti-cancer treatment. 
We believe that the C>T change leads to altered binding of miR-34a, resulting in differential 
translation efficacy of GnT-IVa. Although our analyses cannot clarify any further functional 
correlations, we speculate that the altered GnT-IVa protein level may then influence EGFR 
glycosylation, and thereby form a possible determinant of cetuximab efficacy. 
Although no SNP in the overall analyses reached formal genome wide significance, a 
cluster of SNPs on chromosome 8p23.1 showed very low P-values for the association with 




These markers are not localized within any known gene, but the gene encoding for 
1-acylglycerol-3-phosphate O-acyltransferase 5 (APGAT5), is found approximately 20 kbp 
upstream.19 Again, the topmost significant SNPs are in long ranging LD, which covers this 
candidate gene (HapMap3 data, data not shown). AGPAT5 comes from a family of highly 
conserved enzymes that catalyze the acylation of lysophosphatidic acid (LPA) to phosphatidic 
acid, the second step in the de novo formation of glycerophospholipids.20;21 Although the 
function of most AGPAT isoforms is largely unknown, multiple AGPAT isoforms have been 
linked to cancer. AGPAT9 and 11 are overexpressed in colon cancer tissue, as well as in other 
cancer types.20;22 AGPAT2 inhibition was shown to induce in vitro growth arrest and cell death 
in different tumor types, including several colon cancer cell lines.23
To our knowledge, this is the first prospective GWA study investigating systemic treatment 
efficacy in Caucasian mCRC patients. Only two previous similar studies have been published 
worldwide, and none of the markers identified by those experiments overlap with our results.24;25 
These studies, both by the same Korean research group, followed a three step design, validating 
results from GWA analysis in both an independent patient cohort and transfected colorectal 
cancer cell lines. They found two SNPs with putative influence on efficacy of cetuximab-
containing regimens for colorectal carcinoma25, as well as one SNP influencing disease 
recurrence after adjuvant chemotherapy with 5-FU for stage II or III colorectal carcinoma.24 
In both studies, the selection of markers to be carried forward to the validation studies was 
based on the minor allele frequency and location in a haplotype block in the Asian population, 
and only non-synonymous SNPs were included. Considerable differences in allele frequencies 
exist between Asian and European populations for the relevant genetic markers from both our 
and Kim’s analyses, which in part may explain the lack of overlap between our results.19 Also, 
considerably larger treatment heterogeneity was present in their population, thereby possibly 
diluting the effect of germline genetic markers on treatment efficacy. 
Our study is subject to several limitations. Interpretation of GWA studies in general 
is hampered by the need for large patient populations, to ensure sufficient power to detect 
genotype effects. With 547 patients, our cohort used for this GWA study is larger than many 
other pharmacogenetic study populations. Non-significant results could therefore lead to 
the conclusion that indeed none of the tested SNPs are associated with PFS upon CAPOX-B 
treatment in mCRC. However, the power to detect associations depends not only on population 
size, but also on the size of a SNP-effect and on genotype frequency. Despite a relatively large 
sample size, false negative results could arise for SNPs with low minor allele frequencies. In 
fact, minor allele frequencies of the three topmost significant SNPs from the overall analyses 
are only 0.10 in our population, which may well have led the results to be non-significant, 
despite an actual effect on PFS. 
Obviously, it can be argued that rare variants or markers with a small effect on treatment 
efficacy are not clinically relevant, irrespective of their statistical significance level. However, 
genetic predisposition is unlikely to depend on only a few SNPs for most drug effects. Rather, 
multiple genetic markers could attribute in small amount and interact with each other.26;27 
GWAS for PFS on capecitabine, oxaliplatin and bevacizumab
143
Their combined effect, in conjunction with clinical and pathologic parameters, could be of 
value in predictive models. Such a model has recently been proposed for colorectal cancer 
risk assessment.28 In future, similar models should be constructed for predicting treatment 
response as well as adverse events for diverse systemic treatment regimens. In this scenario, 
any SNP influencing the complex trait ‘drug efficacy’ is of value. 
Another drawback of GWA analyses is that these studies only focus on the influence of 
genetic variation, without taking into consideration most patient and tumor characteristics. 
Whereas in the time the CAIRO2 trial was performed cetuximab was prescribed to 
unselected patients, regardless of tumor characteristics, it was shown shortly thereafter that 
patients carrying a somatic mutation in Kras codon 12 or 13 are resistant to treatment with 
cetuximab.29–32 More recently, patients with mutations in Nras were also shown not to benefit 
from treatment with anti-epidermal growth factor antibodies.33 More somatic mutations 
precluding EGFR inhibitor efficacy may be discovered. 
At the time the study was conducted, EGFR inhibitor therapy was not restricted to Kras 
wild type tumors only. However, Kras mutation status has been analyzed restrospectively 
in those patients for whom tumor DNA was available. For this subgroup, we performed 
additional analyses, taking Kras codon 12 and codon 13 alleles into consideration. We found 
that rs885036 remained an independent predictor for PFS, with only a small change in HR 
(HR 0.466 without Kras, HR 0.472 with Kras as a covariate). Recently, it was found that patient 
survival in colorectal cancer is influenced by different molecular subtypes, including not only 
Kras mutation status, but several other genetic and epigenetic factors.34 Because molecular 
subtype was not determined in the CAIRO2 population, we cannot completely exclude an 
effect of molecular subtype on the outcome of our analyses. However, there is no evidence 
in literature for an association between GnT-IVa genotype and colorectal cancer molecular 
subtype.
Contrary to practice in clinical trials, serum LDH level at baseline, although strongly 
correlated to PFS7, was not included in our multivariate model. Confounding by the prognostic 
effect of LDH cannot be excluded, since there was a slight overrepresentation of patients with 
increased LDH levels in several genotype groups with shorter PFS (data not shown). LDH level 
in itself may be a predictive as well as a prognostic factor, and not completely independent of 
germline genotype. Serum LDH-levels have been associated with intratumoral gene expression 
of vascular endothelial growth factor type A (VEGFA) and vascular endothelial growth factor 
receptor type 1 (VEGFR1).35 Both phenomena are thought to be the result of stimulation of 
hypoxia-inducible factor 1α (HIF-1α), due to the intratumoral aerobic glycolysis known as 
the Warburg effect.36 Results of a recent study suggest that, although high serum LDH levels 
correlate with reduced survival in colorectal cancer patients, treatment with bevacizumab can 
improve PFS for patients with high pretreatment LDH levels to that of patients with normal 
baseline LDH levels.37 Because an interaction of LDH with genotype cannot be excluded, and 
inclusion of LDH in the experimental model could possibly have obscured genotype effects, we 




In this GWA study, investigating the effect of genetic variation on PFS on first line CAPOX-B 
with or without cetuximab in mCRC, we found one marker with a significant effect on treat-
ment efficacy, with opposing results in each treatment arm. 
This SNP, rs885036, may be of predictive importance for patients treated with cetuximab-
containing regimens, and should be further validated in patients with Ras wildtype tumors. 
Patients in our sample carrying the rs885036 GG genotype seem to respond better to CAPOX-B 
plus cetuximab, whereas patients with the AA genotype benefit more from CAPOX-B alone. 
Therefore, it is possible a subgroup of patients carrying the GG genotype may benefit from 
the addition of cetuximab to CAPOX-B, contrary to overall findings for the general study 
population of CAIRO2 and study with comparable design.7;38 Whether this marker also 
predicts PFS in patients treated with cetuximab monotherapy should be subject to further 
research. We formulated a hypothesis for the pathophysiological basis of this effect, which we 
are now testing in preclinical studies. 
In addition, a cluster of SNPs on chromosome 8 with very low P-values was found, 
which may also have functional significance. For these SNPs, we cannot differentiate between 
a prognostic effect of these polymorphisms on PFS and a predictive effect in relation to 
chemotherapy. These results should also be validated in other populations. 
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Over the last decades, colorectal cancer incidence has risen worldwide.1 In the Netherlands, 
9,301 patients were diagnosed with colorectal cancer in 2001, increasing to 13,408 new 
diagnoses in 2012.2 Although with the initiation of population-based screening programs a 
reduction in both colorectal cancer incidence and mortality is anticipated, based on earlier 
studies a considerate number of patients is still expected to present with interval tumors3, 
underscoring the importance of continuing research for optimal treatment strategies. 
In the struggle to reduce colorectal cancer mortality, it is not only important to develop 
new therapeutic strategies, but it is equally essential to optimize the use of currently available 
treatment modalities. Large costs are associated with anti-cancer treatment, both in relation 
to quality of life and in financial terms. Patients frequently experience severe and debilitating 
side-effects, even without any beneficial treatment effect. On the other hand, health care costs 
for colorectal cancer treatment are exceedingly high, especially for patients with advanced 
stage disease.4 Therefore, pretreatment predictors are required, to identify patients with the 
best likelihood of treatment response, as well as those who are most susceptible to toxicity. 
Pharmacogenetics, studying the effect of heritable germline genetic variation on response 
to drug treatment, may provide such a tool. For this thesis, we studied the association of 
germline polymorphisms with effects of capecitabine and oxaliplatin in patients with advanced 
colorectal cancer (ACC). 
General pharmacogenetic considerations
The term “pharmacogenetics” entered medical literature as early as 1961.5 Since then, this 
research field has evolved rapidly and, at the completion of this thesis, more than 12,000 articles 
are indexed in Pubmed for the word “pharmacogenetics”. Chapter 2 summarizes the literature 
regarding pharmacogenetic studies in colorectal cancer available at the start of the research 
leading up to this thesis. It provides an overview of the understanding of genetic variation 
in pathways involved in anti-cancer drug effects, not only for capecitabine and oxaliplatin, 
but also for irinotecan and the newer targeted drugs bevacizumab and cetuximab. Since the 
writing of the article, many newer studies have been published, and our knowledge on the 
effects of germline genetic variation on treatment outcome in colorectal cancer is continuously 
growing.
Pharmacogenetic studies aim at understanding the influence of variation in germline 
DNA on inter-patient differences in drug effects. Preferably, DNA for these studies should be 
derived from healthy tissues, such as peripheral blood leucocytes or buccal swabs. However, 
many of the early pharmacogenetic studies in colorectal cancer have used tumor tissue as the 
primary source of DNA for their analyses. This approach does not account for the potential 
bias of somatic mutations or loss of heterozygosity (LOH) in the tumor, and differences 
between tumor and germline genotype could potentially explain the often contradicting results 
between pharmacogenetic publications. Studies for the association of CYP2D6 genotype 
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with efficacy of tamoxifen in breast cancer have occasionally found significant deviation 
from Hardy-Weinberg equilibrium (HWE) in tumor material, possibly due to hemizygous 
chromosomal deletions in this gene.6-9 This has led some authors to conclude that studies with 
pharmacodynamic endpoints should not use tumor material as a source of DNA.6 In chapter 
3 we addressed this possible cause of confounding, by comparing genotyping results in DNA 
isolated in peripheral blood leukocytes, with results in DNA extracted from archived colorectal 
cancer tumor samples in the same patients. Analyses were restricted to a defined set of genetic 
markers that have been frequently selected for pharmacogenetic studies in colorectal cancer, 
and could successfully be genotyped in all samples.
We found that only 1.4 percent of all blood-tumor pairs showed discordant results. We 
then evaluated if these discrepancies could be the result of LOH, using heterozygous loci 
adjacent to the SNP of interest as a marker for chromosomal loss. In this way, we showed that 
only half of the mismatches could have been induced by LOH. 
Of note, we used macro-dissection for the collection of DNA from colorectal tumor tissue, 
which may have unintentionally led to the inclusion of significant amounts of germline DNA 
from healthy stromal tissue in samples designated as tumor DNA. This may alternatively 
explain the high level of agreement between both sample types. Although this mixture of 
DNA types could have been prevented by the use of micro-dissection for DNA collection from 
tumor samples, this is not the method used by most previous studies. Furthermore, it was not 
our goal to rule out any somatic variation in tumor DNA for these polymorphisms. Regardless 
if the concordance is a reflection of a large stromal component or of actual agreement between 
germline and tumor genotype, our analyses showed that results from previous pharmacogenetic 
studies using DNA from macro-dissected tumor tissue, can reliably be compared with those 
from newer studies using blood-derived DNA. However, the inferior DNA quality in tumor-
derived DNA often leads to lower call-rates. Therefore, for future pharmacogenetic research, 
peripheral blood should be the preferred source of DNA for genotyping. 
Pathway-based approach
Capecitabine
Cytotoxicity for fluoropyrimidines is exerted, at least in part, by binding of the active metabolite, 
fluorodeoxyuridine monophosphate (FdUMP), to thymidylate synthase (TS). This prevents 
the formation of 20-deoxythymidine-50-monophosphate, an essential precursor for DNA 
synthesis. For the binding of FdUMP to TS, 5,10-methylenetetrahydrofolate (5,10-MTHF) is 
required as an essential cofactor. The amount of 5,10-MTHF available for binding to TS is 
under the direct influence of methylene hydrofolate reductase (MTHFR).
In chapter 4, we hypothesized that polymorphisms in the gene encoding for MTHFR 
may affect capecitabine cytotoxicity in colorectal cancer patients, by increasing the availability 
of 5,10-MTHF and thereby the complex formation with TS. Two common, functional 
polymorphisms in MTHFR (MTHFR 677C>T and MTHFR 1298A>C) were evaluated for their 
association with capecitabine-induced toxicity. We found no effect of these polymorphisms on 
Chapter 9
152
the incidence of severe adverse events in our analyses. Whether this absence of association is 
due to the overshadowing effect of other genetic and non-genetic influences, or whether there 
is indeed no effect of these polymorphisms on capecitabine cytotoxicity, cannot conclusively 
be answered by our research. However, correction for common polymorphisms in the gene 
encoding for TS, which have been suggested to influence fluoropyrimidine cytotoxicity, did not 
alter our results. It should be noted, patients who experienced severe toxicity during adjuvant 
treatment with 5-FU or capecitabine, may not have entered the CAIRO study and this selection 
could also confound our pharmacogenetic analyses. Nevertheless, if this selection had been 
due to a specific MTHFR allele, the genotype distribution at baseline would not have adhered 
to Hardy-Weinberg equilibrium. Therefore, we advocate that MTHFR SNPs are not useful in 
the pretreatment prediction of capecitabine-induced adverse effects (or treatment efficacy) in 
ACC patients. 
In addition to MTHFR genotype, other polymorphisms haven been suggested to explain 
the variation in individual response to capecitabine. Recently, a genome wide association 
study (GWAS) in lymfoblastoid cell lines identified new possible markers for capecitabine 
cytotoxicity.10 The most noticeable result was for a SNP, rs4702484, located near the gene 
encoding for 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR), 
which has been studied previously for its effect on fluoropyrimidine-induced cytotoxicity, and 
for its potential role in colorectal carcinogenesis.11;12 In chapter 5 we attempted to confirm the 
influence of the most common MTRR polymorphisms, as well as four other promising SNPs 
from the aforementioned GWAS, on efficacy of capecitabine in our population of ACC patients 
from the Dutch CAIRO trial.13 Although rs4702484 showed a borderline significant association 
with increased progression free survival (PFS) for carriers of the variant allele, this effect was 
only present in univariate analysis in patients treated with capecitabine monotherapy. Thus, 
even if this marker affects capecitabine cytotoxicity, its effect is overshadowed by the influence 
of clinical patient characteristics and it is lost in combination therapy. This also illustrates that 
results from GWAS, especially in vitro studies, are difficult to replicate in clinical practice. 
Our relatively small cohort size may have compromised the power to detect genotype effects. 
However, for almost all analyses, no trend could be discovered for a genotype effect on 
treatment efficacy and it is unlikely that increasing sample size would have led to significant 
results. We therefore conclude that none of the tested genetic markers are helpful in the pre-
treatment prediction of efficacy of capecitabine in ACC patients.
Oxaliplatin
The addition of oxaliplatin to fluoropyrimidine treatment has considerably increased survival 
for patients with metastatic colorectal cancer.14 However, treatment with oxaliplatin is 
often hindered by the occurrence of neurotoxicity, leading to dose reductions or treatment 
discontinuation. Preclinical data suggest that there is a relationship between the presence of 
specific organic cation transporters (OCTs) in dorsal ganglia, responsible for cellular uptake 
of oxaliplatin, and oxaliplatin-induced peripheral neuropathy. For instance, the competitive 
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OCT2 inhibitor cimetidine not only impairs cellular uptake of oxaliplatin in vitro15, but also 
reduces neuropathic symptoms in oxaliplatin-exposed mice.16 However, results from in vitro 
and in vivo studies are not in complete agreement on which cation transporter is most likely 
to be involved in oxaliplatin uptake in dorsal ganglia.15;16 We theorized that SNPs in the genes 
encoding for three cellular transporters (SLC22A1, SLC22A2 and SLC47A1) could explain the 
divergent expression of neurotoxicity between patients treated with oxaliplatin. This hypothesis 
was tested in chapter 6. A functional, non-synonymous SNP in OCT1, SLC22A1 Arg61Cys, 
was associated with a low risk of severe oxaliplatin-induced neurotoxicity for patients carrying 
two variant alleles, even after correction for cumulative oxaliplatin dose. Unfortunately, the 
low population frequency of only 2 percent homozygote variant carriers, in combination with 
a small effect size, impairs the implications of this marker for clinical practice. Moreover, 
because our study was hindered by a low genotyping call rate, as well as a suboptimal clinical 
scoring system for neurotoxicity, this result needs to be validated in independent treatment 
cohorts and mechanistic and functional studies before implementation into clinical practice. 
The anti-tumor effect of oxaliplatin stems from binding of diaminocyclohexane (DACH)-
platinum (Pt) to the DNA helix, causing Pt-DNA cross-links, and ultimately leading to 
programmed cell death. This process is inhibited by the action of cellular DNA repair 
mechanisms, such as the Excision Repair Cross Complementation type I (ERCC1). Chapter 7 
focuses on the hypothesis that a common synonymous SNP in ERCC1 (ERCC1 C118T) alters 
oxaliplatin cytotoxicity depending on genotype, through an effect on DNA repair capacity. 
Transfection experiments were performed, assessing the effect of ERCC1 C118T on DNA 
repair capacity in vitro. In addition, we performed a clinical association study for the effect 
of this SNP on survival upon oxaliplatin-based chemotherapy in ACC patients from the 
CAIRO study.13 We showed that both in vitro cell survival after oxaliplatin-administration, 
and DNA repair-capacity of the transfected cells, depend on the presence of a functional 
ERCC1 gene. However, we found that ERCC1 C118T neither changes the in vitro capacity for 
DNA repair, nor affects survival of ACC patients receiving treatment with oxaliplatin. Strictly 
speaking, the population size for the clinical association study was not sufficiently powered 
to definitely rule out any effect of ERCC1 genotype on patient survival. However, our results 
concur with a meta-analysis published in 2011, showing that PFS following oxaliplatin-based 
chemotherapy for colorectal cancer patients was not influenced by ERCC1 C118T genotype in 
Caucasian populations.17 Although transfection experiments do not account for the normal 
cellular regulation of gene expression, in vivo ERCC1 functionality depends on the co-
expression of ERCC4. Any super-natural ERCC1 protein levels due to unregulated plasmid 
derived transcription would therefore not have resulted in more effective DNA repair in our 
experiments. We therefore believe both the clinical and the transfection model provide valid 




In chapters 4 to 7, a pathway-based, candidate gene approach was used to identify predictive 
markers for efficacy and toxicity of capecitabine and oxaliplatin. However, this approach is 
restricted by the limited knowledge of the pathways and genes involved in individual drug 
response. Therefore, as described in chapter 8, we performed a GWAS to identify novel 
markers for the prediction of PFS on treatment with a multidrug schedule for ACC. For 
this study, patients were accrued from the CAIRO2 trial, which compared treatment with 
capecitabine, oxaliplatin and bevacizumab (CAPOX-B) with CAPOX-B plus cetuximab.18 One 
marker on chromosome 2 showed a significant effect on PFS, that was opposite in patients 
treated with CAPOX-B, compared to those treated with cetuximab in addition to CAPOX-B. 
This marker could therefore be a potential marker for cetuximab efficacy in ACC. This SNP is 
located in GnT-IVa, in an intronic region that is a predicted binding site for microRNA-34A. 
We presented a pathophysiological hypothesis based on this remarkable finding, which will be 
further evaluated in pre-clinical studies. Even if a functional effect of this marker is validated 
in laboratory experiments, these results should also be replicated in clinical patient cohorts. 
However, since cetuximab is no longer prescribed in combination with bevacizumab, and it is 
often included in second- or third-line treatment only, finding a patient cohort similar to ours 
is extremely difficult. 
Future research
Colorectal cancer survival is highly dependent on tumor stage. For patients with stage I-III 
disease, treatment is aimed at curation by surgical removal of the tumor, mostly followed by 
adjuvant systemic treatment for patients with stage III or high risk stage II disease.19;20 Over 
time, the boundaries of what is considered to be curable disease have broadened. In current 
practice, not only liver metastases, but also solitary lung metastases are often treated with 
localized therapies in hope of curation.19 However, for most patients with metastatic disease, 
treatment still consists of systemic therapy with palliative intent. 
Unfortunately, there is great disparity in individual response to chemotherapy, both in 
terms of efficacy and toxic events. Because of the poor prognosis of ACC, and the increasing 
emphasis on quality (rather than prolongation) of life, it can be questioned whether this disease 
should be treated by a one-size-fits-all regime. If the goal is to offer the most effective, least 
toxic therapy to each individual upfront, we need a form of personalized medicine.
Ideally, in the near future, the choice for a specific treatment will become tailor-made, 
taking into account a multitude of biomarkers, as well as clinical factors, such as age, renal 
function, co-medication and patient preference. Pharmacogenetics provides valuable pre-
treatment markers of efficacy and toxicity, and is slowly beginning to enter clinical practice. 
It is now generally accepted that carriers of the rare DPYD*2A allele are prone to severe 
fluoropyrimidine-induced toxicity, and should be treated with reduced dose or alternative 
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treatment.21;22 Patients carrying the variant UGT1A1*28 allele are at increased risk of febrile 
neutropenia when treated with irinotecan, and dose reductions are advised.21-23 A genotype-
based dosing system has recently been proposed according to UGT1A1*28 genotype, which is 
a further step toward genotype-guided, personalized cancer-care.24
In addition to its merits for clinical practice, pharmacogenetic research could also aid in the 
development of new drugs. Currently, new agents are still tested in genetically heterogeneous 
populations, without recognition of genotype-phenotype interactions. In case of insufficient 
survival benefit or intolerable toxicity for the total study population, the drug will not enter 
clinical practice. However, the treatment under investigation could be a safe and effective 
option for a genetically distinct subset of patients, and its development could be continued 
for this specific group. In fact, it has been shown that such stratification markers improve the 
success rate of drug development programs.25 
Our GWAS results, described in chapter 8, also provide support for this assumption. 
Although the addition of cetuximab to CAPOX-B in first-line treatment of ACC has a negative 
effect on survival in unselected, genetically heterogeneous populations18;26, we found that 
carriers of the variant allele of the common SNP rs885036, conversely, may benefit from the 
addition of cetuximab. Although these data are preliminary and need to be further validated, 
they illustrate that analysis of germline genetic variation could indeed identify groups of 
patients who differ significantly in their response to a specific drug regimen. 
As our knowledge of the genome is increasing, so are the technological possibilities 
for genotyping. Whereas the original dogma was that our genome was made up of protein-
encoding genes surrounded by non-functional DNA27, it was later discovered that it harbors 
a vast amount of non-coding RNA isoforms, involved in regulation of transcription.28 New 
technologies for genotyping have been developed, allowing us to include these former “gene 
deserts” into our analyses. GWAS address between 500,000 and 1,000,000 SNPs across the 
genome, although analyses are usually restricted to polymorphisms with a population 
frequency of >0.05. In addition, next generation sequencing (NGS) offers the potential of 
genotyping all coding regions, or even the whole genome.29 
Even if the proof of principle has been delivered, cost-effectiveness and clinical utility 
of pharmacogenetics continue to be questioned.30 Cost-effectiveness is determined by many 
different aspects, including drug price and cost of genotyping. Costs for whole genome 
genotyping with NGS have decreased from $95.000.000 in 2001, to $4.000 in 2014.31 For 
various clinical purposes, a multitude of SNPs are tested at the same time, with complete arrays 
at less than €500 per patient.32 Both these arrays and NGS yield information on a myriad of 
polymorphisms, important for drugs currently prescribed to the patient, but also for potential 
future prescriptions. This reduces cost per genotyped SNP to only a few cents. Independent 
of financial cost, clinical utility is dependent on prevalence and penetrance of the allele in 
question, test specificity and sensitivity, cost of an alternative drug, and on spendings saved 
by increased survival or better quality of life.33 Therefore, clinical applicability is not the same 
for all markers, but dependent on the characteristics of the SNP, the population in which it is 
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tested, the drug and the disease under investigation. With reducing genotyping cost per SNP 
associated with NGS, and with increasing drug cost, the break-even point will be met more 
easily in future.
Despite pharmacogenetics finding its way into clinical practice, we do not know yet which 
amount of inter-individual variation in drug response can ultimately be explained by genetic 
variation, and how many different loci influence each drug effect. Although past studies 
showed that heritability explained around 97-99 percent of the variation in elimination of 
number of non-cancer drugs34-36, an in vitro study using lymphoblastoid cell lines found that 
heritability of 5-FU cytotoxicity is only 26-65 percent, depending on the administered dose.37 
In contrast, DPYD*2A alone predicts 50 percent of all cases of grade IV febrile neutropenia in 
patients treated with standard dose 5-FU.38 The degree to which germline pharmacogenetics 
explains drug behavior is likely to depend not only on the drug and gene at hand, but also on 
the administered dose, the method of administration and whether the endpoint is efficacy or 
toxicity. Furthermore, epigenetic regulation may even lead to day-to-day variations in genetic 
influences on drug behavior. 
The influence of genetic variation on drug behavior is best analyzed in extreme phenotype 
populations, because of the large effect size. Patients experiencing severe toxicity on 
chemotherapeutic treatment form such a population. On the one hand, extreme phenotypes 
could be explained by a small number of rare polymorphisms, each individually evoking the 
phenotype in a proportion of patients, through various mechanisms. Although rare variants 
often embody protein-changing mutations, and are therefore predisposed to causing extreme 
phenotypes, half of all variants at a minor allele frequency of 0.5 percent are found in only 
one single ethnic population, restricting the world-wide implementations in pharmacogenetic 
guidelines.39 The effect of DPYD*2A, with a population frequency of only 1.8 percent hetero-
zygotes in Western populations and a large effect on 5-FU induced toxicity, fits this rare variant 
hypothesis.40 Also consistent with the hypothesis, this SNP is not found in Asian populations 
and therefore cannot explain fluoropyrimidine-induced toxicity in Asian cancer patients.41 
On the other hand, extreme phenotypes may be explained by a multitude of different 
polymorphisms with a higher population frequency, all causing a very small fraction of the 
variation in drug response in each affected individual. Chemotherapy-induced toxicity is not 
an ordinal endpoint, but rather a continuous scale, ranging from minor complaints to severe 
and life-threatening events. Although the array of possible outcomes could be explained by 
the effect of many different rare variants with an equal number of different effect sizes, it is 
better explained by this common variant hypothesis. Because we are far from understanding all 
processes and gene products involved in individual drug behavior, we need a hypothesis-free 
approach to unravel all of these contributing variants. It is only because of modern technologies 
such as GWAS or NGS, that we are now able to perform such broad searches. However, 
because of the relatively small effect sizes, very large patient populations are needed to identify 
and validate these markers, before incorporation into clinical practice. This necessitates the 
inclusion of pharmacogenetic research into all clinical trials involving systemic anti-cancer 
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treatment. For definite conclusions on these small effect genetic markers, the formation of 
consortia and the conduction of meta-analyses from observational studies is indispensable. 
A dedicated, randomized controlled trial, withholding genotyping in half of the patients, may 
be regarded unethical if retrospective evidence for the genotype-phenotype interaction is 
overwhelming. Consequently, focus should also be shifted from clinical validation to gathering 
functional proof by laboratory studies. 
In conclusion, results of pharmacogenetic research are already being incorporated into 
clinical practice of anti-cancer therapy. In a survey in 2012, more than two thirds of oncologists 
in the United States reported using a pharmacogenetic test in the previous six months.42 In 
future, new technological possibilities, increasing availability and decreasing financial costs 
of genotyping will further increase the applicability of pre-emptive pharmacogenetic testing 
for clinical practice. Current knowledge on genes, and molecular and clinical effects is now 
integrated into pathways and registered online, in the Pharmacogenomics Knowledge Base 
(PharmGKB).43 Implications for clinical practice are being formulated by consortia21;44, and the 
applicability for clinical practice is under current investigation.32 
For patients with advanced colorectal cancer, tailoring therapy is of great importance, 
because of the small window of opportunity for effective treatment, and the burden of adverse 
effects associated with anti-cancer drugs. Through its incorporation into drug development 
programs and clinical trials, and through collaborating efforts for the introduction into clinical 
practice, pharmacogenetics will help maximize the chances of efficacy and minimize the risks 
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This thesis describes the results of pharmacogenetic studies for the association of germline 
genetic polymorphisms with drug effects of capecitabine and oxaliplatin in patients with 
advanced colorectal cancer (ACC) from the CAIRO and CAIRO2 study.
The first section of the thesis focuses on general pharmacogenetic considerations. 
Chapter 2 gives an overview of information from pharmacogenetic publications available 
until the time when the research leading up to this thesis was initiated. In addition to 
pharmacogenetic considerations for capecitabine and oxaliplatin, irinotecan and the targeted 
drugs bevacizumab and cetuximab are also addressed. 
In the analyses described in chapter 3, we compared genotyping results in DNA samples 
extracted from peripheral blood derived leukocytes, with results in DNA extracted from 
archived colorectal tumor samples in the same patients. We found an almost complete 
concordance between both sample types for the selected polymorphisms, with only 1.4% of 
sample pairs showing unequal genotypes. Conflicting results were shown to result from logistic 
errors, rather than somatic mutations or loss of heterozygosity in at least half of all discordant 
sample pairs. 
In the second section of this thesis, four candidate-gene studies are described. Capecitabine 
pharmacogenetics is addressed first, followed by two studies focusing on the pharmacogenetics 
of oxaliplatin. 
In chapter 4, we investigated the effect of two common polymorphisms in the gene 
encoding for methylene tetrahydrofolate reductase (MTHFR 677C>T and MTHFR 1298 A>C) 
on capecitabine-induced adverse events. We found that neither polymorphism was associated 
with the incidence of severe (grade 3 or higher) toxicity, regardless whether expressed as 
overall toxicity, or specific adverse events, including hand-foot syndrome, diarrhea and febrile 
neutropenia. Also, no effect of these polymorphisms on patient survival upon capecitabine 
treatment for ACC was found. 
Chapter 5 describes a study for the effect of eight germline polymorphisms on efficacy of 
capecitabine in ACC patients. Four single nucleotide polymorphisms were selected based on 
their location in the methionine synthase reductase (MTRR) gene, and another four markers 
were included because of their significance in a recently published in vitro genome wide 
association study (GWAS). Our results showed, however, that none of the selected markers are 
useful predictors of capecitabine efficacy in ACC. 
In chapter 6, results are presented for our study investigating the association of variation 
in the genes encoding for organic cation transporter 1 (OCT1, SLC22A1), OCT2 (SLC22A2) 
and the human multidrug and compound extrusion protein 1 (hMATE1, SLC47A1) on the 
incidence and severity of oxaliplatin-induced neurotoxicity. We found that homozygote 
carriers of the rare allele of SLC22A1 Arg61Cys had a reduced risk of severe neurotoxicity, 
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regardless of the cumulative dose of oxaliplatin. None of the other selected polymorphisms 
were associated with oxaliplatin-induced neurotoxicity. 
Chapter 7 focuses on the effect of the common, synonymous SNP ERCC1 C118T on DNA 
repair capacity after administration of oxaliplatin. Using in vitro transfection experiments, we 
showed that this SNP does not affect cellular DNA repair, or cell survival upon oxaliplatin 
administration. In addition, our clinical association analysis in ACC patients found no effect 
of ERCC1 C118T genotype on patient survival upon second-line or third-line treatment with 
oxaliplatin. 
After the pathway-based analyses in the previous chapters, the last section of this thesis 
describes a study applying a genome wide association approach.
Chapter 8 describes a GWAS searching for germline genetic markers for the prediction of 
progression free survival (PFS) of ACC patients treated with either capecitabine-oxaliplatin-
bevacizumab (CAPOX-B), or CAPOX-B plus cetuximab. We found that a cluster of SNPs on 
chromosome 8 that was associated with PFS, with almost genome wide significance. More 
importantly, a marker on chromosome 2 showed a significant effect on PFS, that was opposite in 
both treatment arms. The minor allele was associated with increased PFS in patients receiving 




Dit proefschrift beschrijft de resultaten van een aantal farmacogenetische studies naar de 
associatie van kiembaanmutaties met het effect van capecitabine en oxaliplatin bij patiënten 
met gevorderd colorectaal carcinoom, uit de CAIRO en CAIRO2 studies. 
Het eerste gedeelte van het proefschrift richt zich op een aantal algemene farmacogenetische 
beschouwingen. 
Hoofdstuk 2 geeft een overzicht van de beschikbare informatie uit farmacogenetische 
publicaties, op het moment dat het onderzoek uitmondend in dit proefschrift werd gestart. 
Naast farmacogenetische overwegingen ten aanzien van capecitabine en oxaliplatin, wordt 
daarin ook aandacht besteed aan irinotecan en de zogenoemde doelgerichte of “targeted” 
middelen bevacizumab en cetuximab. 
Bij de analyses die in hoofdstuk 3 worden beschreven, vergeleken we resultaten van 
genotypering in DNA geïsoleerd uit leukocyten in perifeer bloed, met de genotyperingsresultaten 
in DNA uit gearchiveerde tumormonsters van dezelfde patiënten. We vonden een vrijwel 
complete overeenkomst tussen beide typen monsters, waarbij slechts 1,4% van de monsterparen 
een verschil in genotype lieten zien. Van de tegenstrijdige resultaten kon worden aangetoond 
dat deze voor minimaal de helft op logistieke onvolkomenheden berustten in plaats van op 
somatische mutaties of verlies van heterozygotie in de tumor. 
In het tweede gedeelte van dit proefschrift, worden vier kandidaat-gen studies beschreven. 
Eerst wordt aandacht besteed aan de farmacogenetica van capecitabine, daarna volgen twee 
studies die zich richten op de farmacogenetica van oxaliplatin. 
In hoofdstuk 4 onderzochten we de associatie van twee veelvoorkomende polymorfismen 
in het gen dat codeert voor methyleentetrahydrofolate reductase (MTHFR 677C>T en MTHFR 
1298A>C) met bijwerkingen ten gevolge van capecitabine. Geen van beide polymorfismen was 
gerelateerd aan de incidentie van ernstige (graad 3 of hoger) toxiciteit; noch voor totale toxi-
citeit, noch voor specifieke bijwerkingen, waaronder hand-voet syndroom, diarree en febriele 
neutropenie, werd een associatie gevonden. Ook werd geen effect gezien van deze polymor-
fismen op de overleving na behandeling met capecitabine bij gevorderd colorectaal carcinoom. 
Hoofdstuk 5 beschrijft een studie naar het effect van acht kiembaanpolymorfismen op 
de effectiviteit van capecitabine bij patiënten met gevorderd colorectaal carcinoom. Vier van 
deze polymorfismen werden geselecteerd op basis van hun ligging in het gen dat codeert 
voor methylsynthase reductase (MTRR). Vier andere werden geïncludeerd, vanwege hun 
significantieniveau in een recent gepubliceerde in vitro genoomwijde associatie studie (GWAS). 
Onze resultaten lieten echter zien dat geen van deze polymorfismen een zinvolle voorspeller is 
voor de effectiviteit van capecitabine bij het gevorderd colorectaal carcinoom. 
In hoofdstuk 6 worden de resultaten gepresenteerd van onze studie naar de associatie 
van variatie in de genen coderend voor organische cation transporter 1 (OCT1, SLC22A1), 
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OCT2 (SLC22A2) en de human multidrug and compound extrusion protein 1 (hMATE1, 
SLC47A1), met de incidentie en ernst van oxaliplatin-geïnduceerde neurotoxiciteit. Hierbij 
vonden we dat homozygote dragers van het zeldzame variant allel van SLC22A1 Arg61Cys een 
verminderd risico hebben op het ontwikkelen van ernstige neurotoxiciteit, onafhankelijk van 
de toegediende cumulatieve dosering oxaliplatin. 
Hoofdstuk 7 richt zich op het effect van de veelvoorkomende, synonieme SNP ERCC1 
C118T op de capaciteit tot DNA herstel na toediening van oxaliplatin. Onze in vitro transfectie 
experimenten lieten zien, dat deze SNP geen invloed heeft op het cellulaire DNA herstel, of 
op de cellulaire overleving na toediening van oxaliplatin. Daarnaast toonde onze klinische 
associatiestudie aan, dat ERCC1 C118T genotype geen effect heeft op de overleving van 
patiënten met gevorderd colorectaal carcinoom, wanneer zij worden behandeld met tweede- 
of derdelijns therapie met oxaliplatin. 
Na de kandidaat-gen studies in de vorige hoofdstukken, beschrijft het laatste gedeelte van dit 
proefschrift een studie waarin een genoomwijde benadering werd gebruikt. 
Hoofdstuk 8 beschrijft een GWAS, waarin gezocht werd naar kiembaan genetische 
voorspellers voor de progressievrije overleving van patiënten met gevorderd colorectaal 
carcinoom, die behandeld werden met capecitabine-oxaplatin-bevacizumab (CAPOX-B), 
danwel met cetuximab in aanvulling op CAPOX-B. We vonden een cluster van SNPs op 
chromosoom 8 dat geassocieerd was met progressievrije overleving, waarbij het vooraf 
gestelde genoomwijde significantieniveau bijna werd bereikt. Tevens vonden we een SNP 
op chromosoom 2 dat significant geassocieerd was met progressievrije overleving, met een 
tegengesteld effect in de beide behandelarmen. Bij patiënten die behandeld werden met 
CAPOX-B en cetuximab was het variant allel geassocieerd met een verlengde progressievrije 
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